{"text": "At week 8 , significant reductions in the HAM - A psychic cluster score were seen with quetiapine XR compared with placebo .The anxiolytic effect of quetiapine XR may be translated through the psychic cluster items ( anxious mood , tension , fears , insomnia , intellectual difficulties , depressed mood , and behavior at interview ) .", "label": "", "metadata": {}, "score": "25.157543"}
{"text": "For example , at week 1 , significant differences between quetiapine XR and placebo were seen for HAM - A total , HAM - A psychic and somatic cluster scores , and CGI - S total score .", "label": "", "metadata": {}, "score": "28.45676"}
{"text": "At week 6 , the pro- portion of HAMD24responders ( patients with o50 % decrease in HAMD24 total score ) and remitters ( HAMD17 score f7 ) was statistically significantly higher in all active treatment groups compared to placebo ( LOCF and OC ) ( Table 3 ) .", "label": "", "metadata": {}, "score": "28.500961"}
{"text": "The analysis using change from randomization in HAM - A total score according to final prescribed quetiapine XR dose ( 150 mg / d or 300 mg / d ) at week 8 also found no statistically significant difference between quetiapine XR and placebo .", "label": "", "metadata": {}, "score": "29.04747"}
{"text": "FIGURE 3B shows the MMRM analysis of mean change in HAM - A total score from randomization at each time point .With the adjustment of each of these effects , at week 8 quetiapine XR + SSRI / SNRI did not demonstrate a statistically significant difference from placebo in HAM - A total score change from randomization .", "label": "", "metadata": {}, "score": "29.932587"}
{"text": "However , the magnitude of change in HAM - A total score seen here for the placebo group ( -9.61 ) was unexpectedly high when compared with those seen in other placebo - controlled adjunct studies .", "label": "", "metadata": {}, "score": "33.37461"}
{"text": "By week 8 , significantly higher proportions of patients treated with quetiapine 300 and 600 mg / day had achieved response and remission when compared with placebo .", "label": "", "metadata": {}, "score": "33.962536"}
{"text": "For Lu AA21004 , a statistically significant difference to placebo was seen in change from baseline in HAMA total score from week 2 ( 10 mg , OC ) or week 3 ( LOCF and OC ) onwards ( Fig .", "label": "", "metadata": {}, "score": "37.4532"}
{"text": "The mean change from randomization in MADRS total score was -2.8 and -1.8 at week 4 , and -3.4 and -2.5 at week 8 with quetiapine XR + SSRI / SNRI and placebo + SSRI / SNRI , respectively .", "label": "", "metadata": {}, "score": "38.332703"}
{"text": "At week 6 , the proportion of MADRS responders ( patients with o50 % decrease in MADRS total score ) and remitters ( MADRS score f10 ) was statistically significantly higher in all active treatment groups than placebo ( LOCF and OC ) ( Table 3 ) .", "label": "", "metadata": {}, "score": "38.882603"}
{"text": "Adverse events included dry mouth , somnolence , sedation , headache , and dizziness .CONCLUSIONS : In patients with GAD and an inadequate response to SSRI / SNRIs , adjunctive quetiapine XR did not show a statistically significant effect for the primary endpoint at week 8 , although some secondary endpoints were statistically significant vs placebo .", "label": "", "metadata": {}, "score": "39.611496"}
{"text": "At week 6 , the proportion of MADRS re- sponders ( patients with o50 % decrease in MADRS total score ) and remitters ( MADRS score f10 ) was statistically significantly greater in all active treatment groups than in placebo ( LOCF and OC ) .", "label": "", "metadata": {}, "score": "39.649403"}
{"text": "At week 1 , concomitant sleep medication was used by 10.0 % and 12.5 % of patients in the quetiapine XR and placebo + SSRI / SNRI groups , respectively ; this level of use remained consistent throughout the randomized period .", "label": "", "metadata": {}, "score": "39.92626"}
{"text": "The primary endpoint was change from randomization to week 8 in Hamilton Anxiety Rating Scale ( HAM - A ) total score .Secondary variables were HAM - A psychic / somatic clusters , response , and remission , and Clinical Global Impression - Severity of Illness ( CGI - S ) score .", "label": "", "metadata": {}, "score": "41.41565"}
{"text": "The mean change MADRS and HAM - D scores of the quetiapine - treated group in each study were higher than that of the placebo - treated group ( see Figures 4 and 5 ) .", "label": "", "metadata": {}, "score": "41.89961"}
{"text": "[17 ] These modi- fied data then showed superior total score changes in BPRS for the low - dosage group compared with pla- cebo at weeks 4 and 5 .", "label": "", "metadata": {}, "score": "41.9383"}
{"text": "2008 ; Thase et al .2008 ) .Confirming the antidepressant efficacy observed on the MADRS scale , both doses of quetiapine were associated with significantly greater improvements in HAM - D total score from week 1 through week 8 .", "label": "", "metadata": {}, "score": "42.27503"}
{"text": "Mean change from baseline in Hamilton Rating Scale for Anxiety ( HAMA ) total scores ( ANCOVA , FAS , OC , over time ) and LOCF ( week 6 ) .", "label": "", "metadata": {}, "score": "43.774628"}
{"text": "At Day 42 , there were statistically significant reductions versus placebo with all doses of SEROQUEL XR for the change in PANSS total , positive subscale , general psychopathology subscale , and hostility and aggression scores .", "label": "", "metadata": {}, "score": "43.82161"}
{"text": "In addi- tion , quetiapine XR 400 mg / day failed to separate from placebo on one primary outcome measure ( CGI - S ) .", "label": "", "metadata": {}, "score": "43.869423"}
{"text": "At each evaluation point , the mean decrease in BPRS total score for the high - dosage group was numerically larger than in the low - dosage group , which in turn was larger than in the placebo group .", "label": "", "metadata": {}, "score": "44.086605"}
{"text": "For venlafaxine , a statistically significant difference to placebo was seen from week 3 ( OC ) or week 4 ( LOCF ) onwards .CGI The mean CGI - S score decreased in all active treat- ment groups from y5.2 at baseline to y2.6 in the LOCF analysis ( Table 4 ) and y2.3 in the OC analysis at week 6 .", "label": "", "metadata": {}, "score": "44.249535"}
{"text": "Table 2 .594 E. Alvarez et al . .Page 7 .( Table 4 ) .For Lu AA21004 ( 5 mg and 10 mg ) , a statistically significant difference to placebo was seen from week 1 onwards .", "label": "", "metadata": {}, "score": "45.383286"}
{"text": "Likewise , failure to statistically separate can not be explained by treatment adherence , as this was similar in the 2 groups .It is important to note that in the current study , benzodiazepine use was slightly lower in the quetiapine XR group ( 10.4 % ) than in the placebo group ( 12.0 % ) .", "label": "", "metadata": {}, "score": "45.53942"}
{"text": "Instead , group means at key study timepoints are displayed , revealing that participants given another antipsychotic PRN were , on average , 6.7 points higher on the OAS on day 1 , with reductions in aggression seen for both groups .", "label": "", "metadata": {}, "score": "46.19407"}
{"text": "Adverse effects noted were sedation , orthostasis , dysphagia and a nocturnal startle reac- tion , which all responded to dose reduction .Total BPRS score was not commented on .", "label": "", "metadata": {}, "score": "46.706604"}
{"text": "The most common adverse events seen in the active treatment groups during the trial were somnolence and dizziness .The incidences of adverse events leading to discontinuation were low : 5.3 % , 2.7 % , and 2.5 % in the SEROQUEL XR 400 , 600 , 800 mg / day groups ; 4.9 % in the immediate release SEROQUEL group ; and 2.5 % in the placebo group .", "label": "", "metadata": {}, "score": "46.772457"}
{"text": "For Lu AA21004 , a statistically significant difference compared to placebo in the change from baseline in MADRS total score , in favour of Lu AA21004 , was seen from week 2 ( 10 mg ) or week 3 ( 5 mg ) onwards ( LOCF and OC ) .", "label": "", "metadata": {}, "score": "47.005394"}
{"text": "Concomitant benzodiazepine use was specifically excluded in the aforementioned quetiapine XR monotherapy studies .At week 8 , significant reductions in CGI - S total score were seen with quetiapine XR compared with placebo .", "label": "", "metadata": {}, "score": "47.19406"}
{"text": "Adverse events potentially related to extrapyramidal symptoms were observed in 12.4 % , 8.8 % , and 6.1 % of the quetiapine 300 mg / day , quetiapine 600 mg / day , and placebo groups , respectively .", "label": "", "metadata": {}, "score": "47.278465"}
{"text": "HAM - A scores were also determined at the start of placebo run - in .CGI - I scores were determined at weeks 1 to 4 , 6 , and 8 .", "label": "", "metadata": {}, "score": "47.573837"}
{"text": "Very few differences in out- come were reported .In the comparison with chlorpromazine,[22 ]no differences were detected in primary outcome mea- sures .Treatment response was defined as a decrease of 50 % in BPRS total score : 65 % of the quetiapine subjects ( mean daily dose 407 mg ) and 52 % of the chlorpromazine group met this criterion , which was a statistically significant difference .", "label": "", "metadata": {}, "score": "48.34555"}
{"text": "Anticholinergics for extrapyramidal symptoms ( EPS ) were permitted except for prophylactic use .Efficacy evaluations .The primary efficacy endpoint was change from randomization to week 8 in HAM - A total score .", "label": "", "metadata": {}, "score": "48.441666"}
{"text": "For venla- faxine , a statistically significant difference to placebo was seen from week 3 onwards ( LOCF ) .At week 6 , the proportion of CGI responders ( CGI - I f2 ) and CGI remitters ( CGI - S f2 ) was statistically significantly higher in all active treatment groups than placebo ( LOCF and OC ) ( Table 3 ) .", "label": "", "metadata": {}, "score": "48.734962"}
{"text": "Page 9 .Dose - Response Relationship of Quetiapine in Schizophrenia 57 Table V. Other variable - dose studies Study design SubjectsNo .At endpoint , PANSS and BPRS total scores , as well as CGI - S score , had shown a numerically greater change from baseline in the quetiapine group compared with the haloperidol group , although this was not statistically significant on any scale .", "label": "", "metadata": {}, "score": "49.30046"}
{"text": "Patients with bipolar II depression in the BOLDER I trial did not show a statistically significant difference in HAM - A total score from placebo ( Hirschfeld et al .", "label": "", "metadata": {}, "score": "49.31218"}
{"text": "The main efficacy parameter was the difference at endpoint ( week 8) in mean change from baseline to end of treatment in MADRS total score between escitalopram and citalopram groups .", "label": "", "metadata": {}, "score": "49.748283"}
{"text": "In this study , statistical separation from placebo with adjunctive quetiapine XR was not achieved in patients with GAD and an inadequate response to previous therapy for the primary efficacy variable .", "label": "", "metadata": {}, "score": "49.77965"}
{"text": "Conversely , more patients in the quetiapine XR + SSRI / SNRI group ( 16.8 % ) experienced a clinically relevant shift ( elevation ) from randomization to treatment end in triglyceride levels than in the placebo + SSRI / SNRI group ( 10.3 % ) .", "label": "", "metadata": {}, "score": "49.799347"}
{"text": "Outcomes for participants with or without another antipsychotic PRN .From the group results displayed in TABLE 2 and FIGURE 2 , it is unclear whether quetiapine XR or the concomitant sedating antipsychotics given PRN were responsible for the improvements observed in psychopathology or aggressive behavior .", "label": "", "metadata": {}, "score": "50.346466"}
{"text": "No significant between - group differences were found at baseline .The mean total MADRS score was 33.062.7 in the escitalopram group , 33.362.8 in the cita- lopram group and 33.463.3 in the placebo group ( 6SD ) .", "label": "", "metadata": {}, "score": "50.491432"}
{"text": "PubMed View Article .Gibbons RD , Hur K , Brown CH , Davis JM , Mann JJ : Benefits From Antidepressants : Synthesis of 6-Week Patient - Level Outcomes From Double - blind Placebo - Controlled Randomized Trials of Fluoxetine and Venlafaxine .", "label": "", "metadata": {}, "score": "50.737175"}
{"text": "Due to the profile of Lu AA21004 , a hierarchical procedure was used to test for onset of action at week 1 .Although not significant on the MADRS , Lu AA21004 displayed onset of antidepressant action , with significant improvement vs. placebo at week 1 onwards for both doses on HAMD24 , and for the 10 mg dose on CGI - I. The proportion of patient withdrawals has been used in recent years as an indirect index of drug effectiveness in the real world ( Kahn et al .", "label": "", "metadata": {}, "score": "50.948814"}
{"text": "In addition to nausea and hy- perhidrosis , the incidence of dry mouth , constipation , and anorgasmia were statistically significantly higher in the venlafaxine group than placebo group .", "label": "", "metadata": {}, "score": "51.034985"}
{"text": "Regarding the response rates of other antidepressants in adults with MDD , the NNTs of fluoxetine and venlafaxine are between 5 and 7 , which are comparable to the NNT of 8 for the quetiapine treatment in this population [ 42 ] .", "label": "", "metadata": {}, "score": "51.406635"}
{"text": "2007 ) .The current pooled analysis extends these observations by demonstrating significant decreases in MADRS total score at week 8 with both quetiapine doses both in patients with bipolar II depression who have rapid cycling and in those with less frequent episodes .", "label": "", "metadata": {}, "score": "51.57011"}
{"text": "Secondary efficacy outcomes .MADRS item analyses .Difference in mean change from baseline in MADRS individual item scores at week 8 ( ITT population ; LOCF ) .", "label": "", "metadata": {}, "score": "51.66201"}
{"text": "Page 15 .Another arm of the study compared subjects with treatment - resistant symptoms who had discontinued in the initial trial and were then randomized to clozapine , olanzapine , risperidone or quetiapine .", "label": "", "metadata": {}, "score": "51.667595"}
{"text": "Hamilton rating scale for depression total score .Hamilton rating scale for anxiety total score .Mean change from baseline to week 8 in HAM - A total score ( ITT population ; LOCF ) .", "label": "", "metadata": {}, "score": "51.72998"}
{"text": "23The change from randomization at week 8 in Q - LES - Q percent maximum total score ( items 1 to 14 ) , item 15 ( satisfaction with medication ) , and item 16 ( overall life satisfaction ) were recorded .", "label": "", "metadata": {}, "score": "52.130917"}
{"text": "Mean change from baseline in Montgomery - A\u02dasberg Depression Rating Scale ( MADRS ) total scores ( ANCOVA , FAS , OC , over time ) and LOCF ( week 6 ) .", "label": "", "metadata": {}, "score": "52.31954"}
{"text": "Analysis of the change in BPRS total and positive factor clusters and CGI - S scales show- ed that at endpoint the numerical superiority of quetiapine over placebo did not reach significance ( table IV ) .", "label": "", "metadata": {}, "score": "52.491974"}
{"text": "When examining the data for the active controls in the included lurasidone studies , the NNH vs. placebo for dis- continuation because of an AE was 12 for haloperidol , 17 for olanzapine and -28 for quetiapine XR ( all ns ) .", "label": "", "metadata": {}, "score": "52.50329"}
{"text": "Benefits and harms can also have different time courses and/or enduring consequences that also require careful con- sideration ( 11 ) .In general , the therapeutic effects of lurasidone vs. placebo resulted in single digit NNT values , as did the active controls olanzapine 15 mg / d and quetiap- .", "label": "", "metadata": {}, "score": "52.578346"}
{"text": "The improvement in HAM - D17 subscales at treatment endpoint is summarised in Table4 .There was a significant or borderline significant improvement in all subscales for severely ill patients treated with escitalopram compared with citalopram - treated patients .", "label": "", "metadata": {}, "score": "52.765648"}
{"text": "Page 5 . parent .Mean differences between treatment groups were in favour of escitalopram for all scales ( MADRS , HAM - D17 , CGI - I and CGI - S ) .", "label": "", "metadata": {}, "score": "52.865906"}
{"text": "At 18 months , 18 % of subjects who had been prescribed quetiapine remained on this treatment , while 21 % , 25 % , 26 % and 36 % remained on ziprasidone , perphenazine , risperidone and olanzapine , respectively .", "label": "", "metadata": {}, "score": "52.883488"}
{"text": "PubMed View Article .Arroll B , Elley CR , Fishman T , Goodyear - Smith FA , Kenealy T , Blashki G , Kerse N , Macgillivray S : Antidepressants versus placebo for depression in primary care .", "label": "", "metadata": {}, "score": "53.100906"}
{"text": "As with the MADRS , the difference in mean change from baseline between escitalopram and citalo- pram was higher than for citalopram and placebo ( -3.4 vs. -0.6 , LOCF analysis ; -4.6 vs. -1.6 , OC analysis ) .", "label": "", "metadata": {}, "score": "53.312702"}
{"text": "Page 6 . relevant measures shows that a true therapeutic effect is attri- butable to escitalopram .And the fact that this study analyses severely depressed patients brings additional evidence of a true effect , because focus on this category of patients minimises the impact of spontaneous remission and the placebo effect .", "label": "", "metadata": {}, "score": "53.348827"}
{"text": "Overall rates of adverse events in the pooled safety population were 73.8 % , 74.3 % , and 67.8 % for the quetiapine 300 mg / day , 600 mg / day , and placebo arms , respectively .", "label": "", "metadata": {}, "score": "53.391987"}
{"text": "The outcome was almost identical for quetiapine ( 150 , 300 , 600 and 750 mg / day ) and haloperidol .All treatments other than quetiapine 75 mg / day were significantly more efficacious than placebo .", "label": "", "metadata": {}, "score": "53.561325"}
{"text": "Results showed that the Vortioxetine 2.5 , 5 , 10 , 15 , 20 mg and overall compared to placebo showed a significance for Nausea and no significance for diarrhea , dry mouth , dizziness , fatigue and headache .", "label": "", "metadata": {}, "score": "53.909786"}
{"text": "In patients with treatment - resistant symptoms,[46 ] the mean modal dosage of 642.9 mg / day does suggest dosage increases in the search for effect .", "label": "", "metadata": {}, "score": "54.02089"}
{"text": "[ 6 ] In this trial , subjects with an acute exacer- bation of schizophrenia were randomized to one of five dosages of quetiapine , placebo or haloperidol 12 mg / day and evaluated over 6 weeks .", "label": "", "metadata": {}, "score": "54.36021"}
{"text": "Results and discussion .Common adverse events associated with quetiapine ( both doses ) included dry mouth , somnolence , sedation , dizziness , and headache .", "label": "", "metadata": {}, "score": "54.38317"}
{"text": "An OC analysis was used for by - visit analysis , because the overall number of patients who discontinued from each treatment group was nearly similar ( 14.8 % in the escitalopram group and 15.2 % in the citalopram group ) .", "label": "", "metadata": {}, "score": "54.384995"}
{"text": "During the 24 weeks , 151 ( 18.4 % ) of the participants dropped out of the study .There was a significant decrease in the mean CGI - S score , from 4.5+/-1.1 at baseline to 2.8+/-1.1 at 24 weeks .", "label": "", "metadata": {}, "score": "54.54754"}
{"text": "This trend suggests that if treatment had been longer , the difference would have been even larger and probably would have become significant within two add- itional weeks .", "label": "", "metadata": {}, "score": "54.681534"}
{"text": "The patients in the current study had an inadequate response to prior treatment and so , compared with treatment - na\u00efve or -responsive patients , may have a reduced capacity for symptom improvement , and any benefits experienced by these patients may not be captured by HAM - A score change .", "label": "", "metadata": {}, "score": "54.731873"}
{"text": "Lower scores indicate less severe panic disorder symptoms .A negative mean change in the scores at the end of 8 weeks represents a decrease in severity of panic disorder symptoms .", "label": "", "metadata": {}, "score": "54.73302"}
{"text": "16In all 5 studies the overall tolerability and safety results among quetiapine XR - treated patients were consistent with the known profile of quetiapine .", "label": "", "metadata": {}, "score": "54.877064"}
{"text": "The efficacy and tolerability of once - daily extended - release quetiapine fumarate ( quetiapine XR ) have been evaluated in GAD ; 3 acute monotherapy studies in adults 12 - 14 and 1 in geriatric patients 15 demonstrated that quetiapine XR was effective at significantly reducing anxiety symptoms compared with placebo .", "label": "", "metadata": {}, "score": "54.93171"}
{"text": "These analyses from the clinical trial data for SEROQUEL XR showed that it was effective versus placebo in patients with an acute exacerbation of symptoms of schizophrenia .", "label": "", "metadata": {}, "score": "54.955082"}
{"text": "Average dos- ages used may give some indication of optimal dosages in practice , assuming the range of dosages allowed includes the optimal dosage .In the earliest of eight studies examining variable doses , quetiapine and placebo were compared in subjects with an acute exacerbation of schizo- phrenia .", "label": "", "metadata": {}, "score": "54.975338"}
{"text": "9 The World Federation of Societies of Biological Psychiatry also includes pregabalin as a first - line option .5 However , for many patients with GAD , initial pharmacotherapy does not lead to remission , 2 and the concept of \" refractory \" or \" treatment - resistant \" GAD has emerged .", "label": "", "metadata": {}, "score": "55.117836"}
{"text": "Response was also defined based on ?60 % reduction in baseline HAM - D17 score .These definitions are the most widely used in the current evaluation of treatment efficacy in depression .", "label": "", "metadata": {}, "score": "55.129997"}
{"text": "No prior Wk 4 : 70.5 \u00b1 13.2 occupancy ( range 750 mg / day .PET scans 2 h diagnosis of illness or trauma score : 16.6 \u00b1 7.9 ranged from after last oral dose schizophrenia , Subjects treated with 15.8 % to 64.3 % 18 - 50 y of age .", "label": "", "metadata": {}, "score": "55.23752"}
{"text": "2010 ; Thase et al .2006 ; Young et al .2010 ) .Briefly , the design of each of the four studies encompassed 8 weeks of double - blind treatment whereby patients were randomized to receive quetiapine ( 300 or 600 mg / day ) or placebo .", "label": "", "metadata": {}, "score": "55.53029"}
{"text": "16Snaith RP , Harrop FM , Newby DA et al .Grade scores of the Montgomery - Asberg Depression and the Clinical Anxiety Scales .", "label": "", "metadata": {}, "score": "55.570114"}
{"text": "PubMed View Article .Bortnick B , El - Khalili N , Banov M , Adson D , Datto C , Raines S , Earley W , Eriksson H : Efficacy and tolerability of extended release quetiapine fumarate ( quetiapine XR ) monotherapy in major depressive disorder : a placebo - controlled , randomized study .", "label": "", "metadata": {}, "score": "55.573044"}
{"text": "In the current study , the primary efficacy variable did not show statistical separation for quetiapine XR compared with placebo .This contrasts with the findings of previous studies conducted with quetiapine XR monotherapy in patients with GAD ( not specified as being treatment - resistant GAD ) that found quetiapine XR to be effective in reducing anxiety symptoms when compared with placebo .", "label": "", "metadata": {}, "score": "55.62171"}
{"text": "In the larger of these trials , efficacy was measured using several rating scales , outcomes for which are shown in table II .[ 12 ] In both 450 mg / day groups , scores improved from baseline when compared with the 50 mg / day group , as measured using the BPRS , but with no difference between these two higher dosage groups .", "label": "", "metadata": {}, "score": "55.654545"}
{"text": "No clinically relevant changes over time were seen in the clinical laboratory results , vital signs , weight , or ECG parameters .In this study , treatment with 5 mg and 10 mg Lu AA21004 for 6 wk was efficacious and well tolerated in patients with MDD .", "label": "", "metadata": {}, "score": "55.73132"}
{"text": "They include the anxiety , depressed mood , sleep disturbance , and melancholia subscales .The primary efficacy parameter in this pooled analysis was the mean change in MADRS total score between escitalopram and citalopram .", "label": "", "metadata": {}, "score": "55.769844"}
{"text": "During the randomized period , anticholinergic medication use was low in both groups : 0.5 % to 1.2 % , quetiapine XR + SSRI / SNRI , and 1.5 % to 1.7 % , placebo + SSRI / SNRI .", "label": "", "metadata": {}, "score": "55.838776"}
{"text": "AE , Adverse events , ITT , intention to treat ; LoE , lack of efficacy ; MADRS , Montgomery - A\u02dasberg Depression Rating Scale ; PBO , placebo ; Ven 225 , venlafaxine XR 225 mg .", "label": "", "metadata": {}, "score": "55.8482"}
{"text": "A second fixed - dose study compared three daily doses ( 400 , 600 and 800 mg ) of quetiapine extend- ed - release ( XR ) with one daily dose of quetiapine IR ( 400 mg ) and placebo ( table I ) .", "label": "", "metadata": {}, "score": "55.887005"}
{"text": "26 ] Design and exclusion criteria are shown in table V. Subjects were initiated at a que- tiapine dosage of 50 mg / day and titrated up to 500 mg / day by day 6 .", "label": "", "metadata": {}, "score": "55.887695"}
{"text": "17 Beasley CM Jr , Holman SL , Potvin JH .Fluoxetine compared with imipramine in the treatment of inpatient depression .A multicenter trial .", "label": "", "metadata": {}, "score": "55.89263"}
{"text": "a Variables were not assessed statistically .b The HAM - A psychic cluster comprised the following items : anxious mood , tension , fears , insomnia , intellectual difficulties , depressed mood , and behavior at interview .", "label": "", "metadata": {}, "score": "55.99321"}
{"text": "Psychopathology .Mean BPRS scores at days 1 , 4 , and 8 are shown in TABLE 2 .The assumption of sphericity was violated for the BPRS Paranoid Disturbance subscale , so the Huynh - Feldt correction was applied to the degrees of freedom .", "label": "", "metadata": {}, "score": "56.02817"}
{"text": "The median compliance with study medication was 98 % .Thesedifferencestoplacebo correspond to a standardized effect size ( Cohen 's d ) of 0.56 ( 5 mg ) and 0.54 ( 10 mg ) .", "label": "", "metadata": {}, "score": "56.190125"}
{"text": "The primary outcomes consisted of measuring change from day 1 to day 8 in OAS scores 33 for the measurement of aggression , and BPRS-18 scores 34 as a measure of psychopathology .", "label": "", "metadata": {}, "score": "56.23346"}
{"text": "The improvements during quetiapine treatment were observed at week 1 and were sustained up to week 8 .Significant improvements in 9 and 8 of the 10 MADRS individual items were apparent with quetiapine 300 and 600 mg / day , respectively , indicating the efficacy of quetiapine over a broad range of depressive symptoms .", "label": "", "metadata": {}, "score": "56.27301"}
{"text": "The more relevant limitation issue is the defini- tion of clinical response to treatment .Most studies generally define a clinical response as at least a 50 % reduction in the baseline MADRS or HAM - D17total score .", "label": "", "metadata": {}, "score": "56.31829"}
{"text": "The NNT value calculated using the end of treatment response data for quetiapine XR was 20.8 .Health - related quality of life .There was no statistically significant difference between treatment groups in change from randomization to week 8 in Q - LES - Q percent maximum total score ( TABLE 2 ) .", "label": "", "metadata": {}, "score": "56.37419"}
{"text": "Response to placebo is high in mild depression , intermediate in moderate depression and low in severe depression ( 5 ) .As a result , focusing on severe patients can reduce the impact of spontan- eous remission and the placebo effect .", "label": "", "metadata": {}, "score": "56.376564"}
{"text": "At endpoint , the mean difference between treatment groups was -3.5 in favour of escitalopram compared to -1.3 between citalopram and placebo in the LOCF analysis .", "label": "", "metadata": {}, "score": "56.421112"}
{"text": "In fact , a change in 9 .Conclusion Before discussing the data presented in this re- view , it is worth first considering the nature of the dose - response relationship seen with antipsychotic drugs .", "label": "", "metadata": {}, "score": "56.56749"}
{"text": "[6,15,18 ] The data from the three trials were pooled in order to determine the efficacy of quetiapine , and data from subjects receiving \u00a9 2008 Adis Data Information BV .", "label": "", "metadata": {}, "score": "56.583435"}
{"text": "The design and conduct of that study was similar to the others with the exception that lurasidone was administered in the evening , in contrast to the five other studies where study medication was adminis- tered in the morning .", "label": "", "metadata": {}, "score": "56.743893"}
{"text": "16 The most common adverse effects of quetiapine IR are somnolence , postural hypotension , and dizziness .Quetiapine IR appears to be no more likely than placebo to cause extrapyramidal symptoms , but most studies conducted have been short term .", "label": "", "metadata": {}, "score": "56.81156"}
{"text": "All patients who completed the study had taken a mean quetiapine dosage of 507.9+/-245.9 mg daily .The decrease of CGI - S score in high - dose group ( the maximum dose was 750 mg / d or above ) was statistically significant than that in recommended - dose group ( the maximum dose was less than 750 mg / d ) .", "label": "", "metadata": {}, "score": "56.914696"}
{"text": "PubMed View Article .Beasley CM Jr , Nilsson ME , Koke SC , Gonzales JS : Efficacy , adverse events , and treatment discontinuations in fluoxetine clinical studies of major depression : a meta - analysis of the 20-mg / day dose .", "label": "", "metadata": {}, "score": "57.079338"}
{"text": "This was the first randomized , placebo - controlled study to evaluate the efficacy of quetiapine XR as an adjunct to antidepressants for the treatment of GAD in patients with an inadequate response to SSRI / SNRI treatment in a large patient population .", "label": "", "metadata": {}, "score": "57.145042"}
{"text": "The mean baseline weight was 72.8 , 80.8 , and 72.4 kg in the lurasidone , risperidone , and quetiapine XR groups , respectively .The mean weight change at month 12 was -0.4 kg with lurasidone , +2.6 kg with risperidone , and +1.2 kg with quetiapine XR .", "label": "", "metadata": {}, "score": "57.15056"}
{"text": "Quetiapine XR generally was well tolerated .Two cases of self - reported sedation-1 was sufficient to prompt withdrawal from the study - were observed , along with 2 cases of self - reported constipation during the 8-day study .", "label": "", "metadata": {}, "score": "57.16781"}
{"text": "Mean final daily dose of quetiapine for those withdrawing at week 12 or before was 362 \u00b1 184.8 mg , while those withdrawing at 25 weeks or less was 592 \u00b1 178.2 mg and those finishing at or after 25 weeks was 614 \u00b1 197.6 mg .", "label": "", "metadata": {}, "score": "57.206284"}
{"text": "46 ] The mean modal dosage of quetiapine used was 642.9 mg / day .[ 48 ] Quetiapine was found to be significantly less effec- tive than haloperidol ( 89 % no longer required hospi- tal care ) , olanzapine ( 92 % ) and risperidone ( 88 % ) .", "label": "", "metadata": {}, "score": "57.232025"}
{"text": "Dose - Response Relationship of Quetiapine in Schizophrenia 53 with placebo .[15 ] Actual mean daily doses used were 360 mg and 209 mg , respectively .", "label": "", "metadata": {}, "score": "57.32505"}
{"text": "About a poster presentation entitled : Efficacy of Once - Daily Extended Release .Quetiapine Fumarate in Patients with Acute Schizophrenia .This first analysis of Study 132 evaluated the efficacy of SEROQUEL XR versus placebo in patients with schizophrenia .", "label": "", "metadata": {}, "score": "57.3302"}
{"text": "For the primary efficacy parameter , the mean difference in change from baseline in MADRS total score between escitalopram and citalopram was significantly differ- ent as early as 1 week after the start of treatment .", "label": "", "metadata": {}, "score": "57.45808"}
{"text": "Patient population .Only patients with bipolar II disorder were included in the current analysis .Current antipsychotic , antidepressant , and mood - stabilizing medications were discontinued in a washout period of at least 5 to 28 days .", "label": "", "metadata": {}, "score": "57.644135"}
{"text": "Seven patients withdrew from the study due to nausea : three ( 3 % ) in the 10 mg Lu AA21004 group and four ( 4 % ) in the venlafaxine group .", "label": "", "metadata": {}, "score": "57.66653"}
{"text": "Logistic regression ( with score at randomization as covariate and treatment included as a fixed effect ) was used to compare quetiapine XR with placebo for categorical variables including HAM - A response , HAM - A remission , and CGI - I. A robustness analysis for the primary efficacy variable using an ANCOVA model on the PP analysis population also was performed .", "label": "", "metadata": {}, "score": "57.759483"}
{"text": "The NNT in order to achieve response was calculated according to the formula : 1/(number of placebo responders - number of quetiapine responders ) ; an equivalent formula calculated the NNT to achieve remission .", "label": "", "metadata": {}, "score": "57.900948"}
{"text": "Only 5 AEs had consistently different rates when comparing most of the doses of lurasidone vs. placebo .These are noted in Table 6B listing the NNH values and are : akathisia , nausea , sedation , somnolence and par- kinsonism .", "label": "", "metadata": {}, "score": "57.922882"}
{"text": "The time to discontinuation was longer for subjects tak- ing risperidone ( median 7.0 months ) and olanzapine ( 6.3 months ) than those taking quetiapine ( 4.0 months ) and ziprasidone ( 2.8 months ) .", "label": "", "metadata": {}, "score": "57.937443"}
{"text": "Change in the PDSS scale total score was the primary efficacy outcome measure .In the early weeks of therapy , XR was flexibly and gradually titrated from 50 to 400 mg / day .", "label": "", "metadata": {}, "score": "57.97317"}
{"text": "One possible explanation is that placebo - treated patients may have taken benzodiazepines because of a lack of symptom improvement .However , benzodiazepine use remained relatively constant over the 8-week randomized period .", "label": "", "metadata": {}, "score": "57.980797"}
{"text": "Quetiapine XR or placebo was administered orally , once daily in the evening .Quetiapine XR was initiated at a dose of 50 mg / d , with the dose increased to 150 mg / d on day 3 .", "label": "", "metadata": {}, "score": "57.983955"}
{"text": "Change from base- line in all scales was significantly greater at end- point for patients who received quetiapine , with scores improving steadily from baseline to endpoint .", "label": "", "metadata": {}, "score": "57.99866"}
{"text": "In addition , a recent meta - analysis in MDD ( 11 ) revealed that escitalopram- treated patients showed statistically significant higher response rates and increased mean change from baseline in MADRS total scores at weeks 1 and 8 compared with citalopram- treated patients .", "label": "", "metadata": {}, "score": "58.02768"}
{"text": "Across all analyses , the lower dose was as effective as the higher dose in patients with bipolar II disorder and tended to be associated with lower reports of adverse events .", "label": "", "metadata": {}, "score": "58.0684"}
{"text": "As all studies had low risks of bias , the data of all three trials were included in the analysis .Table 2 .Risk of bias summary of controlled trials of quetiapine in major depressive disorder .", "label": "", "metadata": {}, "score": "58.332954"}
{"text": "No improvement in symptoms was seen at a dosage of quetiapine of 300 mg / day , but once increased to 1000 mg / day ( 400 mg in the morning and 600 mg at night ) a \" dramatic improvement in his psychiatric symptoms \" was reported .", "label": "", "metadata": {}, "score": "58.345406"}
{"text": "More than 80 % of the patients in each treatment group completed the study ( Fig . 1 ) .There was a slightly larger proportion of patients who completed the study in the 5 mg Lu AA21004 group than in the placebo , 10 mg Lu AA21004 , or venlafaxine groups .", "label": "", "metadata": {}, "score": "58.381622"}
{"text": "Synthesis of results .Efficacy .No significant heterogeneity was found on all efficacy outcomes , except HAM - D scores .According to the pooled response rate obtained from all trials , the NNT ( 95%CI ) was 7.2 ( 5.2 - 11.7 ) .", "label": "", "metadata": {}, "score": "58.408733"}
{"text": "Similarly , a meta - analysis of 7 RCTs found that the response rates of bupropion and SSRIs treatment in MDD patients were 62 and 63 % , respectively , compared with 51 % for placebo [ 40 ] .", "label": "", "metadata": {}, "score": "58.4383"}
{"text": "About a poster presentation entitled : Efficacy of Once - Daily Extended Release .Quetiapine Fumarate across Symptom Domains in Schizophrenia .In this second analysis of Study 132 , the efficacy of SEROQUEL XR was evaluated across a broad range of symptoms in schizophrenia , including positive and negative symptoms as well as symptoms of general psychopathology , aggr ession , and depression .", "label": "", "metadata": {}, "score": "58.582806"}
{"text": "In the present analysis , severity was defined using the cut - off point of ? 30 on the MADRS , the primary efficacy parameter .", "label": "", "metadata": {}, "score": "58.73475"}
{"text": "Thus , 6- or 8-week studies may underestimate the remission rate in patients with severe depression ( 20 ) , and it seems that severely depressed patients may need longer trials to achieve euthymia ( 29 ) .", "label": "", "metadata": {}, "score": "58.77045"}
{"text": "( See Boxed Warning . )Suicidality in children and adolescents -- antidepressants increased the risk of suicidal thinking and behavior ( 4 % vs 2 % for placebo ) in short - term studies of 9 antidepressant drugs in children and adolescents with major depressive disorder and other psychiatric disorders .", "label": "", "metadata": {}, "score": "58.78105"}
{"text": "8 Lepola UM , Loft H , Reines EH .Escitalopram ( 10 - 20 mg / day ) is effective and well tolerated in a placebo - controlled study in depres- sion in primary care .", "label": "", "metadata": {}, "score": "58.8843"}
{"text": "Only 30%-55 % of MDD patients achieve remission state at the end of acute SSRI or SNRI treatment [ 13 , 14 ] .While these antidepressants presumably affect serotonin and norepinephrine neurotransmitters , several lines of evidence support that dopamine neurotransmitters may also play an important role in the treatment of MDD patients [ 18 , 19 ] .", "label": "", "metadata": {}, "score": "58.892303"}
{"text": "NNH for the safety / tolerability outcomes were calculated using all six studies .The 5 most consistently encountered adverse events attributable to lurasi- done were akathisia , nausea , sedation , somnolence and parkinsonism , with NNH vs. placebo for lurasidone 40 - 120 mg / d ranging from 6 ( akathisia with 120 mg / d ) to 30 ( parkinsonism with 80 mg / d ) .", "label": "", "metadata": {}, "score": "58.9299"}
{"text": "44 ] The results of previously included trials are discussed to support the use of quetiapine in the early stages of schizophrenia .[6,15,18 ] Case reports are also included in order to report the successful treat- ment with quetiapine of two patients in the early stages of their illness .", "label": "", "metadata": {}, "score": "58.94198"}
{"text": "PRN use of another sedating antipsychotic , in particular quetiapine IR , was most evident in the first 4 days of participation .Aggression .For the 15 participants who completed the study , the mean OAS total score across each of the study days is displayed in FIGURE 2 .", "label": "", "metadata": {}, "score": "59.06834"}
{"text": "Results Table 2 provides the responder rates and the NNT vs. placebo for the different treatment arms using pooled data for each dose of lurasidone , excluding data from a single failed study where neither lurasidone nor haloperidol sta- tistically separated from placebo ( 15 ) .", "label": "", "metadata": {}, "score": "59.11924"}
{"text": "The change from baseline to each visit in all the secondary efficacy variables , except response and remission , was also analysed using MMRM to compare the treatment groups over all assessment points simultaneously using OC data .", "label": "", "metadata": {}, "score": "59.130104"}
{"text": "Balancing this limitation , however , the sample size still was sufficient to demonstrate a statistically significant reduction in both aggression and psychopathology by day 8 , highlighting a potentially clinically meaningful effect .", "label": "", "metadata": {}, "score": "59.130196"}
{"text": "Rates of discontinuation because of adverse events were 12.1 % for quetiapine 300 mg / day , 17.9 % for quetiapine 600 mg / day , and 5.1 % for placebo .", "label": "", "metadata": {}, "score": "59.18535"}
{"text": "Secondary outcomes consisted of measuring the change from day 1 to day 8 in Simpson - Angus Scale ( SAS ) scores 35 for movement side effects and the Barnes Akathisia Scale ( BAS ) 36 to assess akathisia .", "label": "", "metadata": {}, "score": "59.204178"}
{"text": "2006 ; Leverich et al .2006 ; Vazquez et al .2011 ) .In the current analyses , the rates of treatment - emergent hypomania / mania were similar for the two quetiapine doses and for placebo , indicating that quetiapine poses a minimal risk for affective switching in patients with bipolar II depression .", "label": "", "metadata": {}, "score": "59.21026"}
{"text": "A total of 506 severely depressed patients were included ( 169 received escitalopram , 171 citalopram and 166 placebo ) .Results from secondary efficacy parameters ( Hamilton rating for depression and Clinical Global Impression of Improvement and Severity scales ) were consistent with previous results .", "label": "", "metadata": {}, "score": "59.215202"}
{"text": "Bauer M , Tharmanathan P , Volz HP , Moeller HJ , Freemantle N : The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression : a meta - analysis .", "label": "", "metadata": {}, "score": "59.28328"}
{"text": "Bortnick B , El - Khalili N , Banov M , et al .Efficacy and tolerability of extended release quetiapine fumarate ( quetiapine XR ) monotherapy in major depressive disorder : a placebo - controlled , randomized study .", "label": "", "metadata": {}, "score": "59.31897"}
{"text": "Bortnick B , El - Khalili N , Banov M , et al .Efficacy and tolerability of extended release quetiapine fumarate ( quetiapine XR ) monotherapy in major depressive disorder : a placebo - controlled , randomized study .", "label": "", "metadata": {}, "score": "59.31897"}
{"text": "However , this is not the case in the present study , in which both doses of Lu AA21004 showed significantly greater efficacy than placebo on nine of the 10 MADRS items .", "label": "", "metadata": {}, "score": "59.434116"}
{"text": "Results Six hundred and fourteen patients were randomized .Treatment - emergent sexual dysfunction , suicidal ideation or behavior , and discontinuation symptoms were not significantly different between vortioxetine and placebo .", "label": "", "metadata": {}, "score": "59.502205"}
{"text": "In the exploratory analysis of the relationship between MADRS total score at baseline and end of treatment , there was an indication that the difference between placebo and both quetiapine doses at end of treatment increased as baseline score increased ( Table 2 ; Figure 4 ) .", "label": "", "metadata": {}, "score": "59.510864"}
{"text": "There are a number of single case reports in the literature .The first of these described rapid dose escalation of quetiapine to 600 mg by day 7 of treatment in a 34-year - old male with a diagnosis of treatment - resistant schizophrenia that had been treated with zuclopenthixol decanoate 200 mg weekly immediately before quetiapine .", "label": "", "metadata": {}, "score": "59.514133"}
{"text": "PubMed View Article .Addington DE , Mohamed S , Rosenheck RA , Davis SM , Stroup TS , McEvoy JP , Swartz MS , Lieberman JA : Impact of second - generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia .", "label": "", "metadata": {}, "score": "59.548668"}
{"text": "Page 3 .Occasional use of zolpidem , zopiclone and zaleplon for insomnia was allowed .The patient could be withdrawn from the study if a serious adverse event ( SAE ) occurred .", "label": "", "metadata": {}, "score": "59.597595"}
{"text": "NNH for the safety / tolerability outcomes were calculated using all six studies .The 5 most consistently encountered adverse events attributable to lurasidone were akathisia , nausea , sedation , somnolence and parkinsonism , with NNH vs. placebo for lurasidone 40 - 120 mg / d ranging from 6 ( akathisia with 120 mg / d ) to 30 ( parkinsonism with 80 mg / d ) .", "label": "", "metadata": {}, "score": "59.63437"}
{"text": "Pooled findings from the BOLDER and EMBOLDEN trials showed clear improvements with both doses of quetiapine in overall functioning , individual domains of social and occupational functioning , as well as quality of life ( Gustafsson and Fajutrao 2011 ) .", "label": "", "metadata": {}, "score": "59.686478"}
{"text": "Based on the pooled response rates , the NNT of 7.2 indicates that , by average , every 1 in 8 patients with MDD will respond to quetiapine treatment .", "label": "", "metadata": {}, "score": "59.73517"}
{"text": "To control the overall type I error rate at .05 , 29 a sequential stepwise procedure was used , starting with the primary efficacy variable followed by the Q - LES - Q percent maximum score ; both nominal and adjusted P values were presented .", "label": "", "metadata": {}, "score": "59.75862"}
{"text": "18 Arminen SL , Ikonen U , Pulkkinen P et al .A 12-week double- blind multi - centre study of paroxetine and imipramine in hospitalized depressed patients .", "label": "", "metadata": {}, "score": "59.760628"}
{"text": "Effect size differences from placebo generally became weaker as the threshold for response was increased from 20 to 50 % .A caveat is that studies with high placebo response rates will yield NNT values that are less robust and will make cross - study comparisons difficult to interpret ; this becomes relevant in this report when examining the NNT vs. placebo for the active controls .", "label": "", "metadata": {}, "score": "59.761806"}
{"text": "any time during the trial ) in each of the three groups ( 55 % in both 450 mg / day groups , 53 % in the 50 mg/ day group ) .", "label": "", "metadata": {}, "score": "59.780777"}
{"text": "[ 12,19 ] All patients who responded to the 6-week phase of these trials and continued into the open - label extension phase were included .", "label": "", "metadata": {}, "score": "59.824753"}
{"text": "The baseline symptom severity scores indicated a patient population with moderate to severe depression without mania symptoms .Primary efficacy outcome : Montgomery - \u00c5sberg depression rating scale total score .", "label": "", "metadata": {}, "score": "59.928066"}
{"text": "Gefvert O , Lundberg T , Wieselgren IM , et al .D2 and 5HT2 receptor occupancy of different doses of quetiapine in schizo- phrenia : a PET study .", "label": "", "metadata": {}, "score": "59.952606"}
{"text": "In the venlafaxine group , the incidence of AEs related to sexual dysfunction was significantly higher than that of placebo ( 12.4 % vs. 1.9 % ) .", "label": "", "metadata": {}, "score": "59.97187"}
{"text": "2011 ; Gao et al .2008 ; Judd et al .2003 ; Otto et al .2006 ) .In the combined BOLDER I and II trials , quetiapine was effective in the treatment of bipolar I and II depression regardless of the severity of baseline anxiety ( Lydiard et al .", "label": "", "metadata": {}, "score": "60.050156"}
{"text": "These lines of evidence suggest that almost all antidepressants , including quetiapine , have the same profile of comparable acceptability to and less tolerability than placebo .", "label": "", "metadata": {}, "score": "60.186996"}
{"text": "Conversely , most trials recruited relap- sed and acutely ill , hospitalized patients who might be said to be more likely to require higher dosages than , say , outpatients or first - episode patients .", "label": "", "metadata": {}, "score": "60.197342"}
{"text": "Between 74 % and 80 % of the patients in each treatment group had had a previous MDE and their current episode had started about 5 months prior to enrolment ( Table 1 ) .", "label": "", "metadata": {}, "score": "60.237087"}
{"text": "Studies using fixed ranges of quetiapine dosages are relatively less informative about dose - response relationships but are helpful in some respects .In the largest of these studies , a mean dosage of quetiapine 209 mg / day was not superior to placebo and was clearly inferior to a mean dosage of 360 mg / day .", "label": "", "metadata": {}, "score": "60.29493"}
{"text": "2013;Boulenger et al .2014 ) .The reasons for failure of the vortioxetine 15-mg dose to separate from placebo in the current study remain unclear as this dose did demonstrate statistically significant improvement over placebo in a previous study conducted outside of the USA ( Boulenger et al .", "label": "", "metadata": {}, "score": "60.336754"}
{"text": "View Article .Altamura AC , Moliterno D , Paletta S , Buoli M , Dell'osso B , Mauri MC , Bareggi SR : Effect of quetiapine and norquetiapine on anxiety and depression in major psychoses using a pharmacokinetic approach : a prospective observational study .", "label": "", "metadata": {}, "score": "60.337303"}
{"text": "In comparison , the effect sizes in the bipolar I population were also moderate but numerically higher ( 0.58 for quetiapine 300 mg / day and 0.64 for quetiapine 600 mg / day ) .", "label": "", "metadata": {}, "score": "60.371407"}
{"text": "CNS Drugs 2008 ; 22 ( 1 ) .Page 10 .58 Sparshatt et al .4 weeks , before decreasing to a maintenance dosage of 200 - 600 mg / day .", "label": "", "metadata": {}, "score": "60.39497"}
{"text": "Only one patient treated with venlafaxine withdrew in the first week of treatment , indicating that there was no bias due to early with- drawals in this treatment arm .", "label": "", "metadata": {}, "score": "60.41941"}
{"text": "A total of 506 severely depressed patients were included ( 169 received escitalopram , 171 citalopram and 166 placebo ) .Results from secondary efficacy parameters ( Hamilton rating for depres- sion and Clinical Global Impression of Improvement and Severity scales ) were consistent with previous results .", "label": "", "metadata": {}, "score": "60.471222"}
{"text": "36 ] Patients re- ceived quetiapine at starting dosages of 100 or 400 mg / day , titrating upwards by 50 - 100 mg / day every 1 - 2 days to a maximum daily dose of 1600 mg .", "label": "", "metadata": {}, "score": "60.487957"}
{"text": "The numerically lower incidence of akathisia with lurasidone 160 mg / d compared to 40 , 80 or 120 mg / d will need to be further explored in additional studies , but may be reflective of the different time of administration of the medication ( evening vs. morning dosing ) .", "label": "", "metadata": {}, "score": "60.579853"}
{"text": "Moreover , symptom improvement in patients treated with escitalopram has been shown to be rapid .Decreases in patient Montgomery - A\u02dasberg Depression Rating Scale ( MADRS ) total mean score , the primary endpoint , were significantly greater with escitalopram than with placebo and were noted as early as week 1 ( 10 ) .", "label": "", "metadata": {}, "score": "60.738804"}
{"text": "PubMed View Article .Bech P , Cialdella P : Citalopram in depression - meta - analysis of intended and unintended effects .Int Clin Psychopharmacol 1992 , 6 ( Suppl 5 ) : 45 - 54 .", "label": "", "metadata": {}, "score": "60.743736"}
{"text": "Mean baseline PANSS total score ranged .Page 3 .Neither lurasidone nor the active control statistically separated from placebo on the primary psychopathological outcome measure .", "label": "", "metadata": {}, "score": "60.74575"}
{"text": "Conversely , 14.3 , 1.7 , and 7.7 % of patients , respectively , shifted from overweight / obese to normal / underweight .The work can not be changed in any way or used commercially .", "label": "", "metadata": {}, "score": "60.817837"}
{"text": "[52 ] Also of note is the recruitment in most trials of subjects known to be responsive to treat- ment .Effective dosage ranges may well be different in refractory illness .", "label": "", "metadata": {}, "score": "60.839096"}
{"text": "c Duration of treatment prior to randomization .Study treatment .The mean ( SD ) dose of adjunctive agent ( quetiapine XR or placebo ) was 174.3 ( 49.0 ) mg / d and 190.3 ( 49.6 ) mg / d for quetiapine XR - treated and placebo - treated patients , respectively .", "label": "", "metadata": {}, "score": "60.85903"}
{"text": "Scores [ Time Frame : Baseline and the end of 8 weeks of treatment ] [ Designated as safety issue : No ] .Possible total scores on the PDSS range from 0 - 28 .", "label": "", "metadata": {}, "score": "60.91391"}
{"text": "Male or female outpatients ( age 18 to 65 ) with a DSM - IV 19 diagnosis of GAD as assessed by the Mini International Neuropsychiatric Interview 20 were eligible for inclusion in the study .", "label": "", "metadata": {}, "score": "60.914112"}
{"text": "Tauscher - Wisniewski S , Kapur S , Tauscher J , et al .Quetiapine : an effective antipsychotic in first - episode schizophrenia de- spite only transiently high dopamine-2 receptor blockade .", "label": "", "metadata": {}, "score": "60.940308"}
{"text": "This latter result may be explained by the relatively low power of the subanalyses in each of the trials , where the predominant number of patients had bipolar I rather than bipolar II depression .", "label": "", "metadata": {}, "score": "60.946682"}
{"text": "Although a secondary con- sideration , some studies showed improvement in clinical efficacy measures for quetiapine across dif-A 15-month open - label , variable - dose study examined 35 patients with a diagnosis of schizo- phrenia or other psychotic disorder .", "label": "", "metadata": {}, "score": "60.98839"}
{"text": "It is not yet known whether these differences reflect the true lower remission rate of quetiapine treatment or only the dissimilarity of participants and study designs among the studies .", "label": "", "metadata": {}, "score": "61.004234"}
{"text": "9 There also is an emergent evidence base for oral atypical antipsychotics , including quetiapine , in ABDs of mild - to - moderate severity , 10 because of their capacity to decrease irritability , impulsivity , and aggressiveness .", "label": "", "metadata": {}, "score": "61.005314"}
{"text": "a mean dosage of 307 mg / day did not separate from placebo , but dosages of 750 mg / day were al- lowed .[ 22 ] In each study the maximum allowa- ble dosage was 750 or 800 mg / day .", "label": "", "metadata": {}, "score": "61.005466"}
{"text": "32 High placebo response often is a major contributory factor , although other possibilities include : inclusion / exclusion criteria ; high attrition rates ; outcome measure sensitivity ; unreliable rating scales ; misdiagnosis ; severity of illness ; and study design .", "label": "", "metadata": {}, "score": "61.01226"}
{"text": "Slightly more patients than planned were enrolled in the study , raising the power from 80 % to 84 % .There were no clinically relevant or statistically significant differences between the treat- ment groups in patient demographics or clinical characteristics at baseline ( Table 1 ) .", "label": "", "metadata": {}, "score": "61.057278"}
{"text": "Posttreatment period .This study evaluated the efficacy and tolerability of quetiapine XR as an adjunct to SSRI / SNRI therapy in patients with GAD who demonstrated partial or no ( inadequate ) response to SSRI / SNRI treatment ( alone or in combination with a benzodiazepine ) .", "label": "", "metadata": {}, "score": "61.0944"}
{"text": "CNS Drugs 2008 ; 22 ( 1 ) .Page 17 .Dose - Response Relationship of Quetiapine in Schizophrenia65 tentatively suggests that dosages around 300 - 400 mg / day were observed to be acceptably therapeutic ; there was no clear escalation of dosages in search of effect .", "label": "", "metadata": {}, "score": "61.09639"}
{"text": "In the effectiveness study of McCue and colleagues,[48 ] a mean daily dose of 652.5 mg was inferior to comparator drugs , and dosages of up to 1200 mg / day were allowed .", "label": "", "metadata": {}, "score": "61.1394"}
{"text": "View Article .Storosum JG , Elferink AJ , van Zwieten BJ , van den Brink W , Gersons BP , van Strik R , Broekmans AW : Short - term efficacy of tricyclic antidepressants revisited : a meta - analytic study .", "label": "", "metadata": {}, "score": "61.191826"}
{"text": "Int J Neuropsychopharmacol .Khan A , Joyce M , Atkinson S , et al .A randomized , double - blind study of once - daily extended release quetiapine fumarate ( quetiapine XR ) monotherapy in patients with generalized anxiety disorder .", "label": "", "metadata": {}, "score": "61.217106"}
{"text": "Patient disposition is shown in Figure 1 .A total of 776 ( 35.2 % ) patients with bipolar II depression were included in the ITT population ( 283 , 289 , and 204 patients received quetiapine 300 mg / day , quetiapine 600 mg / day , or placebo , respectively ) .", "label": "", "metadata": {}, "score": "61.25017"}
{"text": "A total of 1,497 participants in three RCTs were included .All trials examined the quetiapine extended - release ( XR ) .The overall response and remission rates were significantly greater in the quetiapine - treated group with RRs ( 95%CIs ) of 1.44 ( 1.26 , 1.64 ) and 1.37 ( 1.12 , 1.68 ) , respectively .", "label": "", "metadata": {}, "score": "61.27146"}
{"text": "The totality of the evidence supports the overall tolerability of lurasidone , with minimal weight gain and no clinically - meaningful alterations in glucose , lipids , or the electrocardiogram corrected QT ( ECG QTc ) interval .", "label": "", "metadata": {}, "score": "61.311718"}
{"text": "The magnitude of the change from baseline in the MADRS totalscorewasnumericallylargerintheescitalopramgroupthan the citalopram group at week 1 and at all subsequent visits ( Table3 ) .", "label": "", "metadata": {}, "score": "61.347595"}
{"text": "Expert Opin Pharmacother .Philip NS , Mello K , Carpenter LL , et al .Patterns of quetiapine use in psychiatric inpatients : an examination of off - label use .", "label": "", "metadata": {}, "score": "61.38475"}
{"text": "El - Khalili N , Joyce M , Atkinson S , et al .Extended - release quetiapine fumarate ( quetiapine XR ) as adjunctive therapy in major depressive disorder ( MDD ) in patients with an inadequate response to ongoing antidepressant treatment : a multicentre , randomized , double - blind , placebo - controlled study .", "label": "", "metadata": {}, "score": "61.43525"}
{"text": "Other , more specific inclusion criteria , such as duration of illness and baseline disease severity , varied among studies .\" [ Show abstract ] [ Hide abstract ] ABSTRACT : The objective of this analysis was to evaluate the effect of 12 months of treatment with lurasidone on weight in patients with schizophrenia .", "label": "", "metadata": {}, "score": "61.47856"}
{"text": "This delays resolution of aggression or agitation , potentially leaving the patient and others vulnerable to aggressive incidents .This has led to several trials of a rapid initiation dosing regimen 26 - 28 that has proven to result in equivalent tolerance but more rapid efficacy .", "label": "", "metadata": {}, "score": "61.520325"}
{"text": "FIGURE 1 : Study design a Enrollment was a maximum of 28 days prior to placebo run - in period .CGI - S : Clinical Global Impression - Severity of illness ; SNRI : serotonin - norepinephrine reuptake inhibitor ; SSRI : selective serotonin reuptake inhibitor .", "label": "", "metadata": {}, "score": "61.541634"}
{"text": "( 28 ) report that patients with severe depression appear to improve at the same speed as those with less severe depression if their response is measured by the proportion of improvement .", "label": "", "metadata": {}, "score": "61.544758"}
{"text": "Two of the studies were performed in specialist settings in the United States and one in primary care in Europe and Canada .The primary measure of efficacy in each study was mean change from baseline to endpoint ( week 8) in the MADRS total score .", "label": "", "metadata": {}, "score": "61.61116"}
{"text": "All studies included an 8-week , double - blind treatment phase in which patients were randomly assigned to treatment with quetiapine 300 mg / day , quetiapine 600 mg / day , or placebo .", "label": "", "metadata": {}, "score": "61.676292"}
{"text": "For example , from the data available at the time of drug approval , akathisia resulted in discontinuation in 1.7 % of patients treated with lurasi- done vs. 0 % for placebo ( 15 ) .", "label": "", "metadata": {}, "score": "61.706474"}
{"text": "Mezhebovsky I , Magi K , She F , et al .Double - blind , randomized study of extended release quetiapine fumarate ( quetiapine XR ) monotherapy in older patients with generalized anxiety disorder .", "label": "", "metadata": {}, "score": "61.72312"}
{"text": "Elderly patients with dementia - related psychosis treated with atypical antipsychotic drugs are at an increased risk ( 1.6 to 1.7 times ) of death compared to placebo ( 4.5 % vs 2.6 % , respectively ) .", "label": "", "metadata": {}, "score": "61.790897"}
{"text": "Moreover , sub - threshold bipolar II disorder has been estimated to affect up to 6.7 % of the general population ( Angst et al .", "label": "", "metadata": {}, "score": "61.80001"}
{"text": "A clinically meaningful measure of the improvement of depression was also assessed by response and remission rates .Using the main efficacy parameter , clinical response was defined by ?", "label": "", "metadata": {}, "score": "61.802425"}
{"text": "The subjects receiving 450 mg / day showed clinical improvement at 6 weeks ( mean change in BPRS , SANS and CGI , p - values not reported ) .", "label": "", "metadata": {}, "score": "61.803078"}
{"text": "In this analysis , we attempted to determine whether escitalopram is more effective than citalopram in patients with severe depression by pooling data from three individual clinical trials ( 8,9,13 ) of similar design comparing escitalopram with citalopram as the active study control .", "label": "", "metadata": {}, "score": "61.805496"}
{"text": "This produced LHH values that were consistently favorable .Clinically , additional consider- ations include the time to onset of the adverse event versus time to onset of a therapeutic response , as well as the sever- ity and duration of the adverse event .", "label": "", "metadata": {}, "score": "61.818523"}
{"text": "Page 7 . higher at baseline in severely depressed than in mildly or moderately depressed patients .If , for example , the MADRS score in a patient with a baseline score of 30 is reduced by 50 % during 6 or 8 weeks of treatment , the endpoint score of 15 may still represent the presence of substantial symptomatology .", "label": "", "metadata": {}, "score": "61.823006"}
{"text": "J Clin Psychiatry .Lindenmayer JP , Brown D , Liu S , et al .The efficacy and tolerability of once - daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia : a 6-week randomized , double - blind , placebo - controlled study .", "label": "", "metadata": {}, "score": "61.828323"}
{"text": "Psychopharmacology 1997 ; 133 ( 1 ) : 102 - 5 46 .McEvoy JP , Lieberman JA , Stroup TS , et al .Effectiveness of clozapine versus olanzapine , quetiapine , and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment .", "label": "", "metadata": {}, "score": "61.84259"}
{"text": "Although orig- inally a 3-year study , only five subjects completed weeks 77 - 96 before the trial terminated .Design and exclusion criteria are shown in table V. Subjects were initiated on quetiapine in hospital before dis- charge and dosages were then adjusted according to response .", "label": "", "metadata": {}, "score": "61.88744"}
{"text": "A further 4-week variable - dose trial of quetiapine in 12 hospitalized patients examined the treatment of schizophrenia refractory to treatment with typical antipsychotics .", "label": "", "metadata": {}, "score": "61.91223"}
{"text": "Khazaal Y , Tapparel S , Chatton A , et al .Quetiapine dosage in bipolar disorder episodes and mixed states .Prog Neuropsycho- pharmacol Biol Psychiatry 2007 ; 31 ( 3 ) : 727 - 30 4 .", "label": "", "metadata": {}, "score": "61.985916"}
{"text": "The dosage of quetiapine XR ranged from 50 to 300 mg / day .Table 1 shows the main characteristics of included studies .Table 1 .", "label": "", "metadata": {}, "score": "62.056396"}
{"text": "2005 ; Weisler et al .2011 ) .However , patients with bipolar II disorder are thought to be more sensitive to side effects than bipolar I disorder patients .", "label": "", "metadata": {}, "score": "62.05709"}
{"text": "10 , 11 Benzodiazepines may be used for short - term ( 2 to 4 weeks ) therapy , 4 , 7 second - line treatment , 6 or treatment - resistant cases .", "label": "", "metadata": {}, "score": "62.099873"}
{"text": "In total , 23 AEs related to sexual dysfunction were reported by 18 patients , comprising seven women and 11 men .Two patients withdrew due to AEs related to sexual dysfunction ; one due to anorgasmia and 1 due to delayed ejacu- lation , both from the venlafaxine group .", "label": "", "metadata": {}, "score": "62.13803"}
{"text": "The adverse event profile in this patient population was qualitatively similar to findings in acute and maintenance studies of quetiapine monotherapy in patients with bipolar I or II disorder ( Bowden et al .", "label": "", "metadata": {}, "score": "62.352627"}
{"text": "Angst J , Cui L , Swendsen J , Rothen S , Cravchik A , Kessler RC , Merikangas KR : Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication .", "label": "", "metadata": {}, "score": "62.40348"}
{"text": "In this 6-wk , multi - site study , 429 patients were randomly assigned ( 1:1:1:1 ) to 5 or 10 mg Lu AA21004 , placebo or 225 mg venlafaxine XR .", "label": "", "metadata": {}, "score": "62.47535"}
{"text": "In this 6-wk , multi - site study , 429 patients were randomly assigned ( 1:1:1:1 ) to 5 or 10 mg Lu AA21004 , placebo or 225 mg venlafaxine XR .", "label": "", "metadata": {}, "score": "62.47535"}
{"text": "2012 ) .Conclusions .These analyses on the largest sample of patients with bipolar II depression studied to date support the efficacy and tolerability of quetiapine 300 and 600 mg / day in treating bipolar II depression .", "label": "", "metadata": {}, "score": "62.480568"}
{"text": "This gap prompted the current study , which was designed to investigate the efficacy and tolerability of quetiapine XR for the management of psychotic aggression or agitation in adult acute psychiatry .", "label": "", "metadata": {}, "score": "62.481136"}
{"text": "40 ] This dose escalation was reported to be achievable without an increased incidence of adverse effects .The case of a patient who had not responded to quetiapine 800 mg / day was discussed .", "label": "", "metadata": {}, "score": "62.51077"}
{"text": "Bandelow B , Chouinard G , Bobes J , et al .Extended - release quetiapine fumarate ( quetiapine XR ) : a once - daily monotherapy effective in generalized anxiety disorder .", "label": "", "metadata": {}, "score": "62.5519"}
{"text": "Entsuah AR , Huang H , Thase ME : Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine , selective serotonin reuptake inhibitors , or placebo .", "label": "", "metadata": {}, "score": "62.559563"}
{"text": "PubMed View Article .Weisler R , Joyce M , McGill L , Lazarus A , Szamosi J , Eriksson H : Extended release quetiapine fumarate monotherapy for major depressive disorder : results of a double - blind , randomized , placebo - controlled study .", "label": "", "metadata": {}, "score": "62.56317"}
{"text": "Table 4 .Lu AA21004 for treatment of MDD595 .Page 8 . treatment groups to y2.0 at week 6 ( LOCF , Table 4 ) .", "label": "", "metadata": {}, "score": "62.67917"}
{"text": ",23 150 - 450 mg / d dosages of immediate - release ( IR ) quetiapine are more effective than placebo treatment .Furthermore , this review showed IR quetiapine dosages averaging between 254 and 525 mg / d are equivalent in efficacy to standard dosages of both conventional and other atypical antipsychotics .", "label": "", "metadata": {}, "score": "62.68337"}
{"text": "PubMed .Fiedorowicz JG , Endicott J , Leon AC , Solomon DA , Keller MB , Coryell WH : Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder .", "label": "", "metadata": {}, "score": "62.688705"}
{"text": "\" Efficacy of Once - Daily Extended Release Quetiapine Fumarate across Symptom Domains in Schizophrenia . \"Annual Meeting of the American Psychiatric Association , 2007 , San Diego , CA , research poster board NR495 .", "label": "", "metadata": {}, "score": "62.77186"}
{"text": "View Article .Brecht S , Kajdasz D , Ball S , Thase ME : Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder .", "label": "", "metadata": {}, "score": "62.787766"}
{"text": "View Article .Chiesa A , Chierzi F , De Ronchi D , Serretti A : Quetiapine for bipolar depression : a systematic review and meta - analysis .", "label": "", "metadata": {}, "score": "62.834385"}
{"text": "For many patients with generalized anxiety disorder ( GAD ) , first - line treatment does not lead to remission .This study investigated the efficacy and tolerability of adjunctive extended - release quetiapine fumarate ( quetiapine XR ) in patients with GAD and an inadequate response to selective serotonin reuptake inhibitors ( SSRIs ) and serotonin - norepinephrine reuptake inhibitors ( SNRIs ) .", "label": "", "metadata": {}, "score": "62.90573"}
{"text": "Encephale 2003 ; 29 : 259 - 65 .25 Sonawalla SB , Fava M. Severe depression : is there a best approach ?CNS Drugs 2001 ; 15 : 765 - 76 .", "label": "", "metadata": {}, "score": "62.980137"}
{"text": "D1447C00135 ] ; EMBOLDEN I [ D1447C00001 ] and II [ D1447C00134 ] ) that evaluated the efficacy of quetiapine monotherapy for depressive episodes in patients with bipolar II disorder .", "label": "", "metadata": {}, "score": "63.026253"}
{"text": "J Clin Psychopharmacol 2006 ; 26 ( 5 ) : 546 - 7 6 .Arvanitis LA , Miller BG .Multiple fixed doses of \" Seroquel \" ( quetiapine ) in patients with acute exacerbation of schizo- phrenia : a comparison with haloperidol and placebo .", "label": "", "metadata": {}, "score": "63.040916"}
{"text": "Known intolerance to quetiapine fumarate or intolerance to SSRI therapy .Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days preceding enrollment including but not limited to : ketoconazole , itraconazole , fluconazole , erythromycin , clarithromycin , troleandomycin , indinavir , nelfinavir , ritonavir , fluvoxamine and saquinavir .", "label": "", "metadata": {}, "score": "63.07571"}
{"text": "Montgomery SA , Sheehan DV , Meoni P , et al .Characterization of the longitudinal course of improvement in generalized anxiety disorder during long - term treatment with venlafaxine XR .", "label": "", "metadata": {}, "score": "63.0922"}
{"text": "Weisler R , Joyce M , McGill L , et al .Extended release quetiapine fumarate monotherapy for major depressive disorder : results of a double - blind , randomized , placebo - controlled study .", "label": "", "metadata": {}, "score": "63.13051"}
{"text": "Aggression was significantly reduced by day 3 .Psychopathology also was significantly reduced , with the greatest improvement in BPRS Thinking Disturbance subscale scores .No significant increase in movement side effects was seen by day 8 .", "label": "", "metadata": {}, "score": "63.160133"}
{"text": "Merideth C , Cutler AJ , She F , et al .Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder : a randomized , placebo - controlled and active - controlled study .", "label": "", "metadata": {}, "score": "63.179955"}
{"text": "12 - 14 Patients in the current study had already received treatment ( SSRI / SNRI ) for their anxiety ; therefore , it might be expected that on study entry some improvement in symptoms would have already occurred .", "label": "", "metadata": {}, "score": "63.23916"}
{"text": "Advantages appear strongest for lurasidone 160 mg / d over lower doses .Page 7 .Page 8 .In the case where the NNH is a negative number , LHH is rendered meaningless .", "label": "", "metadata": {}, "score": "63.327362"}
{"text": "A ) : 55 - 9 .28 Angst J , Delini - Stula A , Stabl M et al .Is a cut - off score a suitable measure of treatment outcome in shirt - trem trials in depression ?", "label": "", "metadata": {}, "score": "63.38091"}
{"text": "In addition to these effects on the 5-HT system , the systemic administration of Lu AA21004 increases the extracellular concentration of dopamine , noradrenaline and acetylcholine ( Haddjeri et al .", "label": "", "metadata": {}, "score": "63.396587"}
{"text": "The continuation phase of the EMBOLDEN studies included 231 patients with bipolar II depression who received quetiapine for 26 to 52 weeks and is one of the largest bipolar II patient populations studied in a continuation phase trial ( Young et al .", "label": "", "metadata": {}, "score": "63.47727"}
{"text": "Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists .Trends in Neuroscience 19 , 378 - 383 .", "label": "", "metadata": {}, "score": "63.520657"}
{"text": "Zhong KX , Sweitzer DE , Hamer RM , et al .Comparison of quetiapine and risperidone in the treatment of schizophrenia : a randomized , double - blind , flexible - dose , 8-week study .", "label": "", "metadata": {}, "score": "63.636894"}
{"text": "J Clin Psychiatry 2002 ; 63 : 331 - 6 . 10 Montgomery SA , Loft H , Sanchez C et al .Escitalopram ( S - enantiomer of citalopram ) : clinical efficacy and onset of action predicted from a rat model .", "label": "", "metadata": {}, "score": "63.720276"}
{"text": "Mean dosage of quetiapine was 525 mg/ day .Neurocognitive and functional assessment was car- ried out at 3 and 6 months .Symptoms were assessed using the BPRS .", "label": "", "metadata": {}, "score": "63.77046"}
{"text": "Adult patients had to meet DSM - IV criteria for MDD .In this meta - analysis , the statistically significant superior efficacy of escitalopram compared to citalopram was shown to be clinically relevant .", "label": "", "metadata": {}, "score": "63.77515"}
{"text": "Moreover , blockade of 5-HT7 receptors has been shown to produce rapid antidepressant- like effects in the rat in behavioural and electro- physiological experimental paradigms ( Mnie - Filali et al .", "label": "", "metadata": {}, "score": "63.786507"}
{"text": "Harv Rev Psychia- try 2002 ; 10 ( 5 ) : 280 - 91 40 .Arango C , Bobes J. Managing acute exacerbations of schizo- phrenia : focus on quetiapine .", "label": "", "metadata": {}, "score": "63.990845"}
{"text": "2009 ) , thereby normal- izing serotonergic cell firing and 5-HT release .On the other hand , given the presence of excitatory 5-HT3 receptors in GABAergic interneurons in cortical and limbic areas ( Morales et al .", "label": "", "metadata": {}, "score": "64.01659"}
{"text": "It can be initiated at 300 mg / d and taken once daily instead of twice daily dosing recommended for quetiapine IR .A recent trial comparing quetiapine XR with quetiapine IR and placebo found that both IR and XR formulations produced significantly greater reductions in symptoms of schizophrenia compared with placebo , and an adverse - event profile that was equivalent to the placebo group .", "label": "", "metadata": {}, "score": "64.12691"}
{"text": "CNS Drugs 2008 ; 22 ( 1 ) .Page 16 .64Sparshatt et al . symptom scores is numerically less at these higher dosages .", "label": "", "metadata": {}, "score": "64.187256"}
{"text": "Of 1,497 participants , 64.3 % were female .All participants were outpatients with MDD , single or recurrent episode .None of them had treatment - resistant depression .", "label": "", "metadata": {}, "score": "64.21099"}
{"text": "The XR formulation allows for achievement of a therapeutic dose more quickly and conveniently ( once daily ) .An effective medication to decrease symptoms of impulsivity , hostility , aggressiveness , and irritability in people with psychotic disorders could be an important asset , particularly if the medication has a favorable side - effect profile .", "label": "", "metadata": {}, "score": "64.21172"}
{"text": "Katzman MA , Brawman - Mintzer O , Reyes EB , et al .Extended release quetiapine fumarate ( quetiapine XR ) monotherapy as maintenance treatment for generalized anxiety disorder : a long - term , randomized , placebo - controlled trial .", "label": "", "metadata": {}, "score": "64.24382"}
{"text": "The primary efficacy analysis was based on the MADRS total score adjusting for multiplicity using a hierarchical testing procedure starting with the highest dose vs. placebo .", "label": "", "metadata": {}, "score": "64.25515"}
{"text": "Data from these active treatment groups have been reported previously ( McElroy et al .2010 ; Young et al .2010 ) .A continuation phase of 26 to 52 weeks ' duration also formed the design of the EMBOLDEN studies , the results for which have been reported previously ( Young et al .", "label": "", "metadata": {}, "score": "64.26928"}
{"text": "However , current findings provide tentative support for quetiapine XR as a safe and effective medication for treating concurrent psychosis and behavioral disturbance , particularly in less severely aggressive patients .", "label": "", "metadata": {}, "score": "64.40466"}
{"text": "Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine .Int Clin Psycho- pharmacol 2000 ; 15 ( 1 ) : 57 - 60 49 .", "label": "", "metadata": {}, "score": "64.45261"}
{"text": "In support of the primary hypotheses , the findings revealed that a significant reduction in aggression was achieved by day 3 and sustained for the remainder of the study period .", "label": "", "metadata": {}, "score": "64.4875"}
{"text": "2010 ) .The efficacy of quetiapine in patients with bipolar II depression has been previously reported in a pooled analysis of the BOLDER I and II studies ( Suppes et al .", "label": "", "metadata": {}, "score": "64.67435"}
{"text": "About 40 % ( range 36 - 41 % ) of the patients in each treatment group had a concur- rent medical condition .Between 21 % and 33 % of the patients took concomitant medication that they continued with , and 26 - 29 % commenced concomitant medication during the study .", "label": "", "metadata": {}, "score": "64.75788"}
{"text": "As a result , it is unclear the extent to which the aggressive behaviors and psychotic symptoms would have resolved independently of active treatment .Future research should consist of a comparator trial in which the efficacy of quetiapine XR is compared against existing evidence - based treatments for psychotic aggression ( eg , olanzapine ) .", "label": "", "metadata": {}, "score": "64.78828"}
{"text": "2013 ) .The analysis was based on 8-week studies and gives an insight into the short - term safety and tolerability of quetiapine in this population .", "label": "", "metadata": {}, "score": "64.818596"}
{"text": "Psychopharmacology 1998 ; 137 ( 2 ) : 139 - 46 13 .Barzega G , Bogetto F , Maina G , et al .Quetiapine in schizo- phrenic patients : a high- and low - dose double - blind compari- son .", "label": "", "metadata": {}, "score": "64.82954"}
{"text": "Other safety parameters comprised weight , clinical laboratory parameters using fasting and nonfasting samples , physical examination , and vital signs .Statistical analyses .Data for patients with a diagnosis of bipolar II depression in the BOLDER I and II and EMBOLDEN I and II studies were pooled in order to enhance the precision of the statistical analyses .", "label": "", "metadata": {}, "score": "64.87338"}
{"text": "PubMed View Article .Barbui C , Furukawa TA , Cipriani A : Effectiveness of paroxetine in the treatment of acute major depression in adults : a systematic re - examination of published and unpublished data from randomized trials .", "label": "", "metadata": {}, "score": "64.91089"}
{"text": "16 ] Dosages used were 25 mg / day , titrating up to 250 mg / day for all patients .The titration schedule did not allow for 250 mg / day to be reached until at least day 16 of the trial period .", "label": "", "metadata": {}, "score": "64.93608"}
{"text": "The relative risk ( 95 % CI ) for suicidal behavior / ideation and possible suicidal behavior / ideation for quetiapine XR + SSRI / SNRI vs placebo + SSRI / SNRI treatment was .96", "label": "", "metadata": {}, "score": "64.98348"}
{"text": "2007 ) .Quetiapine was tested in the four EMBOLDEN and BOLDER studies under rigorous conditions .The only other agent that has been tested under similarly robust circumstances in bipolar II depression is lamotrigine , and the data are inconsistent among studies ( Swartz and Thase 2011 ) .", "label": "", "metadata": {}, "score": "65.01551"}
{"text": "with either escitalopram or citalopram showed significant improvement compared with placebo .The difference between citalopram vs. placebo was large enough to confirm citalo- pram 's efficacy and support its prescription for depression .", "label": "", "metadata": {}, "score": "65.1009"}
{"text": "2008 ) .Overall , there were changes in some glucose and lipid parameters and increases in weight with quetiapine , which were consistent with previous observations ( Calabrese et al .", "label": "", "metadata": {}, "score": "65.10893"}
{"text": "Dose - Response Relationship of Quetiapine in Schizophrenia 55 in depressive symptoms was seen in the quetiapine group ( mean daily dose 253.9 mg ) compared with risperidone .", "label": "", "metadata": {}, "score": "65.18423"}
{"text": "Mean change from baseline to last assessment in MADRS total score was the main efficacy parameter .Responders were defined as patients with ?50 % reduction in baseline MADRS total score .", "label": "", "metadata": {}, "score": "65.20528"}
{"text": "Key words : Depression , Lu AA21004 , MADRS , serotonin receptor affinity , venlafaxine .Based on preclinical data , these affinities are considered to be of clinical rel- evance and involved in the mechanism of action at therapeutic doses .", "label": "", "metadata": {}, "score": "65.21346"}
{"text": "Artigas F , Celada P , Laruelle M , Adell A ( 2001 ) .How does pindolol improve antidepressant action ?Trends in Pharmacological Sciences 22 , 224 - 228 .", "label": "", "metadata": {}, "score": "65.22912"}
{"text": "J Clin Psychiatr 2005 , 66 ( 8) : 974 - 981 .View Article .Machado M , Iskedjian M , Ruiz I , Einarson TR : Remission , dropouts , and adverse drug reaction rates in major depressive disorder : a meta - analysis of head - to - head trials .", "label": "", "metadata": {}, "score": "65.31253"}
{"text": "The response rate of the quetiapine - treated group in each study was significantly greater than that of the placebo - treated group ( see Figure 2 ) .", "label": "", "metadata": {}, "score": "65.32543"}
{"text": "Bauer M , Pretorius HW , Constant EL , et al .Extended - release quetiapine as adjunct to an antidepressant in patients with major depressive disorder : results of a randomized , placebo - controlled , double - blind study .", "label": "", "metadata": {}, "score": "65.32989"}
{"text": "Quetiapine XR ( at doses of 50 , 150 , and 300 mg / d ) previously has demonstrated efficacy in treating depressive symptoms in patients with MDD , as monotherapy 38 , 39 , 41 , 43 and as adjunctive treatment .", "label": "", "metadata": {}, "score": "65.42492"}
{"text": "Table 2 .Relationship between MADRS total score at baseline and of treatment ( ITT ) ( ANCOVA with baseline score as covariate and treatment as fixed effect ) .", "label": "", "metadata": {}, "score": "65.4916"}
{"text": "Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder : a randomized , placebo - controlled trial .Depress Anxiety .", "label": "", "metadata": {}, "score": "65.57038"}
{"text": "Page 6 .Akathisia , nausea , sedation , somno- lence and parkinsonism are considered commonly observed AEs associated with lurasidone ( see Tables 6A and 6B ) .", "label": "", "metadata": {}, "score": "65.58069"}
{"text": "Neuropsychopharmacology .Owens MJ , Krulewicz S , Simon JS , et al .Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine .", "label": "", "metadata": {}, "score": "65.59134"}
{"text": "[19 ] Three further studies compared flexible - dose quetiapine with comparators in studies of varied design .[ 24 - 26 ] The long - term efficacy of quetiapine was examined in 23 male patients .", "label": "", "metadata": {}, "score": "65.61447"}
{"text": "37 In general , aggression took longer to resolve in these patients , and there was a reduction in the rate of improvement in psychopathology between days 4 and 8 .", "label": "", "metadata": {}, "score": "65.64374"}
{"text": "US Public Health Service publication no .MH-9 - 17 50 .Ezewuzie N , Taylor D. Establishing a dose - response relation- ship for oral risperidone in relapsed schizophrenia .", "label": "", "metadata": {}, "score": "65.644966"}
{"text": "2004 ) , their activation by 5-HT may induce a GABA - mediated in- hibition of neurotransmitter release .In support of this view , the 5-HT3receptor antagonist ondansetron aug- ments the increase of extracellular 5-HT in the ventral hippocampus induced by the SSRI paroxetine ( M\u00f8rk et al .", "label": "", "metadata": {}, "score": "65.674515"}
{"text": "Symptoms and side effects were assessed prospectively over an 8-day period .Symptoms were measured by the Overt Aggression Scale and Brief Psychiatric Rating Scale ( BPRS ) , and side effects were measured using the Simpson - Angus Scale and Barnes Akathisia Rating Scale .", "label": "", "metadata": {}, "score": "65.7005"}
{"text": "[ Time Frame : Comparing baseline and the end of 8 weeks of treatment ] [ Designated as safety issue : No ] .Our target daily dose for quetiapine XR was 200 mg / day .", "label": "", "metadata": {}, "score": "65.73513"}
{"text": "This revealed an equal number of males and females , a predominance of a psychotic illness as the primary diagnosis ( with symptoms having been present for a number of years in most cases ) , and that few patients currently were studying or working .", "label": "", "metadata": {}, "score": "65.806"}
{"text": "creased as the threshold for response increased from 20 to 50 % .The most robust NNT values for lurasidone were observed for 160 mg / d ; the data for this dose are limited to one study ( 13 ) .", "label": "", "metadata": {}, "score": "65.849884"}
{"text": "This study evaluated the efficacy and tolerability of quetiapine XR as an adjunct to SSRI / SNRI therapy in patients with GAD with a history of partial or no ( inadequate ) response to SSRI / SNRI treatment either as monotherapy or in combination with a benzodiazepine .", "label": "", "metadata": {}, "score": "65.88989"}
{"text": "The dose of 5 mg / d corresponds to a SERT occupancy of y40 % in human brain and was , therefore , expected to be an effective dose ( Areberg et al .", "label": "", "metadata": {}, "score": "65.896065"}
{"text": "Sexual dysfunction during antidepressant treat- ment is one of the main reasons for the lack of com- pliance ( Kennedy & Rizvi , 2009 ) .", "label": "", "metadata": {}, "score": "65.928024"}
{"text": "No deaths or SAEs occurred during the study .TABLE 3 .Constipation .Nausea .Nasopharyngitis . a MedDRA preferred term .No AEs potentially related to suicidality were reported and no incidences of suicidal behavior / ideation ( Columbia Classification codes 1 , 2 , 3 , 4 ) were reported in either treatment group .", "label": "", "metadata": {}, "score": "65.95918"}
{"text": "Fixed - dose efficacy studies of immediate - release ( IR ) quetiapine suggest dosages of quetiapine of 150 - 450 mg / day are more effective than placebo and no less effective than dosages of 600 or 750 mg / day .", "label": "", "metadata": {}, "score": "65.98828"}
{"text": "PubMed .Goldstein JM , Nyberg S , Brecher M : Preclinical mechanisms for the broad spectrum of antipsychotic , antidepressant and mood stabilizing properties of Seroquel .", "label": "", "metadata": {}, "score": "65.99264"}
{"text": "CNS Drugs 2008 ; 22 ( 1 ) .Page 18 .66 Sparshatt et al .dosage militates against this proposition , although it remains possible , if unproven , that higher dosages might be needed in patients with refractory symp- toms .", "label": "", "metadata": {}, "score": "66.05169"}
{"text": "2011 ; Suppes and Dennehy 2002 ; Valtonen et al .2005 ) .The authors of the BRIDGE study have suggested that bipolar II disorder is even more pernicious than hitherto appreciated ( Angst et al .", "label": "", "metadata": {}, "score": "66.07129"}
{"text": "A further case study reported the use of high - dose quetiapine , up to 1000 mg / day , in a 12-year - old male with conduct disorder and attention - deficit hyperactivity disorder .", "label": "", "metadata": {}, "score": "66.15287"}
{"text": "At these dosages , mild to marked clinical improvements were reported in positive symptoms , violent behaviour , behavioural disturbances and so- ciability .The patients were followed until symptom exacerbation and , therefore , change in treatment or until the end of the study period , whichever occurred first .", "label": "", "metadata": {}, "score": "66.18478"}
{"text": "There is also a report detailing experience with seven hospitalized patients ( aged 27 - 45 years ) who had diagnoses of treatment - resistant schizophrenia or schizoaffective disorder .", "label": "", "metadata": {}, "score": "66.19879"}
{"text": "Lurasidone 160 mg / d appears better tolerated than lurasi- done 40 , 80 and 120 mg / d regarding akathisia , nausea , seda- tion and somnolence .", "label": "", "metadata": {}, "score": "66.2391"}
{"text": "View Article .Stewart DE , Wohlreich MM , Mallinckrodt CH , Watkin JG , Kornstein SG : Duloxetine in the treatment of major depressive disorder : comparisons of safety and tolerability in male and female patients .", "label": "", "metadata": {}, "score": "66.33087"}
{"text": "When an active control was used , it was for the pur- poses of assay sensitivity .Thus , all calculations for NNT or NNH are for antipsychotic vs. placebo .", "label": "", "metadata": {}, "score": "66.340126"}
{"text": "Effectiveness data from the CATIE trials do little to support the ' high - dose ' theory for quetiapine .In largely responsive ( i.e. not clearly treatment resis- tant ) patients[45,47 ] quetiapine dosages averaging be- tween 500 and 600 mg / day were used ( titration to 800 mg / day was allowed ) .", "label": "", "metadata": {}, "score": "66.36323"}
{"text": "The subjects themselves were typical of those enrolled in registration studies for the acute treatment of schizo- phrenia ( 4 , 5 , 13 , 15 ) .", "label": "", "metadata": {}, "score": "66.38461"}
{"text": "Further studies in this area are warranted .Implication of key findings .Quetiapine may be an alternative antidepressant .However , both risk and benefit of this agent should be taken into account for an individual patient with MDD .", "label": "", "metadata": {}, "score": "66.388306"}
{"text": "The mean maintenance dosage used was 654.2 mg / day .The primary efficacy measure was change in total PANSS score .Fifty percent of the subjects had shown response by end- point .", "label": "", "metadata": {}, "score": "66.44237"}
{"text": "Venlafaxine XR ( 225 mg / d ) was used as the active reference .Outpatients with MDD were re- cruited from psychiatric settings from August 2006 to August 2007 .", "label": "", "metadata": {}, "score": "66.452736"}
{"text": "The effect sizes in the bipolar I population in the four trials were 0.58 for quetiapine 300 mg / day and 0.64 for quetiapine 600 mg / day ( Figure 3 ) .", "label": "", "metadata": {}, "score": "66.46344"}
{"text": "The studies with two risks or less were included .The efficacy outcomes were the mean change scores of depression rating scales , the overall response rate , and the overall remission rates .", "label": "", "metadata": {}, "score": "66.516266"}
{"text": "Recently , some randomized - controlled trials of quetiapine have been conducted in patients with MDD [ 30 - 33 ] .Since most of these studies have small samples , a meta - analysis , which is more powerful in estimating the true effect size , may be a strategy to confirm its efficacy and safety .", "label": "", "metadata": {}, "score": "66.552414"}
{"text": "Further investigation into whether lower doses of quetiapine can achieve antiaggressive effects therefore is warranted .Of clinical interest , our findings also revealed that a group of participants displaying more severe aggression at day 1 were more likely to be administered another sedating antipsychotic PRN , particularly within the first 4 days of quetiapine XR commencement .", "label": "", "metadata": {}, "score": "66.57007"}
{"text": "Smith MA , McCoy R , Hamer - Maansson J , et al .Rapid dose escalation with quetiapine : a pilot study .J Clin Psychopharmacol .", "label": "", "metadata": {}, "score": "66.57145"}
{"text": "\" Efficacy of Once - Daily Extended Release Quetiapine Fumarate in Patients with Acute Schizophrenia . \"Annual Meeting of the American Psychiatric Association , 2007 , San Diego , CA , research poster board NR04 .", "label": "", "metadata": {}, "score": "66.62446"}
{"text": "They reported higher rates of comorbid anxiety in bipolar II disorder compared with bipolar I disorder and higher rates of anxiety disorders , eating disorders , substance use , suicide , and borderline personality comorbidity in bipolar II disorder than for unipolar disorder ( Angst et al .", "label": "", "metadata": {}, "score": "66.645454"}
{"text": "Antidepressant effectiveness in severe depression and melancholia .J Clin Psychiatry 1999 ; 60 ( Suppl . 13 Forest Laboratories I. Flexible dose comparison of the safety and efficacy of escitalopram , citalopram and placebo in the treatment of major depressive disorder .", "label": "", "metadata": {}, "score": "66.66032"}
{"text": "The difference between escitalopram and citalopram , and between each active drug and placebo , was tested using a Wald w2test .Analysis of response or remission rates was performed by logistic regression with baseline MADRS score as covariate .", "label": "", "metadata": {}, "score": "66.6745"}
{"text": "The terminal elimination half - life after multiple doses is estimated at y60 - 70 h.The exposure ( Cmaxand area under curve ) increased linearly with dose ( 2.5 - 60 mg ) .", "label": "", "metadata": {}, "score": "66.71512"}
{"text": "SEROQUEL XR is not approved for the treatment of patients with dementia - related psychosis .( See Boxed Warning . )Hyperglycemia , in some cases extreme and associated with ketoacidosis , hyperosmolar coma , or death , has been reported in patients treated with atypical antipsychotics , including quetiapine .", "label": "", "metadata": {}, "score": "66.72272"}
{"text": "TABLE 2 .BPRS WR .BPRS AD . a All values are expressed as mean ( SD ) .AD : Anxiety Depression subscale ; BPRS : Brief Psychiatric Rating Scale ; PD : Paranoid Disturbance subscale ; SD : standard deviation ; TD : Thinking Disturbance subscale ; WR : Withdrawal / Retardation subscale .", "label": "", "metadata": {}, "score": "66.81157"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT00619892 Abstract .Background .Schizophrenia and bipolar depression trials suggest that quetiapine may have an antidepressant effect .", "label": "", "metadata": {}, "score": "66.855034"}
{"text": "Data sources .MEDLINE , EMBASE , CINHL , PsycINFO and Cochrane Controlled Trials Register were searched in February 2012 .Study populations comprised adults with MDD or major depression .", "label": "", "metadata": {}, "score": "66.862785"}
{"text": "Accompanied by improvements in thought disorder in particular , the concurrent treatment of aggressive behavior and acute psychotic symptoms may provide some support for the role of quetiapine XR in the treatment of aggression in patients experiencing acute psychotic symptoms .", "label": "", "metadata": {}, "score": "66.86457"}
{"text": "More commonly encountered adverse events include akathisia , nausea , sedation , somnolence and parkinsonism , but NNH values are generally in the double digits , reflecting an overall toler- able profile .", "label": "", "metadata": {}, "score": "66.86871"}
{"text": "21 Gorman JM , Korotzer A , Su G. Efficacy comparison of escita- lopram and citalopram in the treatment of major depressive disorder : pooled analysis of placebo - controlled trials .", "label": "", "metadata": {}, "score": "66.88237"}
{"text": "Fluoxetine and desipramine in major depressive disorder .J Clin Psychopharmacol 1993 ; 13 : 305 - 11 .20 Hirschfeld RM .Efficacy of SSRIs and newer antidepressants in severe depression : comparison with TCAs .", "label": "", "metadata": {}, "score": "66.88556"}
{"text": "Dropout data and baseline similarity were reported in all studies .Only two studies [ 32 , 33 ] reported sequence generation of randomization and allocation concealment .", "label": "", "metadata": {}, "score": "66.889496"}
{"text": "No significant differences were observed for other outcome measures , but greater improvements were seen with risperidone vs placebo .The authors concluded that , at low doses , risperidone may be efficacious in the management of symptomatic GAD patients .", "label": "", "metadata": {}, "score": "66.89415"}
{"text": "Biol Psychiatry .Kahn RS , Schulz SC , Palazov VD , et al .Efficacy and tolerability of once - daily extended release quetiapine fumarate in acute schizophrenia : a randomized , double - blind , placebo - controlled study .", "label": "", "metadata": {}, "score": "66.94923"}
{"text": "Methods Patients were randomized 1:1:1:1 to vortioxetine 15 mg , vortioxetine 20 mg , duloxetine 60 mg ( active reference ) , or placebo .The primary efficacy endpoint was mean change in Montgomery - \u00c5sberg Depression Rating Scale ( MADRS ) total score at week 8 ( MMRM ) .", "label": "", "metadata": {}, "score": "66.95422"}
{"text": "Efficacy and tolerability were as- sessed at screening , baseline and after 1 , 2 , 3 , 4 , 5 , and 6 wk .", "label": "", "metadata": {}, "score": "66.97487"}
{"text": "50 Sparshatt et al .Overall , robust controlled data strongly suggest that the standard dosage range for quetiapine is appropriate for clinical use .The balance of evidence does not support the belief that higher dosages are required for full therapeutic effect , although higher dosage trials are ultimately required to confirm or refute this hypothesis .", "label": "", "metadata": {}, "score": "66.999725"}
{"text": "Consistently significant trends in dose changes were not observed for the other medications , although quetiapine and olanzapine doses generally increased while aripiprazole and risperidone doses generally decreased .", "label": "", "metadata": {}, "score": "67.009384"}
{"text": "View Article .Thase ME , Entsuah AR , Rudolph RL : Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors .Br J Psychiatry 2001 , 178 : 234 - 241 .", "label": "", "metadata": {}, "score": "67.02797"}
{"text": "In- dividual patient characteristics , values and preferences will need to be considered when selecting lurasidone over other antipsychotics .Page 10 .The analyses were conducted indepen- dently by the author using data provided by Sunovion Phar- maceuticals Inc.", "label": "", "metadata": {}, "score": "67.03549"}
{"text": "Lu AA21004 for treatment of MDD 593 .Page 6 .As a sensitivity analysis , the non - parametric Kruskal - Wallis test showed a statistically significant difference between the active treatments and placebo .", "label": "", "metadata": {}, "score": "67.11155"}
{"text": "More commonly encountered adverse events include akathisia , nausea , sedation , somnolence and parkinsonism , but NNH values are generally in the double digits , reflecting an overall tolerable profile .", "label": "", "metadata": {}, "score": "67.12663"}
{"text": "antihypertensives , Efficacy rating Patients were evaluated using the MADRS from baseline to week 6 .Rater training was undertaken to increase inter - rater reliability , and was chaired by an experienced investigator .", "label": "", "metadata": {}, "score": "67.12908"}
{"text": "25 In a similar way , quetiapine may assist in improving patients ' capacity to self - regulate or inhibit agitated behavior , thus reducing the likelihood of aggressive behavior .", "label": "", "metadata": {}, "score": "67.19809"}
{"text": "There are very few studies of severe depression , probably because clinical trials for this indication have two main lim- itations : the first is lack of a clear definition for severe depres- sion , and the second is differences in response criteria ( 25 ) .", "label": "", "metadata": {}, "score": "67.246124"}
{"text": "The mean ( SD ) quetiapine XR dose at day 1 was 293.3 mg ( 110.0 ) and 673.3 mg ( 240.4 ) at day 8 .", "label": "", "metadata": {}, "score": "67.26435"}
{"text": "Abstract .Background .Despite being present in up to 1 % of the population , few controlled trials have examined the efficacy of treatments for bipolar II depression .", "label": "", "metadata": {}, "score": "67.27233"}
{"text": "Similar to a previous meta - analysis , the acceptability in this review was derived from the overall discontinuation rate [ 17 ] .The tolerability , frequently defined as a measure of antidepressant side effects [ 36 ] , was drawn from the discontinuation rate due to adverse events .", "label": "", "metadata": {}, "score": "67.2964"}
{"text": "PubMed Central PubMed .Hirschfeld RM , Weisler RH , Raines SR , Macfadden W : Quetiapine in the treatment of anxiety in patients with bipolar I or II depression : a secondary analysis from a randomized , double - blind , placebo - controlled study .", "label": "", "metadata": {}, "score": "67.29668"}
{"text": "The problem of the placebo response in clinical trials for psychiatric disorders : culprits , possible remedies , and a novel study design approach .Psychother Psychosom .", "label": "", "metadata": {}, "score": "67.31135"}
{"text": "BMI : body mass index ; CGI - S : Clinical Global Impression - Severity of Illness ; HAM - A : Hamilton Rating Scale for Anxiety ; LSM : least squares means ; MITT : modified intention - to - treat ; Q - LES - Q : Quality of Life Enjoyment and Satisfaction Questionnaire .", "label": "", "metadata": {}, "score": "67.31284"}
{"text": "Liebowitz M , Lam RW , Lepola U , Datto C , Sweitzer D , Eriksson H : Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder : a randomized , placebo - controlled trial .", "label": "", "metadata": {}, "score": "67.31427"}
{"text": "Stroup TS , Lieberman JA , McEvoy JP , et al .Effectiveness of olanzapine , quetiapine , risperidone , and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic .", "label": "", "metadata": {}, "score": "67.33797"}
{"text": "PubMed View Article .Jensen NH , Rodriguiz RM , Caron MG , Wetsel WC , Rothman RB , Roth BL : N - desalkylquetiapine , a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist , as a putative mediator of quetiapine 's antidepressant activity .", "label": "", "metadata": {}, "score": "67.342896"}
{"text": "Two further fixed - dose studies have compared three dosage regimens ( two effective daily doses and one assumed to be inactive ) of IR quetiapine over 6 weeks ( see table II ) .", "label": "", "metadata": {}, "score": "67.37333"}
{"text": "Katzman MA , Vermani M , Jacobs L , et al .Quetiapine as an adjunctive pharmacotherapy for the treatment of non - remitting generalized anxiety disorder : a flexible - dose , open - label pilot trial .", "label": "", "metadata": {}, "score": "67.37715"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Lurasidone is a newer \" atypical \" or \" secondgeneration \" antipsychotic that has received regulatory approval in the US and Canada for the treatment of schizophrenia .", "label": "", "metadata": {}, "score": "67.409836"}
{"text": "However , in some cases , higher doses might be required ( 12,20 ) .The main advantage of a pooled analysis is to increase the sample size and subsequently the power to detect differences between two clinically effective drugs ( 21 ) .", "label": "", "metadata": {}, "score": "67.427475"}
{"text": "J Clin Psychiatry .Lydiard RB , Rickels K , Herman B , et al .Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder .", "label": "", "metadata": {}, "score": "67.43623"}
{"text": "Using Diagnostic and Statistical Manual of Mental Disorders , Fourth Edition ( DSM - IV ) criteria , the reported lifetime prevalence of bipolar II disorder ( 1.0 % ) is similar to the estimate for bipolar I disorder ( 1.1 % ) ( Merikangas et al .", "label": "", "metadata": {}, "score": "67.43988"}
{"text": "May 11 .Kraemer HC , Kupfer DJ .Size of treatment effects and their importance to clinical research and practice .Biol Psychiatry 2006;59(11):990 - 996 .", "label": "", "metadata": {}, "score": "67.49922"}
{"text": "Conclusions .Based on the limited evidence obtained from three RCTs , quetiapine XR is effective for adult patients with MDD .The high dropout rate due to adverse events suggests that some MDD patients may not be able to tolerate quetiapine XR .", "label": "", "metadata": {}, "score": "67.52489"}
{"text": "Aggression was reduced more quickly than psychotic symptoms , suggesting that it was not simply the antipsychotic effects of quetiapine that assisted in resolving the aggressive behavior .", "label": "", "metadata": {}, "score": "67.57634"}
{"text": "No statistically significant disadvantage from placebo on this outcome was observed for any dose of lurasidone or for haloperidol .Table 6A outlines the incidence of the 12 most com- monly encountered spontaneously reported AEs associated with lurasidone ( all doses ; incidence at least 5 % after round- ing ) .", "label": "", "metadata": {}, "score": "67.606064"}
{"text": "SAEs No deaths occurred during the study .Three patients had SAEs : two in the 10 mg Lu AA21004 group ( one patient with worsening of MDD , and one patient with Varicella zoster infection ) and one in the venlafaxine group ( brain tumour ) .", "label": "", "metadata": {}, "score": "67.6372"}
{"text": "This review aims to evaluate whether these differences confer any significant clinical advantage for escitalopram over either citalopram or other frequently used antidepressants .Searches were conducted using PubMed and EMBASE ( up to January 2009 ) .", "label": "", "metadata": {}, "score": "67.65256"}
{"text": "[54 ] ( This ' fast - dissociation ' theory has been put forward by Kapur and Seeman[32 ] ) .In contrast , there are no scientifically robust data suggesting that dos- ages higher than the licensed range provide im- proved response or other clinical benefits .", "label": "", "metadata": {}, "score": "67.65947"}
{"text": "Neuropsychopharmacology 36 , 1275 - 1288 .Moncrieff J , Kirsch I ( 2005 ) .Efficacy of antidepressants in adults .British Medical Journal 331 , 155 - 157 .", "label": "", "metadata": {}, "score": "67.7563"}
{"text": "Page 5 .The mean baseline MADRS total score was 34.0 , indicating a severely depressed patient population , consistent with the mean CGI - S score of 5.1 .", "label": "", "metadata": {}, "score": "67.7854"}
{"text": "Hum Psychopharmacol 1993 ; 8 : 311 - 7 . 29 Schatzberg AF .Treatment of severe depression with the selective serotonin reuptake inhibitors .Depress Anxiety 1996 ; 4 : 182 - 9 . 30 Mendlewicz J. Efficacy of fluvoxamine in severe depression .", "label": "", "metadata": {}, "score": "67.85475"}
{"text": "In this study , the overall tolerability and safety results in quetiapine XR - treated patients were consistent with the known profile of quetiapine .12 - 16 , 37 - 39 , 41 , 43 , 47 - 49 Patients received concomitant SSRI / SNRI therapy and were permitted to receive benzodiazepines ; therefore , safety / tolerability data reported here may be due to the effects of several agents .", "label": "", "metadata": {}, "score": "67.9503"}
{"text": "This may be the case for ziprasidone as well .Dose trends were evaluated using autoregressive time - series models .Data were available for 49180 treatment episodes of schizophrenia ( 4683 Commercial and 44497 Medicaid ) and 83289 treatment episodes of bipolar disorder ( 57961 Commercial and 25328 Medicaid ) .", "label": "", "metadata": {}, "score": "67.97706"}
{"text": "Angst J , Gamma A , Bowden CL , Azorin JM , Perugi G , Vieta E , Young AH : Diagnostic criteria for bipolarity based on an international sample of 5,635 patients with DSM - IV major depressive episodes .", "label": "", "metadata": {}, "score": "68.00875"}
{"text": "Administration of a depot antipsychotic injection within one dosing interval ( for the depot ) before randomization .Substance or alcohol dependence at enrollment ( except dependence in full remission , and except for caffeine or nicotine dependence ) , as defined by DSM - IV criteria .", "label": "", "metadata": {}, "score": "68.02659"}
{"text": "PubMed .J Clin Psychiatry 2010 , 71 ( 2):163 - 74 .PubMed .McIntyre RS , Brecher M , Paulsson B , Huizar K , Mullen J : Quetiapine or haloperidol as monotherapy for bipolar mania - a 12-week , double - blind , randomised , parallel - group , placebo - controlled trial .", "label": "", "metadata": {}, "score": "68.0921"}
{"text": "Efficacy assessments .The primary efficacy outcome measure in all four studies was the change from baseline to week 8 in Montgomery - \u00c5sberg Depression Rating Scale ( MADRS ) total score ( Montgomery and Asberg 1979 ) , and this is consequently utilized in the current post hoc analysis .", "label": "", "metadata": {}, "score": "68.11275"}
{"text": "This reduction in aggression also was accompanied by a significant reduction in psychopathology .However , analysis of the BPRS subscales revealed that while improvement in all BPRS subscales was seen over time , after controlling for multiple comparisons , only the improvement in BPRS Thinking Disturbance subscale remained significant .", "label": "", "metadata": {}, "score": "68.16372"}
{"text": "Other effect size measures are necessary when describing continuous outcomes , such as mean changes in PANSS scores or mean changes in fasting plasma glucose levels ( 17 , 19 ) .", "label": "", "metadata": {}, "score": "68.222855"}
{"text": "Effectiveness of antipsychotic drugs in first - episode schizophrenia and schizophreniform disorder : an open randomised clinical trial .Lancet 371 , 1085 - 1097 .", "label": "", "metadata": {}, "score": "68.22457"}
{"text": "Statistical significance was not reported .A similar analysis pooled data and recruited pa- tients from the open - label phase of four trials[43 ] ( two trials described in the paragraph above[12,19 ] and two PET scan studies of subjects administered quetiapine at dosages of 450 - 750 mg / day[30,31 ] ) .", "label": "", "metadata": {}, "score": "68.24834"}
{"text": "The difference in findings between the OC and LOCF analyses in this analysis for this parameter was expected .Indeed , the LOCF analysis is a more conservative approach in which data from patients discontinuing treatment are carried forward to subsequent visits , whereas the OC analysis includes only data observed at each time point and may be more representative of clinical practice .", "label": "", "metadata": {}, "score": "68.28333"}
{"text": "During the posttreatment period , a modified 18-item treatment discontinuation signs and symptoms ( TDSS ) scale was used .This scale was a hybrid of the 43-item discontinuation emergent signs and symptoms scale 27 and the 17-item discontinuation scale 28 and included additional AEs of vomiting , nausea , and trouble sleeping , insomnia .", "label": "", "metadata": {}, "score": "68.29373"}
{"text": "As a consequence , and because , ideally , all depressed patients should be treated until they are well and have attained an euthymic state , this may require longer and more intense trials ( 25 ) .", "label": "", "metadata": {}, "score": "68.2969"}
{"text": "Haddjeri N , Etievant A , Moore N , Miller S , et al .( 2009 ) .Electrophysiological study of the effects of the novel antidepressant Lu AA21004 on the rat 5-HT neuronal activity .", "label": "", "metadata": {}, "score": "68.32196"}
{"text": "Seroquel SR .Seroquel XR .Placebo Comparator : Placebo .Subjects received identical - appearing placebo tablets provided by Astra Zeneca ( 50 , 200 , and 300 mg designations ) .", "label": "", "metadata": {}, "score": "68.34912"}
{"text": "Additionally , there has been a tendency across studies to see increasing efficacy at higher doses ( Alvarez et al .2012;Henigsberg et al .2012;Baldwin et al .", "label": "", "metadata": {}, "score": "68.3668"}
{"text": "Up to 31 % of MDD patients may have insomnia [ 48 ] .In addition , insomnia is a common adverse effect of many antidepressants , e.g. , SSRIs [ 49 ] and SNRIs [ 50 ] .", "label": "", "metadata": {}, "score": "68.43542"}
{"text": "18 Studies have shown antipsychotic efficacy in the dose range of 300 mg / d to 800 mg / d .19 - 21 A recent study in an acute - care psychiatric hospital also found that the most common dose of quetiapine used as needed ( PRN ) was 50 mg for treating agitation or insomnia .", "label": "", "metadata": {}, "score": "68.49014"}
{"text": "[ 9 ] This comparatively large study gives a somewhat different view of the dose - res- ponse relationship of quetiapine .Dosages of que- tiapine XR 600 and 800 mg / day were numerically superior to 400 mg / day ( XR and IR ) and there appeared to be a statistically significant relationship between increasing dosage and therapeutic effect .", "label": "", "metadata": {}, "score": "68.51362"}
{"text": "b Four subjects had PET scans .Page 14 .62Sparshatt et al . gate markers .A series of trials reported during 2005 - 2006 , known as the CATIE ( Clinical Anti- psychotic Trials in Intervention Effectiveness ) trials,[45 - 47 ] compared the efficacy of several antipsy- chotics .", "label": "", "metadata": {}, "score": "68.516556"}
{"text": "Cutler AJ , Montgomery SA , Feifel D , et al .Extended release quetiapine fumarate monotherapy in major depressive disorder : a placebo- and duloxetine- controlled study .", "label": "", "metadata": {}, "score": "68.52519"}
{"text": "Robertson JB , Treosti L , Walker KD .Successful use of high dose quetiapine in a patient with a psychiatric disorder resis- tant to olanzapine .", "label": "", "metadata": {}, "score": "68.52763"}
{"text": "PubMed .Cutler AJ , Montgomery SA , Feifel D , Lazarus A , Astrom M , Brecher M : Extended release quetiapine fumarate monotherapy in major depressive disorder : a placebo- and duloxetine - controlled study .", "label": "", "metadata": {}, "score": "68.596924"}
{"text": "It has been estimated that an 80 % occu- pancy of the human SERT is achieved at standard doses of SSRIs or SNRIs ( Meyer , 2007 ) .", "label": "", "metadata": {}, "score": "68.59746"}
{"text": "Long - term efficacy , safety and tolerability , including maintenance of response are also important considerations in the selection of antipsychotics .Dichotomous outcomes from long - term trials , such as relapse and weight gain ex- ceeding a predefined threshold , will be of interest in further appraising the clinical profile of lurasidone .", "label": "", "metadata": {}, "score": "68.67394"}
{"text": "Kapur S , Zipursky R , Jones C , et al .A positron emission tomography study of quetiapine in schizophrenia : a prelim- inary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy .", "label": "", "metadata": {}, "score": "68.722694"}
{"text": "The primary efficacy analysis was repeated on observed cases ( OC ) data , using both an ANCOVA and a mixed model for repeated measurements ( MMRM ) .", "label": "", "metadata": {}, "score": "68.83706"}
{"text": "Eur Neuropsychopharmacol 1999 ; 9 : 259 - 64 .6 Wade A , Michael LO , Bang HK .Escitalopram 10 mg / day is effective and well tolerated in a placebo - controlled study in depres- sion in primary care .", "label": "", "metadata": {}, "score": "68.88994"}
{"text": "Response and Remission A significant difference was observed between escitalopram and citalopram in the response rates .The differ- ence between percentages of remitters in each treatment group grew larger as treatment progressed .", "label": "", "metadata": {}, "score": "68.90186"}
{"text": "There was no indication of increased QTc interval in either group .TABLE 4 presents changes in body weight , glucose and lipid data and the proportions of patients with clinically relevant shifts from normal in these parameters from randomization to treatment end in the fasting status confirmed safety population .", "label": "", "metadata": {}, "score": "68.903435"}
{"text": "A total of 320/409 ( 78.2 % ) patients completed the study : 152/209 quetiapine XR - treated and 168/200 placebo - treated patients .Treatment groups were generally well matched with respect to demographic and clinical characteristics at randomization and the SSRI or SNRI used ( TABLE 1 ) .", "label": "", "metadata": {}, "score": "68.90814"}
{"text": "The efficacy of quetiapine has also been com- pared with haloperidol,[19 ] risperidone[20,21 ] and chlorpromazine[22 ] in separate variable - dose studies .These trials ranged in duration from 6 weeks to 4 months , with dosages of all drugs titrated against patient response and tolerability .", "label": "", "metadata": {}, "score": "69.07542"}
{"text": "It might be argued , however , that restricting the dosage to 800 mg / day ( or even 1200 mg / day ) unfairly constrained clinicians in seeking to gain the optimal effect from the drug .", "label": "", "metadata": {}, "score": "69.08969"}
{"text": "This greater power suggests an important difference in effect between 400 mg / day and 600 or 800 mg/ day dosages ( the lowest dosage is less efficacious ) but not between 600 and 800 mg / day ( outcomes were nearly identical ) .", "label": "", "metadata": {}, "score": "69.09563"}
{"text": "These findings suggest that 450 mg / day is a more efficacious dos- age than 50 mg / day .The smaller study observed six subjects over an initial 6-week observation period of the above dos- ages , followed by a 52-week open treatment phase of dosages up to 800 mg / day .", "label": "", "metadata": {}, "score": "69.10604"}
{"text": "2007 ) .There has been a paucity of evidence regarding the treatment of bipolar II depression , and , in consequence , there are few consensus recommendations for the management of these patients ( Swartz and Thase 2011 ) .", "label": "", "metadata": {}, "score": "69.13841"}
{"text": "PubMed View Article .Breslau N , Roth T , Rosenthal L , Andreski P : Sleep disturbance and psychiatric disorders : a longitudinal epidemiological study of young adults .", "label": "", "metadata": {}, "score": "69.19024"}
{"text": "[ 33 ] 5 .Neuroimaging Studies 6 .Case Series and Cohort Studies Neuroimaging techniques such as positron emis- sion tomography ( PET ) and single photon emission computerized tomography ( SPECT ) have been ap- plied to the use of quetiapine in humans .", "label": "", "metadata": {}, "score": "69.23022"}
{"text": "CGI - S score ( mean dosage 438.5 mg / day ) [ n ] 4.81 ( 95 % CI 4.73 , 4.90 ) [ 259 ] 3.00 ( 95 % CI 2.88 , 3.11 ) [ 259 ] Baseline 6 wk 156 wk [ 23 ] phrenia .", "label": "", "metadata": {}, "score": "69.288956"}
{"text": "Depression is the prevailing phase of illness in patients with bipolar II disorder ( Judd et al .2003 ; Kupka et al .2007 ) .", "label": "", "metadata": {}, "score": "69.30217"}
{"text": "Kjelby E , Jorgensen HA , Kroken RA , Loberg EM , Johnsen E : Anti - depressive effectiveness of olanzapine , quetiapine , risperidone and ziprasidone : a pragmatic , randomized trial .", "label": "", "metadata": {}, "score": "69.31503"}
{"text": "Previous meta - analyses found that the remission rates of TCAs , SSRIs , and SNRIs were 44.1 , 37.7 and 31 - 55 % respectively [ 41 ] .", "label": "", "metadata": {}, "score": "69.34009"}
{"text": "Dose - Response Relationship of Quetiapine in Schizophrenia 59 A commentary article discussed clinical experi- ence with rapid dose escalation of quetiapine up to dosages of 400 mg / day by day 4 of treatment in patients with schizophrenia .", "label": "", "metadata": {}, "score": "69.363785"}
{"text": "2010 ; Thase et al .2006 ; Young et al .2010 ) .The prescribing information for quetiapine recommends appropriate clinical monitoring for alterations in lipids , including blood lipid testing at the beginning of and periodically during treatment ( Seroquel Prescribing Information 2012 ) .", "label": "", "metadata": {}, "score": "69.378784"}
{"text": "1 Patients with GAD experience impaired functioning , decreased work productivity , and increased healthcare utilization .Published guidelines recommend selective serotonin reuptake inhibitors ( SSRIs ) or serotonin - norepinephrine reuptake inhibitors ( SNRIs ) as first - line treatment for GAD .", "label": "", "metadata": {}, "score": "69.39941"}
{"text": "Results are shown in table IX .A further review by the same author discusses the importance of early intervention in treating schizo- 7 .Review Articles and Meta - Analysis There have been numerous review articles con-", "label": "", "metadata": {}, "score": "69.50956"}
{"text": "Both doses of Lu AA21004 resulted in a significant improvement Table 5 .Lu AA21004 for treatment of MDD597 .Page 10 .compared to placebo on the primary efficacy analysis .", "label": "", "metadata": {}, "score": "69.513306"}
{"text": "Secondary analyses reported nominal 5 % levels of significance .No confirmatory analyses were made for secondary variables other than Q - LES - Q percent maximum total score .", "label": "", "metadata": {}, "score": "69.550964"}
{"text": "View Article .Papakostas GI , Nelson JC , Kasper S , Moller HJ : A meta - analysis of clinical trials comparing reboxetine , a norepinephrine reuptake inhibitor , with selective serotonin reuptake inhibitors for the treatment of major depressive disorder .", "label": "", "metadata": {}, "score": "69.57156"}
{"text": "No patients withdrew due to weight change .No clinically relevant abnormalities in ECG values were found after administration of Lu AA21004 .Discussion This is the first double - blind , randomized , placebo- controlled study to evaluate the efficacy , safety and tolerability of Lu AA21004 in patients with MDD .", "label": "", "metadata": {}, "score": "69.58536"}
{"text": "PubMed View Article .Sanford M , Keating GM : Quetiapine : a review of its use in the management of bipolar depression .CNS Drugs 2012 , 26 ( 5 ) : 435 - 460 .", "label": "", "metadata": {}, "score": "69.64457"}
{"text": "Subjects will receive daily dosing at night with caplets matching the appearance of the active drug .However , caplets will not contain any active medication .", "label": "", "metadata": {}, "score": "69.65224"}
{"text": "5 ] The possibility that the licensed dosage range for quetiapine does not include optimal dosages for some patients has important consequences , both clinical and pharmacoeconomic .", "label": "", "metadata": {}, "score": "69.734955"}
{"text": "[51 ] These threshold dosages are also the dosages at which maximal effect is seen ; dosage increases provide no additional effect .Given the uniformity of the shape of anti- psychotic dose - response relationships , one might expect quetiapine to show similar properties .", "label": "", "metadata": {}, "score": "69.76849"}
{"text": "The pooled discontinuation rate due to adverse event was greater in the quetiapine group with an RR ( 95%CI ) of 2.90 ( 1.87 , 4.48 ) .", "label": "", "metadata": {}, "score": "69.77486"}
{"text": "The nonsignificant differences in this respect have been found in a number of meta - analyses of paroxetine [ 43 ] and duloxetine [ 44 ] and TCAs [ 10 ] for the treatment of MDD .", "label": "", "metadata": {}, "score": "69.859055"}
{"text": "Suppes T , Datto C , Minkwitz M , et al .Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression .", "label": "", "metadata": {}, "score": "69.86244"}
{"text": "Patients were contacted for a safety follow - up 4 wk after the completion visit .Down - taper medication was also offered to patients who withdrew .", "label": "", "metadata": {}, "score": "69.87917"}
{"text": "Montgomery SA : The under - recognized role of dopamine in the treatment of major depressive disorder .Int Clin Psychopharmacol 2008 , 23 ( 2 ) : 63 - 69 .", "label": "", "metadata": {}, "score": "69.906784"}
{"text": "The aim of this report is to apply NNT , NNH and LHH in order to appraise the lurasidone acute schizophrenia clin- ical trial data .", "label": "", "metadata": {}, "score": "69.92302"}
{"text": "Safety and tolerability .Adverse events .The overall incidence of AEs was 73.7 % and 60.0 % in the quetiapine XR + SSRI / SNRI and placebo + SSRI / SNRI groups , respectively .", "label": "", "metadata": {}, "score": "69.9256"}
{"text": "Overall JE , Gorham DR .The brief psychiatric rating scale .Simpson GM , Angus JWS .A rating scale for extrapyramidal side effects .", "label": "", "metadata": {}, "score": "69.940765"}
{"text": "Purdon SE , Malla A , Labelle A , et al .Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol .J Psychiatry Neurosci .", "label": "", "metadata": {}, "score": "69.947"}
{"text": "The prevalence of bipolar II disorder in clinical practice may well be underestimated .Temporally , depression usually precedes hypomania ( Berk et al .2007 ) .", "label": "", "metadata": {}, "score": "70.005066"}
{"text": "Entsuah AR , Rudolph RL , Chitra R : Effectiveness of venlafaxine treatment in a broad spectrum of depressed patients : a meta - analysis .", "label": "", "metadata": {}, "score": "70.05771"}
{"text": "PubMed .Cruz N , Sanchez - Moreno J , Torres F , Goikolea JM , Valenti M , Vieta E : Efficacy of modern antipsychotics in placebo - controlled trials in bipolar depression : a meta - analysis .", "label": "", "metadata": {}, "score": "70.1596"}
{"text": "Due to the balance of its efficacy benefit and risk of side effects , as the overall discontinuation rate shown , the acceptability of this agent is not more than placebo .", "label": "", "metadata": {}, "score": "70.16555"}
{"text": "Due to the balance of its efficacy benefit and risk of side effects , as the overall discontinuation rate shown , the acceptability of this agent is not more than placebo .", "label": "", "metadata": {}, "score": "70.16555"}
{"text": "PubMed View Article .Furukawa TA , McGuire H , Barbui C : Meta - analysis of effects and side effects of low dosage tricyclic antidepressants in depression : systematic review .", "label": "", "metadata": {}, "score": "70.182175"}
{"text": "Areberg J , Dragheim M , Brennum L , Stensb\u00f8l TB , et al .( 2009 ) .Lu AA21004 : efficacy at low serotonin transporter occupancy at clinically effective doses - from animal studies to depressed patients .", "label": "", "metadata": {}, "score": "70.194336"}
{"text": "The roles of different types of serotonin receptors in activation of the hypophyseal - testicular complex induced in mice by the presence of a female .", "label": "", "metadata": {}, "score": "70.20266"}
{"text": "2011 ) .While the debilitating effects of bipolar I disorder are well established , the burden imposed by bipolar II disorder is gaining increasing recognition ( Benazzi 2007 ; MacQueen and Young 2001 ; Valtonen et al .", "label": "", "metadata": {}, "score": "70.22012"}
{"text": "PubMed .Vazquez G , Tondo L , Baldessarini RJ : Comparison of antidepressant responses in patients with bipolar vs. unipolar depression : a meta - analytic review .", "label": "", "metadata": {}, "score": "70.24565"}
{"text": "Although average weight gain was only about 1 kg greater in the two groups receiving quetiapine , the proportions of patients in both arms gaining at least 7 % body weight was higher in both quetiapine arms ( Table 4 ) .", "label": "", "metadata": {}, "score": "70.27069"}
{"text": "Rickels K , Rynn M , Iyengar M , et al .Remission of generalized anxiety disorder : a review of the paroxetine clinical trials database .", "label": "", "metadata": {}, "score": "70.323654"}
{"text": "Some patients were excluded due to the use of a non - validated scale in France .596E. Alvarez et al . .Page 9 . baseline was seen in all treatment groups at all weeks .", "label": "", "metadata": {}, "score": "70.447655"}
{"text": "Using the more stringent criterion of remission , the percentages of remit- ters show a pattern similar to that for response but do not reach statistical significance .", "label": "", "metadata": {}, "score": "70.487274"}
{"text": "Patients repeatedly or severely nonadherent were discontinued at the investigator 's discretion .Concomitant treatment .Chloral hydrate ( 1 g ) , zaleplon ( 20 mg ) , zolpidem tartrate ( 10 mg ) , or zopiclone ( 7.5 mg ) were permitted twice weekly for insomnia up to day 14 ( except before study assessments ) .", "label": "", "metadata": {}, "score": "70.48889"}
{"text": "NNH for discontinuation due to an AE .Completion rates vs. placebo demonstrated a statistically significant advan- tage for lurasidone 80 and 160 mg / d , as well as for the active controls olanzapine and quetiapine extended - release .", "label": "", "metadata": {}, "score": "70.519135"}
{"text": "Citrome L. Adjunctive aripiprazole , olanzapine , or quetiapine for major depressive disorder : an analysis of number needed to treat , number needed to harm , and likelihood to be helped or harmed .", "label": "", "metadata": {}, "score": "70.52856"}
{"text": "Thase ME , Macfadden W , Weisler RH , Chang W , Paulsson B , Khan A , Calabrese JR : Efficacy of quetiapine monotherapy in bipolar I and II depression : a double - blind , placebo - controlled study ( the BOLDER II study ) .", "label": "", "metadata": {}, "score": "70.56877"}
{"text": "Page 2 .NNT and NNH can help quantify efficacy , safety and tolerability outcomes and place lurasidone into clinical perspec- tive .Advantages for lurasidone include a low propensity for weight gain and metabolic abnormalities .", "label": "", "metadata": {}, "score": "70.583755"}
{"text": "The generalizability of results from this study to the broad population of depressed patients , like most randomized controlled trials , is limited by the in- clusion and exclusion criteria .", "label": "", "metadata": {}, "score": "70.5959"}
{"text": "PubMed .Merikangas KR , Akiskal HS , Angst J , Greenberg PE , Hirschfeld RM , Petukhova M , Kessler RC : Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication .", "label": "", "metadata": {}, "score": "70.6322"}
{"text": "Many of these are general overviews of the various clinical trials using quetiapine , while others are pooled data and meta - analyses of the data presented in this article .", "label": "", "metadata": {}, "score": "70.663025"}
{"text": "Several cut - off values have been used to differentiate between moderate and severe depression .Snaith et al .( 16 ) first proposed a cut - off value of 35 on the MADRS as the definition of severe depression .", "label": "", "metadata": {}, "score": "70.66656"}
{"text": "Treatment .Following placebo run - in , patients were randomized ( 1:1 ratio using a computer - based system to generate the randomization list ) to quetiapine XR + SSRI / SNRI or placebo + SSRI / SNRI for 8 weeks .", "label": "", "metadata": {}, "score": "70.676025"}
{"text": "The most common AEs reported in the active treat- ment groups were nausea , headache , hyperhidrosis , and dry mouth .No possibly suicide - related AEs were found .", "label": "", "metadata": {}, "score": "70.69232"}
{"text": "A recent study exploring the use of quetiapine IR on a PRN basis for agitation or insomnia at an acute care psychiatric hospital , found that the mean dose used was 50 mg / d .", "label": "", "metadata": {}, "score": "70.73467"}
{"text": "KEYWORDS : clinical trial , phase 3 , anxiety disorders , sustained - release preparations , antipsychotics , treatment efficacy .Generalized anxiety disorder ( GAD ) is a chronic condition with low recovery rates and a high likelihood of recurrence .", "label": "", "metadata": {}, "score": "70.77739"}
{"text": "CNS Drugs 2008 ; 22 ( 1 ) Table II .Single fixed - dose studies , vs low - dose quetiapine Study design Subjects No .", "label": "", "metadata": {}, "score": "70.826515"}
{"text": "( + ) Schizophrenic symptomatology measured on 30-item Positive and Negative Syndrome Scale ( PANSS ) scale .Each symptom was rated on a severity scale from 1 - 7 .", "label": "", "metadata": {}, "score": "70.83872"}
{"text": "Remission rate , response rates , overall discontinuation rates , and discontinuation due to adverse events were also reported in all studies .Risk of bias within studies .", "label": "", "metadata": {}, "score": "70.85533"}
{"text": "J Clin Psychiatry 1994 ; 55 ( Suppl .A ) : 62 - 8 .3 Thase ME .Treatment of severe depression .J Clin Psychiatry 2000 ; 61 ( Suppl . 4 Keitner GI , Ryan CE , Miller IW et al .", "label": "", "metadata": {}, "score": "70.85922"}
{"text": "PubMed .Calabrese JR , Huffman RF , White RL , Edwards S , Thompson TR , Ascher JA , Monaghan ET , Leadbetter RA : Lamotrigine in the acute treatment of bipolar depression : results of five double - blind , placebo - controlled clinical trials .", "label": "", "metadata": {}, "score": "70.89823"}
{"text": "SNRI Duloxetine Mean dose b Treatment duration ( days ) c Venlafaxine Mean dose b Treatment duration ( days ) c .a All patients in the MITT population received an SSRI / SNRI ; one patient received escitalopram and venlafaxine prior to and at randomization .", "label": "", "metadata": {}, "score": "70.92199"}
{"text": "Further exploring the potential for medications such as quetiapine to promote impulse inhibition and emotional regulation may enhance the capacity for managing aggression in patients with psychosis .", "label": "", "metadata": {}, "score": "70.96739"}
{"text": "2010 ; Swartz and Thase 2011 ) .Among these agents is quetiapine , which is the only medication approved by the United States Federal Drug Administration for monotherapy of both bipolar I and II disorder depressive episodes ( Seroquel Prescribing Information 2012 ) .", "label": "", "metadata": {}, "score": "70.994"}
{"text": "Discussion .Our review found only three randomized , placebo - controlled trials of quetiapine carried out in adult patients with MDD .All studies had the same study designs .", "label": "", "metadata": {}, "score": "71.022385"}
{"text": "Comparative effective- ness of second - generation antipsychotics and haloperidol in acute schizophrenia .Br J Psychiatry 2006 ; 189 : 433 - 40 37 .", "label": "", "metadata": {}, "score": "71.034096"}
{"text": "PubMed .Mallinckrodt CH , Watkin JG , Liu C , Wohlreich MM , Raskin J : Duloxetine in the treatment of Major Depressive Disorder : a comparison of efficacy in patients with and without melancholic features .", "label": "", "metadata": {}, "score": "71.06868"}
{"text": "Simpson GM , Angus JWS .A rating scale for extrapyramidal side effects .Acta Psychiatr Scand Suppl .Barnes TR .A rating scale for drug - induced akathisia .", "label": "", "metadata": {}, "score": "71.10635"}
{"text": "11 , 12 , 39 Regarding the amelioration of psychopathology , the strongest treatment effect was for thought disorder ; this is the symptom subtype that most strongly distinguishes patients who are physically aggressive from those who are not , according to several studies .", "label": "", "metadata": {}, "score": "71.12613"}
{"text": "High degree of tolerability for monotherapy with high doses of quetiapine : a case report .J Clin Psychiatry 2002 ; 63 ( 11 ) : 1048 - 9 5 .", "label": "", "metadata": {}, "score": "71.13253"}
{"text": "Several lines of research suggest that quetiapine may have an antidepressant effect .Some clinical trials found that quetiapine reduced depressive symptoms considerably in schizophrenic patients [ 25 ] and bipolar depression [ 26 , 27 ] .", "label": "", "metadata": {}, "score": "71.15346"}
{"text": "AEs potentially related to somnolence ( MedDRA preferred terms : lethargy , sedation , sluggishness , and somnolence ) were reported by 35.9 % and 14.5 % of patients in the quetiapine XR + SSRI / SNRI and placebo + SSRI / SNRI groups , respectively .", "label": "", "metadata": {}, "score": "71.173225"}
{"text": "This makes it difficult to detect significant differences in clinical measures and response / remission rates between treatment groups .This analysis is exhaustive because all trials in which the maximum dose for escitalopram ( 20 mg ) was allowed are included in the pooled analysis .", "label": "", "metadata": {}, "score": "71.18444"}
{"text": "Timdahl K , Carlsson A , Stening G .An analysis of safety and tolerability data from controlled comparative studies of quetiapine in patients with schizophrenia , focusing on extrapyramidal symptoms .", "label": "", "metadata": {}, "score": "71.19902"}
{"text": "In January 2007 , we searched EMBASE and MEDLINE using the terms quetiapine , schizo- phrenia , dose , placebo , trial , efficacy and effective- ness .", "label": "", "metadata": {}, "score": "71.209045"}
{"text": "PubMed Central PubMed .Am J Psychiatry 2006 , 163 ( 2):232 - 9 . PubMed .Li CT , Bai YM , Huang YL , Chen YS , Chen TJ , Cheng JY , Su TP : Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder : cohort study .", "label": "", "metadata": {}, "score": "71.23953"}
{"text": "In total , 674 subjects were included , with a mean daily dose of 472.4 \u00b1 175.5 mg and a mean duration of exposure of 42.2 \u00b1 67.3 weeks .", "label": "", "metadata": {}, "score": "71.30738"}
{"text": "( 5 ) Over 2 million American adults -- about 1 percent of the population age 18 and older -- suffer from schizophrenia .Medications are important in the management of symptoms .", "label": "", "metadata": {}, "score": "71.42126"}
{"text": "Both vortioxetine doses were well tolerated .BACKGROUND :This study was conducted to explore the efficacy and tolerability of quetiapine extended release ( XR ) to treat psychosis and accompanying acute behavioral disturbance in hospitalized psychiatric patients .", "label": "", "metadata": {}, "score": "71.42933"}
{"text": "The incidence and severity of adverse events ( AEs ) , and AEs leading to withdrawal were recorded throughout the study .Serious AEs ( SAEs ) were recorded until 30 days after the last dose of study medication .", "label": "", "metadata": {}, "score": "71.46601"}
{"text": "Effectiveness studies using quetiapine in daily doses averaging between 565 and 653 mg revealed quetiapine to be somewhat less effective than some comparator drugs .Abstract .", "label": "", "metadata": {}, "score": "71.50449"}
{"text": "The most common AEs reported in the active treatment groups were nausea , headache , hyperhidrosis , and dry mouth .For Lu AA21004 , nausea ( 5 and 10 mg ) , hyper- hidrosis ( 10 mg ) , and vomiting ( 10 mg ) were the only AEs reported with an incidence statistically sig- nificantly higher than placebo .", "label": "", "metadata": {}, "score": "71.53524"}
{"text": "In this review , we examine the clinical and neuroimaging data relating to the use of quetiapine in acute exacerbations of schizophrenia .Fixed - dose efficacy studies of immediate - release ( IR ) quetiapine suggest dosages of quetiapine of 150 - 450 mg / day are more effective than placebo and no less effective than dosages of 600 or 750 mg / day .", "label": "", "metadata": {}, "score": "71.55309"}
{"text": "PubMed .Thase ME , Jonas A , Khan A , Bowden CL , Wu X , McQuade RD , Carson WH , Marcus RN , Owen R : Aripiprazole monotherapy in nonpsychotic bipolar I depression : results of 2 randomized , placebo - controlled studies .", "label": "", "metadata": {}, "score": "71.55432"}
{"text": "Response and remission seem less likely to be achieved for patients suffering from severe depression than for those with milder degrees of the disorder ( 3 ) .", "label": "", "metadata": {}, "score": "71.55789"}
{"text": "In these studies , the duration of the treatment ranged from 4 to 12 weeks , with a majority lasting 6 weeks ( 29 ) .", "label": "", "metadata": {}, "score": "71.55902"}
{"text": "CORRESPONDENCE : Arifulla Khan , MD Department of Psychiatry and Behavioral Sciences Duke Medical Hospital Northwest Clinical Research Center 1951 152nd Place NE , Suite 200 Bellevue , WA 98007 USA E - MAIL : akhan@nwcrc.net The primary objective of this study is to test the hypothesis that a SSRI plus quetiapine SR ( Seroquel SR ) will result in superior early ( first 1 - 3 weeks of treatment ) stabilization of panic symptoms in SSRI - resistant , comorbid Panic Disorder patients versus a SSRI plus placebo .", "label": "", "metadata": {}, "score": "71.66275"}
{"text": "Other Scales : CGI - I and CGI - S On both the CGI - I and CGI - S scales , patients showed a significant improvement at treatment endpoint in favour of escitalopram when compared with citalopram treatment .", "label": "", "metadata": {}, "score": "71.67646"}
{"text": "Included were the following interventions : fixed doses of lurasidone 20 , 40 , 80 , 120 and 160 mg / d ; haloperidol 10 mg / d ; olanzapine 15 mg / d ; quetiapine extended - release 600 mg / d ; placebo .", "label": "", "metadata": {}, "score": "71.70191"}
{"text": "Included were the following interventions : fixed doses of lurasidone 20 , 40 , 80 , 120 and 160 mg / d ; haloperidol 10 mg / d ; olanzapine 15 mg / d ; quetiapine extended - release 600 mg / d ; placebo .", "label": "", "metadata": {}, "score": "71.70191"}
{"text": "Kapur S , Zipursky R , Jones C , et al .Relationship between dopamine D2 occupancy , clinical response , and side effects : a double - blind PET study of first - episode schizophrenia .", "label": "", "metadata": {}, "score": "71.78473"}
{"text": "PubMed .Vieta E , Calabrese JR , Goikolea JM , Raines S , Macfadden W : Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid - cycling disease course : a randomized , double - blind , placebo - controlled study .", "label": "", "metadata": {}, "score": "71.82625"}
{"text": "PubMed .Seroquel Prescribing Information : Prescribing information .Wilmington , DE : AstraZeneca Pharmaceuticals LP ; 2012 .Simon GE , Bauer MS , Ludman EJ , Operskalski BH , Unutzer J : Mood symptoms , functional impairment , and disability in people with bipolar disorder : specific effects of mania and depression .", "label": "", "metadata": {}, "score": "71.86948"}
{"text": "The selectivity ratio for serotonin uptake over dopamine uptake is 25,000 for escitalopram and 10,000 for citalopram .This implies that escitalopram , like citalopram , will not be associated with significant adverse side effects caused by enhanced catecholaminergic ( noradrenaline and dopamine ) activity due to reuptake inhibition .", "label": "", "metadata": {}, "score": "71.87059"}
{"text": "Kasper S , Brecher M , Fitton L , et al .Maintenance of long - term efficacy and safety of quetiapine in the open - label treatment of schizophrenia .", "label": "", "metadata": {}, "score": "71.87532"}
{"text": "The data from the ITT patients were evaluated by using the more conservative LOCF method for the primary ana- lyses , including response and remission .", "label": "", "metadata": {}, "score": "71.916214"}
{"text": "Am J Psychiatry 1992 ; 149 : 93 - 9 . 5 Montgomery SA , Lecrubier Y. Is severe depression a separate indication ?ECNP Consensus Meeting September 20 , 1996 , Amsterdam .", "label": "", "metadata": {}, "score": "72.01519"}
{"text": "PubMed .Weisler RH , Nolen WA , Neijber A , Hellqvist A , Paulsson B : Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder ( trial 144 : a randomized controlled study ) .", "label": "", "metadata": {}, "score": "72.02057"}
{"text": "Suppes T , Hirschfeld RM , Vieta E , Raines S , Paulsson B : Quetiapine for the treatment of bipolar II depression : analysis of data from two randomized , double - blind , placebo - controlled studies .", "label": "", "metadata": {}, "score": "72.0295"}
{"text": "View Article .Amit BH , Weizman A : Antidepressant treatment for acute bipolar depression : an update .Depress Res Treat 2012 , 2012 : 684725 .", "label": "", "metadata": {}, "score": "72.03042"}
{"text": "This meta - analysis aimed to determine the efficacy , acceptability and tolerability of quetiapine treatment for major depressive disorder ( MDD ) .Only the randomized controlled trials ( RCTs ) comparison between quetiapine and placebo were included .", "label": "", "metadata": {}, "score": "72.12693"}
{"text": "PubMed View Article .Bakken GV , Rudberg I , Molden E , Refsum H , Hermann M : Pharmacokinetic variability of quetiapine and the active metabolite N - desalkylquetiapine in psychiatric patients .", "label": "", "metadata": {}, "score": "72.15579"}
{"text": "Also of note here is the observation that analyses of pooled data have failed to demonstrate advantages to higher dosages .It is possible ( although unlikely given the results of the two studies conducted ) that dos- ages of , say , 1000 or 2000 mg / day provide better efficacy than lower licensed dosages .", "label": "", "metadata": {}, "score": "72.1606"}
{"text": "Patients who have started a new course of psychotherapy ( CBT , supportive , insight - oriented ) within 1 month of the screening visit .", "label": "", "metadata": {}, "score": "72.178375"}
{"text": "Am J Psychiatry 2011;168(9):957 - 967 .Citrome L. Lurasidone for schizophrenia : a review of the efficacy and safety profile for this newly approved second - generation antipsychotic .", "label": "", "metadata": {}, "score": "72.22094"}
{"text": "[ 1 ] Higher than maximum dosages have also been used in refractory schizophrenia[2 ] and non-schizophrenic disorders .[ 3 ] Such dosages are report- edly well tolerated,[2,4 ] although unexpected adverse events are occasionally reported .", "label": "", "metadata": {}, "score": "72.22774"}
{"text": "Peuskens J , Link CG .A comparison of quetiapine and chlor- promazine in the treatment of schizophrenia .Acta Psychiatr Scand 1997 ; 96 ( 4 ) : 265 - 73 23 .", "label": "", "metadata": {}, "score": "72.23213"}
{"text": "Lohoff FW , Etemad B , Mandos LA , et al .Ziprasidone treatment of refractory generalized anxiety disorder : a placebo - controlled , double - blind study .", "label": "", "metadata": {}, "score": "72.258896"}
{"text": "Using rating scales that provide a defining cut - off point is more accepted , albeit arbitrary , as severe depression is considered to lie at one extreme of a continuum of severity .", "label": "", "metadata": {}, "score": "72.260086"}
{"text": "Lancet 2009 , 373 ( 9665 ) : 746 - 758 .PubMed View Article .Nutt DJ : The role of dopamine and norepinephrine in depression and antidepressant treatment .", "label": "", "metadata": {}, "score": "72.30101"}
{"text": "Clarifying the mode of action and the interplay of serotonin receptors with pharmacological agents should help antidepressant mechanisms and typical side effects to be better understood . \"", "label": "", "metadata": {}, "score": "72.4324"}
{"text": "Conclusion : It is necessary to do more studies so as to better assess and much more powerful than the evidence for the use of this drug in the treatment of depression .", "label": "", "metadata": {}, "score": "72.44056"}
{"text": "23 Cryan JF , Markou A , Lucki I. Assessing antidepressant activity in rodents : recent developments and future needs .Trends Pharmacol Sci 2002 ; 23 : 238 - 45 .", "label": "", "metadata": {}, "score": "72.49794"}
{"text": "\" Both analyses show that SEROQUEL XR was superior to placebo , demonstrating it is another viable treatment option for schizophrenia , \" said Charles Schulz , MD , Professor and Head , Department of Psychiatry , University of Minnesota Medical School . \" These analyses are significant because SEROQUEL XR may provide greater convenience and simplicity in patient treatment plans . \"", "label": "", "metadata": {}, "score": "72.51291"}
{"text": "This study suggests that higher than recommended quetiapine dosages could be more effective in some patients . \"\" Examples of these differences include disease severity , chronicity , and the presence of comorbid psychiatric and medical conditions .", "label": "", "metadata": {}, "score": "72.54254"}
{"text": "29 Hence , monitoring for these side effects is warranted .There also were low levels of observed akathisia or movement side effects that did not increase significantly following enrollment in the study .", "label": "", "metadata": {}, "score": "72.598656"}
{"text": "It should also be noted that the probability levels were not adjusted for multiplicity .Categorical changes , such as MADRS response and remission , were analyzed with the Cochran - Mantel - Haenszel test .", "label": "", "metadata": {}, "score": "72.682556"}
{"text": "Extended - release quetiapine fumarate ( quetiapine XR ) as adjunctive therapy in patients with generalized anxiety disorder and a history of inadequate treatment response : A randomized , double - blind study .", "label": "", "metadata": {}, "score": "72.71857"}
{"text": "Among patients with bipolar II disorder , the risk of suicide , comorbidity , and role impairment is generally comparable with that of bipolar I disorder ( Angst et al .", "label": "", "metadata": {}, "score": "72.753525"}
{"text": "All tests were two - sided .Results of statistical analyses were considered to be significant when the p - value was ?RESULTS Study Population Patient baseline characteristics are presented in Table2 .", "label": "", "metadata": {}, "score": "72.78288"}
{"text": "Current practice in managing aggression in acute psychiatry often involves administering atypical antipsychotics , often with benzodiazepines as adjuncts . 8 The antipsychotic may then be continued as a primary treatment for the underlying psychotic disorder .", "label": "", "metadata": {}, "score": "72.90886"}
{"text": "Official Title : .An 8-week , Randomized , Double - Blind , Placebo - Controlled Trial of Seroquel SR Co - administration for SSRI - Resistant , Comorbid Panic Disorder .", "label": "", "metadata": {}, "score": "72.94595"}
{"text": "Limitations .Variety of quetiapine XR doses and the small number of RCTs were key limitations of this meta - analysis .Conclusions .Based on the limited evidence obtained from three RCTs , quetiapine XR is effective for adult patients with MDD .", "label": "", "metadata": {}, "score": "72.955696"}
{"text": "He is a Lead Investigator for EMBOLDEN Study ( AstraZeneca ) , BCI Neuroplasticity study , and Aripiprazole Mania Study .Also , he is an investigator which initiated studies from AZ , Eli Lilly , Wyeth .", "label": "", "metadata": {}, "score": "73.1338"}
{"text": "Patients unable to tolerate the higher dose returned to 150 mg / d at any time at the investigator 's discretion .Patients continued to receive the same SSRI or SNRI at the same dose as at enrollment throughout the study .", "label": "", "metadata": {}, "score": "73.14503"}
{"text": "Arvanitis LA , Miller BG .Multiple fixed doses of \" Seroquel \" ( quetiapine ) in patients with acute exacerbation of schizophrenia : a comparison with haloperidol and placebo .", "label": "", "metadata": {}, "score": "73.145294"}
{"text": "The primary endpoint was assessed using the Positive and Negative Syndrome Scale ( PANSS)(+ ) .In the study , SEROQUEL XR was generally well - tolerated .", "label": "", "metadata": {}, "score": "73.1526"}
{"text": "Controversies in the diagnosis and treatment of severe depression .J Clin Psychiatry 1996 ; 57 : 554 - 61 .27 Nierenberg AA .The treatment of severe depression : Is there an efficacy gap between SSRI and TCA antidepressant generations ?", "label": "", "metadata": {}, "score": "73.22946"}
{"text": "J Clin Psychiatry 2005 , 66 ( 1):111 - 21 .PubMed .Calabrese JR , Keck PE Jr , Macfadden W , Minkwitz M , Ketter TA , Weisler RH , Cutler AJ , McCoy R , Wilson E , Mullen J : A randomized , double - blind , placebo - controlled trial of quetiapine in the treatment of bipolar I or II depression .", "label": "", "metadata": {}, "score": "73.262024"}
{"text": "Neuroimaging studies Study design and method Subjects No . 27 ( 6 - 54 ) at 12 h 7.2 at 26 ha 29 days .diagnosis of Day 90 : 60 SPECT scan days 14 and 90 schizophrenia CGI NA Continued next page .", "label": "", "metadata": {}, "score": "73.281746"}
{"text": "No relevant , unpublished study meeting the inclusion criteria was identified .Study characteristics .The study periods of the three trials ranged from 8 to 11 weeks .", "label": "", "metadata": {}, "score": "73.3465"}
{"text": "Page 4 .The change from baseline to each visit in all the secondary efficacy variables , except response and re- mission , was analysed using an ANCOVA , adjusting for baseline score , site , and treatment , using both OC and LOCF data .", "label": "", "metadata": {}, "score": "73.35554"}
{"text": "World J Biol Psychiatry 2010 , 11 ( 2):81 - 109 .PubMed .Gustafsson U , Fajutrao L : Effect of quetiapine on functioning and quality of life in bipolar depression [ abstract].", "label": "", "metadata": {}, "score": "73.38809"}
{"text": "Dosages of IR quetiapine averaging between 254 and 525 mg / day have been shown to be equivalent in efficacy to standard dosages of conventional and other atypical antipsychotics .", "label": "", "metadata": {}, "score": "73.3941"}
{"text": "Dosages of IR quetiapine averaging between 254 and 525 mg / day have been shown to be equivalent in efficacy to standard dosages of conventional and other atypical antipsychotics .", "label": "", "metadata": {}, "score": "73.3941"}
{"text": "However , not all samples could be confirmed as fasted despite there being an 8-hour interval since the last meal , as patients could have had caloric intake .", "label": "", "metadata": {}, "score": "73.54127"}
{"text": "Baldwin DS , Anderson IM , Nutt DJ , et al .Evidence - based guidelines for the pharmacological treatment of anxiety disorders : recommendations from the British Association for Psychopharmacology .", "label": "", "metadata": {}, "score": "73.57719"}
{"text": "A review article , based on a PubMed search to obtain all articles related to high - dose quetiapine use , discussed the high dosages of quetiapine used in clinical practice .", "label": "", "metadata": {}, "score": "73.66305"}
{"text": "This six - week , double - blind , randomized , placebo - controlled study investigated the efficacy and safety of once - daily SEROQUEL XR .", "label": "", "metadata": {}, "score": "73.6693"}
{"text": "Differing provisions from the publisher 's actual policy or licence agreement may be applicable .Escitalopram has demonstrated efficacy in the treatment of major depressive disorder ( Einarson , 2004 ; Llorca et al . , 2005 ; Moore et al . , 2005 ) , and its metabolite N - desmethylescitalopram has also been shown to be active ( Tatsumi et al . , 1997 ) .", "label": "", "metadata": {}, "score": "73.77265"}
{"text": "Eligible studies were randomized , placebo - controlled trials of quetiapine monotherapy carried out in adults with MDD and presenting endpoint outcomes relevant to : i ) depression severity , ii ) response rate , iii ) overall discontinuation rate , or iv ) discontinuation rate due to adverse events .", "label": "", "metadata": {}, "score": "74.00711"}
{"text": "The efficacy , safety , and tolerability of Lu AA21004 vs. placebo using venlafaxine XR as active reference in patients with DSM - IV - TR major depressive disorder ( MDD ) were evaluated .", "label": "", "metadata": {}, "score": "74.086"}
{"text": "Prog Neuropsychopharmacol Biol Psychiatry .Scharre DW , Chang SI .Cognitive and behavioral effects of quetiapine in Alzheimer disease patients .Alzheimer Dis Assoc Disord .", "label": "", "metadata": {}, "score": "74.18193"}
{"text": "Measures of efficacy were not reported other than numbers of patients still taking quetiapine at each timepoint .Single Fixed - Dose Study One study used a single fixed - dose of quetiapine compared with a fixed dose of haloperidol .", "label": "", "metadata": {}, "score": "74.2383"}
{"text": "MADRS , HAM - D , HAM - A , CGI - S , CGI - I , PSQI , SAS , BARS , CSFQ , Q - LES - Q , 18-item TDSS scale .", "label": "", "metadata": {}, "score": "74.25469"}
{"text": "MADRS , HAM - D , HAM - A , CGI - S , CGI - I , PSQI , SAS , BARS , CSFQ , Q - LES - Q , 18-item TDSS scale .", "label": "", "metadata": {}, "score": "74.25469"}
{"text": "A rule of thumb is that a single digit NNT vs. pla- cebo for an efficacy measure suggests that the intervention has potentially useful advantages , and that double digit or higher NNHs vs. placebo for adverse outcomes indicate that the intervention is potentially tolerable .", "label": "", "metadata": {}, "score": "74.26279"}
{"text": "For some drugs the slope is nearly vertical , such that once a threshold dosage is reached almost all of the clinical effect is seen ( examples include parace- tamol [ acetaminophen ] and thiazide diuretics ) .", "label": "", "metadata": {}, "score": "74.30612"}
{"text": "Horacek J , Bubenikova - Valesova V , Kopecek M , Palenicek T , Dockery C , Mohr P , Hoschl C : Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia .", "label": "", "metadata": {}, "score": "74.326614"}
{"text": "PubMed .Bipolar Disord 2013 , 15 ( 1):1 - 44 .PubMed .Young RC , Biggs JT , Ziegler VE , Meyer DA : A rating scale for mania : reliability , validity and sensitivity .", "label": "", "metadata": {}, "score": "74.40709"}
{"text": "Chengappa KN , Goldstein JM , Greenwood M , et al .A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia .", "label": "", "metadata": {}, "score": "74.41345"}
{"text": "CNS Spectr .Khan A , Khan S , Brown WA .Are placebo controls necessary to test new antidepressants and anxiolytics ?Int J Neuropsychopharmacol .", "label": "", "metadata": {}, "score": "74.57895"}
{"text": "The incidence of potentially clinically significant ( PCS ) values was generally low and evenly distributed among the treatment groups for vital signs , weight or clinical laboratory values , and no patients withdrew due to a PCS value .", "label": "", "metadata": {}, "score": "74.580925"}
{"text": "Older age was also associated with higher concentrations of escitalopram .[ Show abstract ] [ Hide abstract ] ABSTRACT : The aim of this review was to assess the clinical relevance of the relative antidepressant efficacy of escitalopram and citalopram by meta - analysis .", "label": "", "metadata": {}, "score": "74.58783"}
{"text": "REFERENCES 1 American Psychiatric Association .Practice guidelines for major depressive disorder in adults .Am J Psychiatry 1993 ; 150 ( Suppl .4 ) : S1-S26 . 2 Feighner JP .", "label": "", "metadata": {}, "score": "74.60516"}
{"text": "\" [ Show abstract ] [ Hide abstract ] ABSTRACT : Rationale Vortioxetine has reduced depressive symptoms in adults with major depressive disorder ( MDD ) in multiple clinical trials .", "label": "", "metadata": {}, "score": "74.62915"}
{"text": "Vital signs and body weight were recorded at enrollment and all subsequent visits .Simpson - Angus Scale ( SAS ) 25 and Barnes Akathisia Scale ( BAS ) 26 total scores were assessed at randomization and weeks 2 , 4 , 6 , and 8 .", "label": "", "metadata": {}, "score": "74.71236"}
{"text": "PubMed View Article .Furukawa T , McGuire H , Barbui C : Low dosage tricyclic antidepressants for depression .Cochrane Database Syst Rev 2003 , ( 3 ) :", "label": "", "metadata": {}, "score": "74.714455"}
{"text": "The treating psychiatrist was responsible for determining the treatment regimen .Concomitant use of a benzodiazepine , benztropine , or another sedating antipsychotic on a PRN basis was permitted .", "label": "", "metadata": {}, "score": "74.71654"}
{"text": "CNS Drugs 2008 ; 22 ( 1 ) .Page 20 .68 Sparshatt et al .34 .Tauscher J , Kufferle B , Asenbaum S , et al .", "label": "", "metadata": {}, "score": "74.72461"}
{"text": "Scales The most widely used scales for measurement of antidepres- sant effects are the MADRS ( 14 ) , the 17-item Hamilton rating scale for depression ( HAM - D17 ) ( 15 ) , and the Clinical Global Impression of Improvement and Severity ( CGI - I and CGI - S ) scales .", "label": "", "metadata": {}, "score": "74.74492"}
{"text": "PubMed .Young AH , McElroy SL , Olausson B , Paulsson B : A randomised , placebo - controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder .", "label": "", "metadata": {}, "score": "74.77453"}
{"text": "The principal statistical soft- ware used was SAS1version 9.1 ( SAS Institute Inc. , USA ) .Tolerability assessments Each patient was asked a non - leading question ( such as , ' how do you feel ? ' ) at each visit , starting at baseline .", "label": "", "metadata": {}, "score": "74.80295"}
{"text": "Yudofsky SC , Silver JM , Jackson W , et al .The Overt Aggression Scale for the objective rating of verbal and physical aggression .", "label": "", "metadata": {}, "score": "74.82214"}
{"text": "We used quetiapine XR tablets provided by Astra Zeneca ( 50 , 200 , and 300 mg designations ) .Drug : quetiapine XR .Subjects will receive daily dosing at night , with a flexible dosing schedule , 50 - 400 mg .", "label": "", "metadata": {}, "score": "74.88792"}
{"text": "23This suggests a possible direct effect of quetiapine on calming agitated or hostile behavior .The high affinity of quetiapine for serotonin receptors may offer a potential mechanism for this direct calming effect .", "label": "", "metadata": {}, "score": "74.93157"}
{"text": "One important observa- tion , however , is that high dosages seem to be well tolerated , indicating that tolerability is unlikely to be a constraining influence on dosages in clinical trials .", "label": "", "metadata": {}, "score": "74.935776"}
{"text": "European Neuropsychopharmacology 18 , 623 - 627 .Meyer JH ( 2007 ) .Imaging the serotonin transporter during major depressive disorder and antidepressant treatment .", "label": "", "metadata": {}, "score": "74.97079"}
{"text": "\" Eligible patients were adults aged between 18 and 75 years with a diagnosis of schizophrenia ( all studies ) or schizoaffective disorder ( Citrome et al .", "label": "", "metadata": {}, "score": "74.99431"}
{"text": "OAS : Overt Aggression Scale .Adverse events .During the 8-day study period , 2 participants ( 12.5 % ) reported sedation , 1 reported slurred speech , and 2 ( 12.5 % ) reported constipation .", "label": "", "metadata": {}, "score": "75.0097"}
{"text": "Magalhaes PV , Dean OM , Bush AI , Copolov DL , Malhi GS , Kohlmann K , Jeavons S , Schapkaitz I , Anderson - Hunt M , Berk M : N - acetyl cysteine add - on treatment for bipolar II disorder : a subgroup analysis of a randomized placebo - controlled trial .", "label": "", "metadata": {}, "score": "75.05058"}
{"text": "In conclusion , this study clearly shows consistent results in terms of efficacy in favour of escitalopram compared with citalopram , two effective antidepressant treatments with simi- lar safety profiles .", "label": "", "metadata": {}, "score": "75.098694"}
{"text": "( 6 ) National Alliance for the Mentally Ill : About Mental .Illness / Schizophrenia fact sheet .Reviewed by Kenneth Duckworth , M.D. : . February 2007 .", "label": "", "metadata": {}, "score": "75.108894"}
{"text": "Mullen J , Jibson MD , Sweitzer D. A comparison of the relative safety , efficacy , and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disor- ders : the quetiapine experience with safety and tolerability ( QUEST ) study .", "label": "", "metadata": {}, "score": "75.119995"}
{"text": "The comparable design of the BOLDER and EMBOLDEN trials facilitated a pooling of the data for patients with bipolar II depression data to increase the power of the statistical analyses .", "label": "", "metadata": {}, "score": "75.13953"}
{"text": "Escitalopram has at least comparable efficacy to available serotonin - norepinephrine reuptake inhibitors , venlafaxine XR and duloxetine , and may offer some tolerability advantages over these agents .", "label": "", "metadata": {}, "score": "75.162415"}
{"text": "A ' high - dose ' theory of quetiapine activity has developed , leading many prescribers to disregard the formal upper limit of the quetiapine dosage range ( 750 or 800 mg / day , depending on local labelling ) .", "label": "", "metadata": {}, "score": "75.17186"}
{"text": "PubMed Central PubMed .Gao K , Tolliver BK , Kemp DE , Verduin ML , Ganocy SJ , Bilali S , Brady KT , Shim SS , Findling RL , Calabrese JR : Differential interactions between comorbid anxiety disorders and substance use disorder in rapid cycling bipolar I or II disorder .", "label": "", "metadata": {}, "score": "75.17337"}
{"text": "As a result , escitalopram is more selective than the other SSRIs in clinical use ( 24 ) .The selectivity ratio for serotonin uptake over noradrenaline uptake , defined as the ratio between affinity for the transporters , is 7100 for escita- lopram and 3900 for citalopram .", "label": "", "metadata": {}, "score": "75.293495"}
{"text": "2 This , in turn , may increase the risk of injury to patients and others , including clinicians .3 The experience of confusion or thought disorder also can increase the likelihood of ABDs or aggression .", "label": "", "metadata": {}, "score": "75.31301"}
{"text": "2005 ; Trivedi et al .2006 ) .The analysis of withdrawal rates in patients treated with Lu AA21004 indicates a better tolerability profile com- pared to the active reference , venlafaxine .", "label": "", "metadata": {}, "score": "75.35228"}
{"text": "J Clin Psychiatry .Hamilton M .The assessment of anxiety states by rating .Br J Med Psychol .Guy W .Clinical Global Impressions .", "label": "", "metadata": {}, "score": "75.38098"}
{"text": "Patients with comorbid major depression , dysthymia or other anxiety problems are eligible to participate as well .Exclusion criteria : .Any DSM - IV TR Axis I disorder not mentioned in the inclusion requirements .", "label": "", "metadata": {}, "score": "75.38515"}
{"text": "Bandelow B , Zohar J , Hollander E , et al ; WFSBP Task Force on Treatment Guidelines for Anxiety .Obsessive - Compulsive and Post - Traumatic Stress Disorders .", "label": "", "metadata": {}, "score": "75.41885"}
{"text": "J Clin Psychopharmacol 1996 ; 16 ( 2 ) : 158 - 69 19 .Copolov DL , Link CG , Kowalcyk B. A multicentre , double- blind , randomized comparison of quetiapine ( ICI 204,636 , ' Seroquel ' ) and haloperidol in schizophrenia .", "label": "", "metadata": {}, "score": "75.41915"}
{"text": "Hence , SERT blockade by SSRIs evokes a series of negative feedback mechanisms that attenuate the increase in extracellular ( synaptic ) concentration of 5-HT , including the acti- vation of 5-HT1Aand 5-HT1Bautoreceptors on sero- tonergic neurons ( Artigas et al .", "label": "", "metadata": {}, "score": "75.42738"}
{"text": "Depressive symptoms in bipolar disorder have a substantial impact on patients ' quality of life and their ability to function in everyday activities ( Rosa et al .", "label": "", "metadata": {}, "score": "75.44705"}
{"text": "Rosa AR , Reinares M , Michalak EE , Bonnin CM , Sole B , Franco C , Comes M , Torrent C , Kapczinski F , Vieta E : Functional impairment and disability across mood states in bipolar disorder .", "label": "", "metadata": {}, "score": "75.47809"}
{"text": "The benefits of escitalopram compared with citalopram are demonstrated both in terms of magnitude of effect and time of onset of action .The evidence clearly supports the use of escitalopram as a legitimate first- line treatment for MDDs .", "label": "", "metadata": {}, "score": "75.660675"}
{"text": "Methods .The authors searched such clinical trials carried out between 1991 and February 2012 .Eligibility criteria .The included studies were randomized , placebo - controlled trials of quetiapine monotherapy in adults ( 18 - 65 years old ) with MDD .", "label": "", "metadata": {}, "score": "75.67247"}
{"text": "Quetiapine treatment resulted in significant improvements in the symptoms of anxiety in the current analysis among this larger population with bipolar II depression , the majority of whom had mild - to - moderate anxiety at baseline .", "label": "", "metadata": {}, "score": "75.68841"}
{"text": "We selected for review those reports describing the clinical evaluation of quetiapine in acute exacerbations of schizophrenia .In July 2007 , the search was repeated and AstraZeneca in the UK was contacted to confirm that our search had re- vealed all relevant reports published in any form .", "label": "", "metadata": {}, "score": "75.724655"}
{"text": "The Journal of Mental Health Training Education and Practice .Trauer T , Hamilton B , Rogers C , et al .Evaluation of the effect of a structured intervention for the management of behavioural disturbance on the level of seclusion in an acute psychiatric inpatient ward .", "label": "", "metadata": {}, "score": "75.72524"}
{"text": "Patients were then randomized to que- tiapine 600 mg / day or haloperidol 20 mg / day for 8 weeks .Study design and exclusion criteria are The effect of quetiapine on cognitive and func- tional improvement was compared with convention- al antipsychotics in 40 outpatients with schizo- phrenia .", "label": "", "metadata": {}, "score": "75.76808"}
{"text": "Measured mean striatal D2 occupancies range from 2 % at 150 mg / day[30 ] to 62 % at 750 mg / day .[ 31 ] In the latter study , responders had significantly higher mean peak occupancies ( 65.9 % ) than nonresponders ( 60.3 % ) .", "label": "", "metadata": {}, "score": "75.80574"}
{"text": "Table 1 provides an outline of the number of subjects in each arm for each of the six clini- cal trials included in this report .", "label": "", "metadata": {}, "score": "75.81787"}
{"text": "I and II ( Calabrese et al .2005 ; Thase et al .2006 ) .These findings were subsequently confirmed in the similarly designed EMBOLDEN ( Efficacy of Monotherapy Seroquel in BipOLarDepressioN ) I and II trials ( McElroy et al .", "label": "", "metadata": {}, "score": "75.88959"}
{"text": "Tignol J , Stoker MJ , Dunbar GC : Paroxetine in the treatment of melancholia and severe depression .Int Clin Psychopharmacol 1992 , 7 ( 2 ) : 91 - 94 .", "label": "", "metadata": {}, "score": "75.95897"}
{"text": "Quetiapine was associated with a reduced risk of any mood event or depressive relapse compared with placebo ( Young et al .2012 ) , suggesting that it is an efficacious treatment in both the short and long term in patients with bipolar II depression .", "label": "", "metadata": {}, "score": "76.00123"}
{"text": "PubMed .Br J Psychiatry 2006 , 189 : 20 - 5 .PubMed .Perugi G , Angst J , Azorin JM , Bowden C , Vieta E , Young AH : The bipolar - borderline personality disorders connection in major depressive patients .", "label": "", "metadata": {}, "score": "76.01809"}
{"text": "PubMed Central PubMed .Angst J , Gamma A , Azorin JM , Bowden CL , Perugi G , Vieta E , Young AH : Evidence - based efforts to re - define bipolar disorders .", "label": "", "metadata": {}, "score": "76.09239"}
{"text": "Quetiapine XR was generally well - tolerated .Important limitations were the small sample size , and the relatively low average dose of quetiapine XR used .", "label": "", "metadata": {}, "score": "76.10129"}
{"text": "Data analysis was conducted by Standardized Mean Differences ( SMD ) for Mont - gomery - \u00c5sberg Depression Rating Scale ( MADRS ) , and Odds Ratio ( OR ) for adverse events .", "label": "", "metadata": {}, "score": "76.13444"}
{"text": "270 ESCITALOPRAM IN SEVERE DEPRESSION \u00aa 2005 Blackwell Publishing Ltd Int J Clin Pract , March 2005 , 59 , 3 , 268 - 275 .", "label": "", "metadata": {}, "score": "76.15451"}
{"text": "PubMed .Mallinckrodt CH , Prakash A , Andorn AC , Watkin JG , Wohlreich MM : Duloxetine for the treatment of major depressive disorder : a closer look at efficacy and safety data across the approved dose range .", "label": "", "metadata": {}, "score": "76.156204"}
{"text": "Drug Saf .DeVane CL , Nemeroff CB .Clinical pharmacokinetics of quetiapine : an atypical antipsychotic .Clin Pharmacokinet .Kasper S , M\u00fcller - Spahn F .", "label": "", "metadata": {}, "score": "76.258644"}
{"text": "These results support those shown by the larger and more informative trial .[ 12 ] 2 .Flexible Dosage within Fixed - Dose Range Studies An alternative to rigid fixed - dose studies is to randomize subjects to separate ranges of dosages within which flexible dosing is allowed .", "label": "", "metadata": {}, "score": "76.285324"}
{"text": "An initial quetiapine dose of 50 mg / day was subsequently increased in 100-mg increments to achieve a final target dose of 300 or 600 mg / day at day 4 or day 8 , respectively .", "label": "", "metadata": {}, "score": "76.311295"}
{"text": "Endicott J , Nee J , Harrison W , et al .Quality of Life Enjoyment and Satisfaction Questionnaire : a new measure .Psychopharmacol Bull .", "label": "", "metadata": {}, "score": "76.33971"}
{"text": "PubMed Central PubMed .Arch Gen Psychiatry 2011 , 68 ( 3):241 - 51 .PubMed Central PubMed .Montgomery SA , Asberg M : A new depression scale designed to be sensitive to change .", "label": "", "metadata": {}, "score": "76.36756"}
{"text": "PubMed .Swartz HA , Thase ME : Pharmacotherapy for the treatment of acute bipolar II depression : current evidence .J Clin Psychiatry 2011 , 72 ( 3):356 - 66 .", "label": "", "metadata": {}, "score": "76.46574"}
{"text": "An absolute neutrophil count ( ANC ) of 1.5 x 109 per liter .A lifetime history of a pre - existing CNS / neurological disorder e.g. epilepsy , TBI , brain tumor .", "label": "", "metadata": {}, "score": "76.5045"}
{"text": "Effectiveness studies using quetiapine in daily doses averaging between 565 and 653 mg revealed quetiapine to be somewhat less effective than some comparator drugs .Overall , robust controlled data strongly suggest that the standard dosage range for quetiapine is appropriate for clinical use .", "label": "", "metadata": {}, "score": "76.593414"}
{"text": "Triglycerides ( mg / dL ) b .Prolactin ( ng / mL ) .Randomization Change .Weight , kg .a Numbers of patients include only those who were assessed .", "label": "", "metadata": {}, "score": "76.61046"}
{"text": "Quetiapine XR was generally well tolerated and its safety profile was consistent with the known profile of quetiapine .Further studies to evaluate the efficacy of adjunctive quetiapine XR in patients with GAD and an inadequate response to previous treatment should take into consideration the methodological difficulties that may be encountered .", "label": "", "metadata": {}, "score": "76.62578"}
{"text": "Rapid dose titration of quetiapine for the treatment of acute schizophrenia and acute mania : a case series .J Psychopharmacol .Kahn RS , Schulz SC , Palazov VD , et al .", "label": "", "metadata": {}, "score": "76.63782"}
{"text": "The maxi- mum recommended dose is 80 mg / d .When examining data from the 4 positive trials available at the time of FDA approval , fixed doses of 120 mg / d did not produce greater improvement than seen at lower doses , but were associated with a higher propensity for somnolence and akathisia .", "label": "", "metadata": {}, "score": "76.64102"}
{"text": "Citrome L , Krakowski M , Greenberg WM , et al .Antiaggressive effect of quetiapine in a patient with schizoaffective disorder .J Clin Psychiatry .", "label": "", "metadata": {}, "score": "76.67078"}
{"text": "Sexual dysfunction , depression , and the impact of antidepressants .Journal of Clinical Psychopharmacology 29 , 157 - 164 .Kirsch I , Moore TJ , Scoboria A , Nicholls SS ( 2002 ) .", "label": "", "metadata": {}, "score": "76.69707"}
{"text": "Discussion .To our knowledge this pooled post hoc analysis of patients with bipolar II disorder experiencing an acute episode of depression represents the largest population available for evaluation to date .", "label": "", "metadata": {}, "score": "76.70098"}
{"text": "Three case reports have described the use of quetiapine in treatment - resistant schizophrenia .These case reports support the findings of the single fixed - dose study already dis- cussed , indicating a possible role for quetiapine in treatment - resistant schizophrenia .", "label": "", "metadata": {}, "score": "76.91623"}
{"text": "Nagy J. Efficacy , safety and tolerability of quetiapine : short- term high doses with long - term follow - up .Int J Psychiatry Clin Pract 2005 ; 9 ( 1 ) : 16 - 21 48 .", "label": "", "metadata": {}, "score": "76.91738"}
{"text": "This was explained in part by limited power , with only 17 participants having completed the trial .Difficulties with recruitment for the current study were in part a reflection of the stringent inclusion and exclusion criteria ; for example , review of baseline blood results may have precluded enrollment of some participants who may have otherwise consented to participation .", "label": "", "metadata": {}, "score": "76.921844"}
{"text": "Comparison of escitalo- pram and citalopram efficacy : a meta - analysis .Int J Psychol Clin Pract 2003 ; 7 : 259 - 68 .", "label": "", "metadata": {}, "score": "77.00585"}
{"text": "TD may remit , partially or completely , if antipsychotic treatment is withdrawn .Quetiapine should be prescribed in a manner that is most likely to minimize the occurrence of TD .", "label": "", "metadata": {}, "score": "77.07843"}
{"text": "Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine .Neuropsychopharmacology 2006 ; 31 ( 9 ) : 1991 - 2001 \u00a9 2008 Adis Data Information BV .", "label": "", "metadata": {}, "score": "77.14368"}
{"text": "All efficacy analyses were based on a modified intent - to - treat set ( ITT ) - the full - analysis set ( FAS ) , comprising all patients in the APTS who had at least onevalidpost - baselineMADRStotalscoreassessment .", "label": "", "metadata": {}, "score": "77.251114"}
{"text": "Data from analyses of patient - reported outcome measures of functioning and quality of life have been reported elsewhere ( Gustafsson and Fajutrao 2011 ) .", "label": "", "metadata": {}, "score": "77.36382"}
{"text": "ESCITALOPRAM IN SEVERE DEPRESSION 269 \u00aa 2005 Blackwell Publishing Ltd Int J Clin Pract , March 2005 , 59 , 3 , 268 - 275 .", "label": "", "metadata": {}, "score": "77.38626"}
{"text": "PubMed .Keck PE , Perlis RH , Otto MW , Carpenter D , Ross R , Docherty JP : The expert consensus guideline series : treatment of bipolar disorder .", "label": "", "metadata": {}, "score": "77.47938"}
{"text": "Risk of bias in individual studies .Two reviewers ( NM and BM ) rated the internal validity ( quality ) of each eligible randomized trial .", "label": "", "metadata": {}, "score": "77.5378"}
{"text": "Evid Based Ment Health 2004 , 7 ( 3):91 .PubMed .J Affect Disord 2007 , 103 ( 1 - 3):181 - 6 .PubMed .", "label": "", "metadata": {}, "score": "77.58255"}
{"text": "PubMed .Judd LL , Akiskal HS , Schettler PJ , Coryell W , Endicott J , Maser JD , Solomon DA , Leon AC , Keller MB : A prospective investigation of the natural history of the long - term weekly symptomatic status of bipolar II disorder .", "label": "", "metadata": {}, "score": "77.60187"}
{"text": "Dosages in excess of 1200 mg / day were also being used .The efficacy of these high dosages is not described and the trials reported on in the review have been discussed previously .", "label": "", "metadata": {}, "score": "77.61174"}
{"text": "FIGURE 2 : Patient disposition a Completed the randomized treatment period and the 2-week posttreatment period .b Subset of MITT population that includes only patients who completed 8 weeks of treatment and entered the posttreatment period .", "label": "", "metadata": {}, "score": "77.6449"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Antipsychotic dosing used in clinical practice can differ from dosing originally recommended in product labeling .", "label": "", "metadata": {}, "score": "77.668365"}
{"text": "LHH was favorable for lurasidone when contrasting PANSS reductions vs. adverse events .Conclusions : NNT and NNH can help quantify efficacy , safety and tolerability outcomes and place lurasidone into clinical perspective .", "label": "", "metadata": {}, "score": "77.701096"}
{"text": "Studies with any duration of treatment for single or recurrent major depressive episodes diagnosed by any set of criteria were included .No language restriction was applied .", "label": "", "metadata": {}, "score": "77.74021"}
{"text": "Lieberman JA , McEvoy JP , Swartz MS , et al .Effectiveness of antipsychotic drugs in patients with chronic schizophrenia .N Engl J Med 2005 ; 353 : 1209 - 23 \u00a9 2008 Adis Data Information BV .", "label": "", "metadata": {}, "score": "77.74893"}
{"text": "The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population .", "label": "", "metadata": {}, "score": "77.810036"}
{"text": "PubMed .Maina G , Albert U , Bellodi L , Colombo C , Faravelli C , Monteleone P , Bogetto F , Cassano GB , Maj M : Health - related quality of life in euthymic bipolar disorder patients : differences between bipolar I and II subtypes .", "label": "", "metadata": {}, "score": "77.85677"}
{"text": "Keywords : SSRI ; escitalopram ; severe depression ; efficacy ; pooled analysis ?2005 Blackwell Publishing Ltd INTRODUCTION The therapeutic approach to treating major depressive disor- der ( MDD ) still presents challenges for clinicians . Antidepres-", "label": "", "metadata": {}, "score": "77.92819"}
{"text": "Escitalopram is well toler- ated and more efficacious than citalopram in long - term treatment of moderately depressed patientsPoster presented at the 3rd International Forum on Mood and Anxiety Disorders ( IFMAD ) , Monte Carlo , Monaco 27 - 30 November 2002 .", "label": "", "metadata": {}, "score": "77.940186"}
{"text": "Papakostas GI , Charles D , Fava M : Are typical starting doses of the selective serotonin reuptake inhibitors sub - optimal ?A meta - analysis of randomized , double - blind , placebo - controlled , dose - finding studies in major depressive disorder .", "label": "", "metadata": {}, "score": "77.9599"}
{"text": "Some clinicians continue to use TCAs for severely depressed patients .However , the risk/ benefit ratio largely favours SSRIs because of their good safety profile , especially considering anticholinergic and cardiovas- cular side effects .", "label": "", "metadata": {}, "score": "77.959915"}
{"text": "D'action rapide , une diff\u00e9rence significative avec le placebo \u00e9tait observ\u00e9e d\u00e8s la premi\u00e8re semaine de traitement ( j3 \u00e0 j7 ) .Les r\u00e9sultats des \u00e9tudes ne sugg\u00e8rent pas de relation dose - efficacit\u00e9 pour des posologies comprises entre 40 et 160 mg / jour de lurasidone .", "label": "", "metadata": {}, "score": "78.018814"}
{"text": "Additional studies are desirable to directly compare and contrast lurasidone 's efficacy with other antipsychotic agents .Escitalopram is an effective , well - tolerated treatment for major depressive disorder in both primary and specialist settings .", "label": "", "metadata": {}, "score": "78.082184"}
{"text": "Treatment of agitation and aggression in bipolar mania : efficacy of quetiapine .J Affect Disord .Takahashi H , Yoshida K , Sugita T , et al .", "label": "", "metadata": {}, "score": "78.10945"}
{"text": "Krakowski M .Violence and serotonin : influence of impulse control affect regulation , and social functioning .J Neuropsychiatry Clin Neurosci .Krakowski MI , Czobor P , Citrome L , et al .", "label": "", "metadata": {}, "score": "78.19147"}
{"text": "Individual patient characteristics , values and preferences will need to be considered when selecting lurasidone over other antipsychotics . binding affinity ( antagonist ) for the serotonin 5-HT7 recep- tor .", "label": "", "metadata": {}, "score": "78.19636"}
{"text": "There were several limitations of this review .Firstly , the doses of quetiapine were different across the included studies .While a study used a flexible dose with titration , the others applied fixed and multiple doses in several arms .", "label": "", "metadata": {}, "score": "78.20195"}
{"text": "Maintenance treatment for schizophrenia with que- tiapine .Hum Psychopharmacol 2004 ; 19 ( 2 ) : 121 - 4 54 .Seeman P , Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors : an explanation for low receptor occupancy and early clinical relapse upon withdrawal of cloza- pine or quetiapine .", "label": "", "metadata": {}, "score": "78.26312"}
{"text": "Evi- dence suggesting improved response at higher dos- ages is limited to uncontrolled case reports of pa- tients with treatment - resistant schizophrenia and is , on a theoretical basis , supported only by an uncon- ventional interpretation the results of receptor occu- pancy studies .", "label": "", "metadata": {}, "score": "78.26323"}
{"text": "The randomization code was bro-ken for one patient ( accidentally ) who had completed the study before this was discovered , and was there- fore not withdrawn from the study .", "label": "", "metadata": {}, "score": "78.28265"}
{"text": "Rosenbaum JF , Fava M , Hoog SL , et al .Selective serotonin reuptake inhibitor discontinuation syndrome : a randomized clinical trial .Biol Psychiatry .", "label": "", "metadata": {}, "score": "78.41821"}
{"text": "Papakostas GI , Fava M : A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder .", "label": "", "metadata": {}, "score": "78.42082"}
{"text": "Antidepressants influencing serotonin mainly aim at raising serotonin concentrations , thereby increasing serotonergic transmission at the level of the synapse , for example by inhibiting the serotonin transporter .", "label": "", "metadata": {}, "score": "78.46251"}
{"text": "Kapur S , Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors : implications for atypical antipsychotic action .J Psychiatry Neurosci 2000 ; 25 ( 2 ) : 161 - 6 33 .", "label": "", "metadata": {}, "score": "78.50897"}
{"text": "CNS Drugs 2008 ; 22 ( 1 ) .Data provided are for informational purposes only .Although carefully collected , accuracy can not be guaranteed .", "label": "", "metadata": {}, "score": "78.64013"}
{"text": "Australas Psychiatry .Pajonk FG , Schwertner AK , Seelig MA .Rapid dose titration of quetiapine for the treatment of acute schizophrenia and acute mania : a case series .", "label": "", "metadata": {}, "score": "78.81442"}
{"text": "Novel antipsychotic agents and their implications for forensic psychiatry .J Am Acad Psychiatry Law .Srisurapanont M , Maneeton B , Maneeton N .Quetiapine for schizophrenia .", "label": "", "metadata": {}, "score": "78.85321"}
{"text": "Acute behavioral disturbance ( ABD ) is a common psychiatric emergency , occurring in 10 % to 25 % of acute psychiatric admissions . 1 Aggression may compound the experience of ABDs in psychotic patients in acute psychiatric settings .", "label": "", "metadata": {}, "score": "78.934364"}
{"text": "There is limited information on the role of these receptors on sexual drive , although the increase 598 E. Alvarez et al . .Page 11 .", "label": "", "metadata": {}, "score": "78.95328"}
{"text": "Translational pharmacology of quetiapine and norquetiapine : preclinical findings support multifunctional psychotropic properties .Eur Psychiatry .2010 ; 25(suppl 1 ) : 1446 .Jensen NH , Rodriguiz RM , Caron MG , et al .", "label": "", "metadata": {}, "score": "78.962814"}
{"text": "This may have been caused by collecting spontaneous reports of side effects rather than utilizing a systematic side - effect screen .Future research would benefit from the use of a standardized screen assessing for a broader array of potential medication - induced side effects alongside psychopathology and aggression measures .", "label": "", "metadata": {}, "score": "79.06583"}
{"text": "Patient ratings were assessed by the same investigator at each visit , whenever possible .Allocation to treatment The medication was given as capsules of identical ap- pearance .", "label": "", "metadata": {}, "score": "79.08394"}
{"text": "As there was no significant effect of site on the primary outcomes , the remaining analyses were conducted with participants from both sites as a single data set .", "label": "", "metadata": {}, "score": "79.098495"}
{"text": "Publisher conditions are provided by RoMEO .Differing provisions from the publisher 's actual policy or licence agreement may be applicable .Two low - dose studies ( 2.5 mg / day and 5 mg / day of vortioxetine ) did not yield differences to placebo .", "label": "", "metadata": {}, "score": "79.20566"}
{"text": "Study Completion Shaded entries represent NNH values where the 95 % CI does not include infinity and , hence , considered statistically significant .Page 5 .", "label": "", "metadata": {}, "score": "79.28577"}
{"text": "PubMed View Article .Pre - publication history .Copyright .\u00a9 Maneeton et al . ; licensee BioMed Central Ltd. 2012 .This article is published under license to BioMed Central Ltd. Quetiapine is a widely used second - generation antipsychotic that is effective in the treatment of schizophrenia and bipolar mania .", "label": "", "metadata": {}, "score": "79.31932"}
{"text": "NNT and NNH can help quantify efficacy , safety and tolerability outcomes and place lurasidone into clinical perspective .Advantages for lurasidone include a low pro- pensity for weight gain and metabolic abnormalities .", "label": "", "metadata": {}, "score": "79.38803"}
{"text": "Only those studies relating to depression or major depressive disorder were included .The search identified over 250 citations , of which 21 studies and 18 pooled or meta - analyses studies were deemed suitable for inclusion .", "label": "", "metadata": {}, "score": "79.45599"}
{"text": "This was an 11-week , multicenter , randomized , double - blind , parallel - group , placebo - controlled study ( D1441L00016 , Palladium ; NCT00534599 ) .", "label": "", "metadata": {}, "score": "79.47613"}
{"text": "Detailed Description : .This was a single - site , double - blind , placebo - controlled ( PLAC ) , randomized , parallel group ( 2 groups ) , 8-week , quetiapine extended release ( XR ) coadministration trial .", "label": "", "metadata": {}, "score": "79.53734"}
{"text": "In the MITT population , 95.1 % and 95.5 % of patients in the quetiapine XR + SSRI / SNRI and placebo + SSRI / SNRI groups , respectively , were treatment adherent .", "label": "", "metadata": {}, "score": "79.56356"}
{"text": "Changes in glucose and lipid data and body weight and the proportions of patients with clinically relevant shifts from normal in these parameters from randomization to treatment end ( safety population ) .", "label": "", "metadata": {}, "score": "79.60162"}
{"text": "A relative risk of one indicates no difference between comparison groups .For an unwanted outcome , an RR lesser than one suggests the less likelihood of the occurrence of such outcome .", "label": "", "metadata": {}, "score": "79.69959"}
{"text": "TD may remit , partially or completely , if antipsychotic treatment is withdrawn .SEROQUEL should be prescribed in a manner that is most likely to minimize the occurrence of TD .", "label": "", "metadata": {}, "score": "79.754364"}
{"text": "May 22 2007 /PRNewswire - FirstCall/ --AstraZeneca t ..On May 17 2007 the U.S. Food and Drug Administration ( FDA)approved ...Both analyses show that SEROQUEL XR was superior to placebodemonstr ...", "label": "", "metadata": {}, "score": "79.762474"}
{"text": "LHH was favorable for lurasidone when contrasting PANSS reductions vs. adverse events .NNT and NNH can help quantify efficacy , safety and tolerability outcomes and place lurasidone into clinical perspective .", "label": "", "metadata": {}, "score": "79.76797"}
{"text": "AEs potentially related to sexual dysfunction ( MedDRA preferred terms : libido decreased and ejaculation delayed ) were reported by 2.9 % of patients in the quetiapine XR + SSRI / SNRI group and no patients in the placebo + SSRI / SNRI group .", "label": "", "metadata": {}, "score": "79.79756"}
{"text": "Escitalopram may have a favourable benefit - risk ratio compared with citalopram and possibly with several other antidepressant agents .", "label": "", "metadata": {}, "score": "79.80169"}
{"text": "Many trials , for example , excluded subjects with a history of misuse of alcohol or elicit substances .It is possible that dose - response rela- \u00a9 2008 Adis Data Information BV .", "label": "", "metadata": {}, "score": "79.81059"}
{"text": "Glassman AH , Bigger JT Jr .Antipsychotic drugs : prolonged QTc interval torsade de pointes , and sudden death .Am J Psychiatry .Dev V , Raniwalla J .", "label": "", "metadata": {}, "score": "79.9353"}
{"text": "Lu AA21004 for treatment of MDD 599 .Page 12 .Guy W ( ed . )ECDEU Assessment Manual for Psychopharmacology , revised edn .", "label": "", "metadata": {}, "score": "79.94065"}
{"text": "A NNT of 50 would mean little difference between the two interventions , as it would take treating 50 patients to encounter a difference in outcome .", "label": "", "metadata": {}, "score": "79.94392"}
{"text": "Lu AA21004 : a novel potential treatment for mood disorders .European Neuropsychopharmacology 18 ( Suppl . 4 ) , S321 .Morales M , Battenberg E , de Lecea L , Bloom FE ( 1996 ) .", "label": "", "metadata": {}, "score": "79.99957"}
{"text": "Schleifer JJ .Management of acute agitation in psychosis : an evidence - based approach in the USA .Advances in Psychiatric Treatment .Ganesan S , Levy M , Bilsker D , et al .", "label": "", "metadata": {}, "score": "80.008934"}
{"text": "3 December 2010 .cfm [ Last accessed 2010 December 16].Dainippon Sumitomo Pharma .Dainippon Sumitomo Pharma announces Pan - Asia study results for lurasidone , an atypical antipsychotic agent , in the treatment of schizophrenia .", "label": "", "metadata": {}, "score": "80.00926"}
{"text": "A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome ( NMS ) has been reported in association with administration of antipsychotic drugs , including quetiapine .", "label": "", "metadata": {}, "score": "80.02461"}
{"text": "A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome ( NMS ) has been reported in association with administration of antipsychotic drugs , including SEROQUEL .", "label": "", "metadata": {}, "score": "80.07205"}
{"text": "Objective : To describe the efficacy , safety and tolerability of lurasidone for the acute treatment of schizophrenia using the metrics number needed to treat ( NNT ) and number needed to harm ( NNH ) .", "label": "", "metadata": {}, "score": "80.12094"}
{"text": "Am J Psychiatry .Pollack MH .Refractory generalized anxiety disorder .J Clin Psychiatry .Wittchen HU .Generalized anxiety disorder : prevalence burden , and cost to society .", "label": "", "metadata": {}, "score": "80.13038"}
{"text": "SEROQUEL is indicated for the treatment of depressive episodes in bipolar disorder ; acute manic episodes in bipolar I disorder , as either monotherapy or adjunct therapy to lithium or divalproex ; and schizophrenia .", "label": "", "metadata": {}, "score": "80.162994"}
{"text": "When a curve is drawn using the major fixed - dose study of IR que- tiapine[6 ] ( figure 1 ) , the curve demonstrates a near- vertical linear portion , with the threshold dosage at 150 mg / day .", "label": "", "metadata": {}, "score": "80.177536"}
{"text": "On - label on the table : what the package insert in- forms us about the tolerability profile of oral atypical antipsychotics , and what it does not .", "label": "", "metadata": {}, "score": "80.18179"}
{"text": "The CGI - S and CGI - I scores were analysed at the last visit ( OC and LOCF ) using ANCOVA .Unless otherwise stated , the terms ' significant ' and ' significantly ' refer to statisti- cal significance at the 5 % level , two - sided .", "label": "", "metadata": {}, "score": "80.2245"}
{"text": "PubMed .Wiebe N , Vandermeer B , Platt RW , Klassen TP , Moher D , Barrowman NJ : A systematic review identifies a lack of standardization in methods for handling missing variance data .", "label": "", "metadata": {}, "score": "80.254814"}
{"text": "Risk of bias across studies .To detect the reporting biases , a funnel plot , a simple plot of the intervention effect estimating from individual studies against some measure of each study 's size or precision [ 38 ] , was applied .", "label": "", "metadata": {}, "score": "80.26425"}
{"text": "PRIZE Study Group .Int Clin Psychopharmacol 2000 ; 15 ( 3 ) : 121 - 31 28 .Hellewell JS .Treatment - resistant schizophrenia : reviewing the options and identifying the way forward .", "label": "", "metadata": {}, "score": "80.31928"}
{"text": "Borison RL , Arvanitis LA , Miller BG .ICI 204,636 , an atypical antipsychotic : efficacy and safety in a multicenter , placebo- controlled trial in patients with schizophrenia .", "label": "", "metadata": {}, "score": "80.442955"}
{"text": "tors .Lurasidone has little to no appreciable affinity for hista- mine H1 and acetylcholine M1 receptors .The efficacy and short - term tolerability of lurasidone for the treatment of acute schizophrenia has been tested in several 6-week , randomized , placebo - controlled trials at fixed doses ranging from 20 to 160 mg , administered once daily ( 2 - 6 ) .", "label": "", "metadata": {}, "score": "80.44356"}
{"text": "Additional clinical trials are underway for the use of lurasidone in patients with bipolar disorder , including major depressive episodes in patients with bipolar I disorder , and in bipolar and schizophrenia maintenance .", "label": "", "metadata": {}, "score": "80.47677"}
{"text": "2009 ) and maximum plasma concentrations are reached 3 - 16 h after dosing .The rationale for choosing the Lu AA21004 doses ( 5 and 10 mg ) in this proof - of - concept study was based on non - clinical and phase I data .", "label": "", "metadata": {}, "score": "80.514435"}
{"text": "Arch Gen Psychiatry .Pae CU , Kim JJ , Lee CU , et al .Rapid versus conventional initiation of quetiapine in the treatment of schizophrenia : a randomized , parallel - group trial .", "label": "", "metadata": {}, "score": "80.539734"}
{"text": "Benazzi F : Bipolar II , disorder : epidemiology , diagnosis and management .CNS Drugs 2007 , 21 ( 9):727 - 40 .PubMed .", "label": "", "metadata": {}, "score": "80.57666"}
{"text": "14 Montgomery SA , Asberg M. A new depression scale designed to be sensitive to change .Br J Psychiatry 1979 ; 134 : 382 - 9 . 15 Hamilton M. A rating scale for depression .", "label": "", "metadata": {}, "score": "80.68465"}
{"text": "The recommended starting dose is 40 mg / day .Initial dose titration is not required .Efficacy for the treatment of acute episodes of schizophrenia was established in five , 6-week , fixed - dose , randomized , placebo - controlled trials .", "label": "", "metadata": {}, "score": "80.766495"}
{"text": "Lieberman JA , Stroup TS , McEvoy JP , Swartz MS , et al .( 2005 ) .Clinical Antipsychotic Trials of Intervention Effectiveness ( CATIE ) Investigators .", "label": "", "metadata": {}, "score": "80.87991"}
{"text": "PubMed .Suppes T , Dennehy EB : Evidence - based long - term treatment of bipolar II disorder .J Clin Psychiatry 2002 , 63 ( Suppl 10):29 - 33 .", "label": "", "metadata": {}, "score": "80.91202"}
{"text": "Full - text .Efficacy of escitalopram in patients with severe depression : a pooled analysis P - M. LLORCA,1J - M. This analysis compared the efficacy of escitalo- pram with citalopram in the treatment of patients with severe depression [ defined as a score of ? 30 Montgomery- A\u02dasberg Depression Rating Scale ( MADRS)].", "label": "", "metadata": {}, "score": "80.959435"}
{"text": "Steinert T , W\u00f6lfle M , Gebhardt RP .Measurement of violence during in - patient treatment and association with psychopathology .Acta Psychiatr Scand .", "label": "", "metadata": {}, "score": "80.99684"}
{"text": "The incidences of AEs potentially related to EPS ( MedDRA preferred terms : akathisia , psychomotor hyperactivity , restlessness , and tremor ) were 3.8 % and 2.0 % in the quetiapine XR + SSRI / SNRI and placebo + SSRI / SNRI groups , respectively .", "label": "", "metadata": {}, "score": "81.012665"}
{"text": "Summary measures .Outcomes of interest included efficacy , acceptability and tolerability .Efficacy measures relied on the mean change scores of a rating scale for MDD and the response rates defined by any set of criteria .", "label": "", "metadata": {}, "score": "81.03227"}
{"text": "IMPORTANT SAFETY INFORMATION FOR SEROQUEL XR .SEROQUEL XR is indicated for the treatment of schizophrenia .Patients should be periodically reassessed to determine the need for treatment beyond the acute response .", "label": "", "metadata": {}, "score": "81.11514"}
{"text": "Original Contributions Lurasidone for the Acute Treatment of Adults with Schizophrenia : What is the Number Needed to Treat , Number Needed to Harm , and Likelihood to be Helped or Harmed ?", "label": "", "metadata": {}, "score": "81.150116"}
{"text": "Major depressive disorder ( MDD ) is a common mental illness with a lifetime prevalence rate of 6.7 % ( 3.8 % for men and 7.5 % for women ) [ 1 ] .", "label": "", "metadata": {}, "score": "81.1558"}
{"text": "PubMed .Lydiard RB , Culpepper L , Schioler H , Gustafsson U , Paulsson B : Quetiapine monotherapy as treatment for anxiety symptoms in patients with bipolar depression : a pooled analysis of results from 2 double - blind , randomized , placebo - controlled studies .", "label": "", "metadata": {}, "score": "81.233055"}
{"text": "Kupka RW , Luckenbaugh DA , Post RM , Leverich GS , Nolen WA : Rapid and non - rapid cycling bipolar disorder : a meta - analysis of clinical studies .", "label": "", "metadata": {}, "score": "81.25354"}
{"text": "[ Epub ahead of print ) .Citrome L. Relative vs. absolute measures of benefit and risk : what 's the differ- ence ?Acta Psychiatr Scand 2010;121(2):94 - 102 .", "label": "", "metadata": {}, "score": "81.33313"}
{"text": "Citrome L , Kantrowitz J. Antipsychotics for the treatment of schizophrenia : likelihood to be helped or harmed , understanding proximal and distal benefits and risks .", "label": "", "metadata": {}, "score": "81.38785"}
{"text": "Dose - Response Relationship of Quetiapine in Schizophrenia61 \u00a9 2008 Adis Data Information BV .All rights reserved .CNS Drugs 2008 ; 22 ( 1 ) Table VII .", "label": "", "metadata": {}, "score": "81.49362"}
{"text": "Recently , norquetiapine has been found to be a potent inhibitor for norepinephrine transporter shared commonality with TCAs and SNRIs , and a moderate - to - high affinity for D2 , 5HT1A , 5HT2A , and 5HT2C receptors shared some properties with SSRIs [ 20 , 21 ] .", "label": "", "metadata": {}, "score": "81.53464"}
{"text": "PubMed Central PubMed .MacQueen GM , Young LT : Bipolar II disorder : symptoms , course , and response to treatment .Psychiatr Serv 2001 , 52 ( 3):358 - 61 .", "label": "", "metadata": {}, "score": "81.57344"}
{"text": "Previous enrollment or randomization of treatment in the present study .Participation in another drug trial within 4 weeks prior enrollment into this study or longer in accordance with local requirements .", "label": "", "metadata": {}, "score": "81.57355"}
{"text": "Int J Psychiatry Clin Pract .Arango C , Bernardo M .The effect of quetiapine on aggression and hostility in patients with schizophrenia .Hum Psychopharmacol .", "label": "", "metadata": {}, "score": "81.66676"}
{"text": "PubMed .Am J Psychiatry 2005 , 162 ( 7):1273 - 80 .PubMed .Bipolar Disord 2007 , 9 ( 5):531 - 5 .PubMed .", "label": "", "metadata": {}, "score": "81.67389"}
{"text": "In 2000 , depression was an important cause of disease burden accounting for 4.4 % of the total disability adjusted life years or 12 % of all total years lived with disability worldwide [ 4 ] .", "label": "", "metadata": {}, "score": "81.734764"}
{"text": "Buckley PF .Efficacy of quetiapine for the treatment of schizo- phrenia : a combined analysis of three placebo - controlled trials .Curr Med Res Opin 2004 ; 20 ( 9 ) : 1357 - 63 42 .", "label": "", "metadata": {}, "score": "81.84401"}
{"text": "Medical conditions that would affect absorption , distribution , metabolism , or excretion of study treatment .Unstable or inadequately treated medical illness ( e.g. angina pectoris , hypertension ) as judged by the investigator .", "label": "", "metadata": {}, "score": "81.95571"}
{"text": "Primary efficacy analysis Four hypotheses were part of the primary efficacy analysis , which was fully adjusted for multiplicity using a hierarchical testing procedure at the 5 % level of significance as long as the previous hypothesis was rejected .", "label": "", "metadata": {}, "score": "81.959625"}
{"text": "Therefore , the cross - trial comparisons of the response and remission rates of quetiapine with those of other antidepressants may not be justified .Absolute risk reduction ( ARR ) is the difference between the control group 's event rate and the experimental group 's event rate .", "label": "", "metadata": {}, "score": "81.984535"}
{"text": "Paper received September 2004 , accepted November 2004 ESCITALOPRAM IN SEVERE DEPRESSION 275 \u00aa 2005 Blackwell Publishing Ltd Int J Clin Pract , March 2005 , 59 , 3 , 268 - 275 .", "label": "", "metadata": {}, "score": "82.00795"}
{"text": "In addition to the measure of efficacy , the number needed to treat ( NNT ) , the number of patients who must receive a particular therapy for one to benefit , was also calculated .", "label": "", "metadata": {}, "score": "82.06072"}
{"text": "The discontinuation rate due to adverse events was a measure of tolerability .Relative risks ( RRs ) and weighted mean differences ( WMDs ) with 95 % confidence intervals ( CIs ) were computed by using a random effect model .", "label": "", "metadata": {}, "score": "82.084816"}
{"text": "274 ESCITALOPRAM IN SEVERE DEPRESSION \u00aa 2005 Blackwell Publishing Ltd Int J Clin Pract , March 2005 , 59 , 3 , 268 - 275 .", "label": "", "metadata": {}, "score": "82.122086"}
{"text": "Barnes TR .A rating scale for drug - induced akathisia .Br J Psychiatry .Castle D , Daniel J , Knott J , et al .", "label": "", "metadata": {}, "score": "82.164856"}
{"text": "Clinical manifestations of NMS are hyperpyrexia , muscle rigidity , altered mental status , and evidence of autonomic instability ( irregular pulse or blood pressure , tachycardia , diaphoresis , and cardiac dysrhythmia ) .", "label": "", "metadata": {}, "score": "82.22792"}
{"text": "Clinical manifestations of NMS are hyperpyrexia , muscle rigidity , altered mental status , and evidence of autonomic instability ( irregular pulse or blood pressure , tachycardia , diaphoresis , and cardiac dysrhythmia ) .", "label": "", "metadata": {}, "score": "82.22792"}
{"text": "A new depression scale designed to be sensitive to change .British Journal of Psychiatry 134 , 382 - 389 .Moore NA , Bang - Andersen B , Brennum LT , Frederiksen K , et al .", "label": "", "metadata": {}, "score": "82.23854"}
{"text": "In general , a LHH greater than 1 would mean the likelihood to be helped is greater than the likelihood to be harmed .For a LHH less than 1 , the reverse is true .", "label": "", "metadata": {}, "score": "82.25315"}
{"text": "Some ad- vocate for using the terms number needed to treat for an ad- ditional beneficial outcome ( NNTB ) and number needed to treat for an additional harmful outcome ( NNTH ) , instead of NNT and NNH , respectively ( 8) .", "label": "", "metadata": {}, "score": "82.28257"}
{"text": "[ 30 ] This is believed to be because of the low affinity of que- tiapine for D2 receptors .[ 32 ] Dosages of quetiapine ranged from 150 to 750 mg / day .", "label": "", "metadata": {}, "score": "82.41223"}
{"text": "Zimbroff DL .Pharmacological control of acute agitation : focus on intramuscular preparations .CNS Drugs .Battaglia J .Pharmacological management of acute agitation .", "label": "", "metadata": {}, "score": "82.48187"}
{"text": "Psychol Med 2011 , 42 ( 6 ) : 1 - 19 .Ust\u00fcn TB , Ayuso - Mateos JL , Chatterji S , Mathers C , Murray CJ : Global burden of depressive disorders in the year 2000 .", "label": "", "metadata": {}, "score": "82.70688"}
{"text": "Patients starting treatment with atypical antipsychotics who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and during treatment .", "label": "", "metadata": {}, "score": "82.70822"}
{"text": "La lurasidone se distingue des autres antipsychotiques de seconde g\u00e9n\u00e9ration par un profil de tol\u00e9rance m\u00e9tabolique et cardiovasculaire favorable .Cependant , il semble exister un lien significatif quoique mod\u00e9r\u00e9 avec l'apparition d'akathisie , de sympt\u00f4mes extrapyramidaux et d'hyperprolactin\u00e9mie en d\u00e9but de traitement .", "label": "", "metadata": {}, "score": "82.74524"}
{"text": "The broad spectrum of efficacy demonstrated by quetiapine XR against symptoms of anxiety and depression may be explained by its mechanism of action .Quetiapine and norquetiapine ( the major active metabolite of quetiapine ) have moderate to high affinity for serotonin 5-HT2A and dopamine D2 receptors ; norquetiapine is also a potent inhibitor of the norepinephrine transporter ( NET ) .", "label": "", "metadata": {}, "score": "82.76105"}
{"text": "World J Biol Psychiatry .Canadian Psychiatric Association .Management of anxiety disorders .Can J Psychiatry .NICE guidelines .Anxiety : management of anxiety ( panic disorder , with or without agoraphobia , and generalised anxiety disorder ) in adults in primary , secondary and community care .", "label": "", "metadata": {}, "score": "82.76354"}
{"text": "Further research in a larger patient sample that also compares treatment outcomes for quetiapine XR with other best - practice treatment approaches is needed before any concrete recommendations can be made about the role of quetiapine XR as a treatment for ABD in psychotic patients .", "label": "", "metadata": {}, "score": "82.805725"}
{"text": "PubMed .Bauer M , Beaulieu S , Dunner DL , Lafer B , Kupka R : Rapid cycling bipolar disorder - diagnostic concepts .Bipolar Disord 2008 , 10 ( 1 Pt 2):153 - 62 .", "label": "", "metadata": {}, "score": "83.00899"}
{"text": "Psychol Med 2008 , 38 ( 2 ) : 289 - 300 .PubMed View Article .Higgins JPT , Altman DG : Assessing risk of bias in included studies .", "label": "", "metadata": {}, "score": "83.11028"}
{"text": "Latuda ( lurasidone ) .Revised October 2010 .Nakamura M , Ogasa M , Guarino J , Phillips D , Severs J , Cucchiaro J , et al .", "label": "", "metadata": {}, "score": "83.14313"}
{"text": "To reduce scoring variability , the same rater conducted all assessments for a given patient for a specific scale whenever possible .Health - related quality of life .", "label": "", "metadata": {}, "score": "83.25566"}
{"text": "J Clin Psychiatry 2009;70(6):829 - 836 .Meltzer HY , Cucchiaro J , Silva R , Ogasa M , Phillips D , Xu J , et al .", "label": "", "metadata": {}, "score": "83.41202"}
{"text": "This study aimed to examine the effectiveness of quetiapine and the effects of dosage relates to its effectiveness on schizophrenia and schizoaffective disorder in a naturalistic setting in Korean people .", "label": "", "metadata": {}, "score": "83.50923"}
{"text": "The most common AEs were nausea , headache , hyperhidrosis , and dry mouth .No clinically relevant changes over time were seen in the clinical laboratory results , vital signs , weight , or ECG parameters .", "label": "", "metadata": {}, "score": "83.58751"}
{"text": "Journal of Clinical Psychiatry 59 ( Suppl .20 ) , 22 - 33 , quiz 34 - 57 .Trivedi MH , Rush AJ , Wisniewski SR , Nierenberg AA , et al .", "label": "", "metadata": {}, "score": "83.87196"}
{"text": "New England Journal of Medicine 353 , 1209 - 1223 .Melander H , Salmonson T , Abadie E , van Zwieten - Boot B ( 2008 ) .", "label": "", "metadata": {}, "score": "83.92755"}
{"text": "When an outcome is measured by different instruments across studies , it may not be possible to compare or combine study results directly .By expressing the effect as a standardized value , the results can be combined since they have no unit .", "label": "", "metadata": {}, "score": "83.996475"}
{"text": "Hamilton M ( 1959 ) .The assessment of anxiety states by rating .British Journal of Medical Psychology 32 , 50 - 55 .Hamilton M ( 1960 ) .", "label": "", "metadata": {}, "score": "84.040596"}
{"text": "Two studies have used flexible dosages of que- tiapine within set dosage ranges to evaluate the efficacy and tolerability of the drug in schizo- phrenia .", "label": "", "metadata": {}, "score": "84.22376"}
{"text": "All rights reserved .CNS Drugs 2008 ; 22 ( 1 ) Table I. Multiple fixed - dose studies , vs placebo and haloperidol Study design Subjects No .", "label": "", "metadata": {}, "score": "84.266846"}
{"text": "The major limitation for the current study was that the final sample size was lower than initially anticipated , limiting the robustness of study findings .", "label": "", "metadata": {}, "score": "84.27805"}
{"text": "Gefvert O , Bergstrom M , Langstrom B , et al .Time course of central nervous dopamine - D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of que- tiapine ( Seroquel ) in patients with schizophrenia .", "label": "", "metadata": {}, "score": "84.29367"}
{"text": "Enhancing the technology of clinical trials and the trials model to evaluate newly developed , targeted antidepressants .Neuropsychopharmacology .Brawman - Mintzer O , Knapp RG , Nietert PJ .", "label": "", "metadata": {}, "score": "84.29619"}
{"text": "PubMed .Young AH , McElroy SL , Bauer M , Philips N , Chang W , Olausson B , Paulsson B , Brecher M : A double - blind , placebo - controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression ( EMBOLDEN I ) .", "label": "", "metadata": {}, "score": "84.45298"}
{"text": "This was done by observing the results presented by graphical display and using the test of heterogeneity .An I 2 of 50 % or higher was considered as significant heterogeneity of results .", "label": "", "metadata": {}, "score": "84.51669"}
{"text": "However , epidemiological studies suggest an increased risk of treatment - emergent , hyperglycemia - related adverse events in patients treated with atypical antipsychotics .Patients starting treatment with atypical antipsychotics who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and during treatment .", "label": "", "metadata": {}, "score": "84.60454"}
{"text": "The research nurse would then speak with patients to obtain informed consent .The research nurse was responsible for completing the OAS on a daily basis through both clinical interview and a review of the patient 's medical record .", "label": "", "metadata": {}, "score": "84.64439"}
{"text": "He is an Honorary Consultant WLMHT ( NHS ) .He was paid for lectures and advisory boards for all major pharmaceutical companies with drugs used in affective and related disorders .", "label": "", "metadata": {}, "score": "84.84996"}
{"text": "Straus SE .Individualizing treatment decisions .The likelihood of being helped or harmed .Eval Health Prof 2002;25(2):210 - 224 .Loebel A , Cucchiaro J , Sarma K , Xu J , Hsu J , Kalali AH , et al .", "label": "", "metadata": {}, "score": "84.88962"}
{"text": "He has received grant / research support from Agency for Healthcare Research and Quality , Eli Lilly , Forest Laboratories , GlaxoSmithKline , National Institute of Mental Health , Otsuka , and Sepracor .", "label": "", "metadata": {}, "score": "84.93416"}
{"text": "Department of Psychiatry , Faculty of Medicine , Chiang Mai University .Brandon Lane Neuropsychiatry Clinic .References .Waraich P , Goldner EM , Somers JM , Hsu L : Prevalence and incidence studies of mood disorders : a systematic review of the literature .", "label": "", "metadata": {}, "score": "85.02637"}
{"text": "Schizophr Res 2004 ; 69 ( 2- 3 ) : 325 - 31 27 .Emsley RA , Raniwalla J , Bailey PJ , et al .", "label": "", "metadata": {}, "score": "85.02701"}
{"text": "Taylor D. Establishing a dose - response relationship for halo- peridol decanoate .Psychiatr Bull 2005 ; 29 ( 3 ) : 104 - 7 52 .", "label": "", "metadata": {}, "score": "85.030876"}
{"text": "Hamilton M : The assessment of anxiety states by rating .Br J Med Psychol 1959 , 32 ( 1):50 - 5 .PubMed .Hamilton M : A rating scale for depression .", "label": "", "metadata": {}, "score": "85.033585"}
{"text": "Full - text .CNS Drugs 2008 ; 22 ( 1 ) : 49 - 68 1172 - 7047/08/0001 - 0049/$48.00/0 REVIEW ARTICLE \u00a9 2008 Adis Data Information BV .", "label": "", "metadata": {}, "score": "85.04961"}
{"text": "Citrome L. Lurasidone for schizophrenia : a brief review of a new second- generation antipsychotic .Clin Schizophr Relat Psychoses 2011;4(4):251 - 257 .Citrome L. Iloperidone , asenapine , and lurasidone : a brief overview of 3 new second - generation antipsychotics .", "label": "", "metadata": {}, "score": "85.063515"}
{"text": "In the present review , the WMDs or the SMDs were planned to be calculated if the retrieved studies used the same rating scale or different rating scales , respectively .", "label": "", "metadata": {}, "score": "85.06726"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : In vitro work shows CYP2C19 and CYP2D6 contribute to the metabolism of escitalopram to its primary metabolite , N - desmethylescitalopram .", "label": "", "metadata": {}, "score": "85.070694"}
{"text": "Eligiblepatientswere ( 1:1:1:1 ) to one of the four treatment arms for a 6-wk double - blind treatment period .Randomized patients were given 1-wk wallet cards at each visit and were instructed to take two capsules per day , orally , at the same time every day ( preferably in the morning ) .", "label": "", "metadata": {}, "score": "85.10392"}
{"text": "There was no significant heterogeneity on both discontinuation outcomes .Risk of bias across studies .Tests for funnel plot asymmetry is normally used in the meta - analysis with at least 10 studies included ; the power of the tests is too low to distinguish chance from real asymmetry , if fewer studies [ 38 ] .", "label": "", "metadata": {}, "score": "85.10713"}
{"text": "Effect of food on the pharmacokinetics of Lu AA21004 in healthy volunteers .Journal of Clinical Pharmacology 49 , 1115 .WMA ( 1964 ) .", "label": "", "metadata": {}, "score": "85.12413"}
{"text": "PubMed View Article .Sterne JAC , Egger M , Moher D : Addressing Reporting Biases .In Cochrane Handbook for SystematicReviews of Interventions .Version 5.1.0 ( Updated March 2011 ) edition .", "label": "", "metadata": {}, "score": "85.3221"}
{"text": "Citalopram is a chiral compound , which means it consists of two enantiomers , R - citalopram and S - citalopram .Escitalopram is the pharmacologically active enantiomer of citalopram ( 22 ) as shown by the results of a number of behavioural tests of antidepressant and anxiolytic activity performed in vitro and in vivo in rats ( 23 ) .", "label": "", "metadata": {}, "score": "85.462906"}
{"text": "Citrome L. Quantifying risk : the role of absolute and relative measures in in- terpreting risk of adverse reactions from product labels of antipsychotic medi- cations .", "label": "", "metadata": {}, "score": "85.52118"}
{"text": "The International Journal of Neuropsychopharmacology .[ Show abstract ] [ Hide abstract ] ABSTRACT : The majority of currently marketed drugs contain a mixture of enantiomers ; however , recent evidence suggests that individual enantiomers can have pharmacological properties that differ importantly from enantiomer mixtures .", "label": "", "metadata": {}, "score": "85.58383"}
{"text": "Dr. Thase has equity holdings in MedAvante and receives royalty income from American Psychiatric Publishing , Guilford Publications , Herald House , and W.W. Norton .", "label": "", "metadata": {}, "score": "85.59809"}
{"text": "All rights reserved .CNS Drugs 2008 ; 22 ( 1 ) .Page 3 .Dose - Response Relationship of Quetiapine in Schizophrenia 51 quetiapine 150 mg / day .", "label": "", "metadata": {}, "score": "85.648575"}
{"text": "Dhossche DM , Ghani SO .Who brings patients to the psychiatric emergency room ?Psychosocial and psychiatric correlates .Gen Hosp Psychiatry .Hodgins S .", "label": "", "metadata": {}, "score": "85.66984"}
{"text": "Analyses of safety variables were performed on the pooled safety population ( i.e. , patients who received at least one dose of the study medication ) and were presented descriptively .", "label": "", "metadata": {}, "score": "85.75112"}
{"text": "An important consideration is its post hoc nature .Furthermore , the generalizability of the findings should be considered in the context of the inclusion and exclusion criteria of the BOLDER and EMBOLDEN trials .", "label": "", "metadata": {}, "score": "85.953964"}
{"text": "Prevention and Treatment 5 , Article 23 , pp . 1 - 11 .Laughren T ( 2006 ) .Memorandum on Suicidality . pdf ) .", "label": "", "metadata": {}, "score": "86.17569"}
{"text": "The partial agonist activity of Lu AA21004 at 5-HT1Breceptors may therefore help counteract the inhibition of terminal 5-HT synthesis and release evoked by 5-HT1B receptor activation .", "label": "", "metadata": {}, "score": "86.272255"}
{"text": "Publisher conditions are provided by RoMEO .Differing provisions from the publisher 's actual policy or licence agreement may be applicable .\" It is generally well - known that , within the recommended dose range , quetiapine is well - tolerated and clinically effective for the treatment of schizophrenia .", "label": "", "metadata": {}, "score": "86.30081"}
{"text": "Searches were limited to humans and adults only .Additional studies were also searched from the databases of AstraZeneca , the producer of the original quetiapine .", "label": "", "metadata": {}, "score": "86.302155"}
{"text": "All relevant randomized - controlled trials ( RCTs ) and clinical - controlled trials ( CCTs ) were included .Searches .Similarly , these search strategies were used in the rest of databases .", "label": "", "metadata": {}, "score": "86.3721"}
{"text": "Nevertheless , NNT and NNH offer the clinician a means of quantifying clinical relevance or \" clinical significance .\"Lower NNTs ( or NNHs ) are evidenced when there are large differences between the interventions in question .", "label": "", "metadata": {}, "score": "86.45683"}
{"text": "In between these extremes , successively larger dosages give rise to successively larger effects .This is the so - called linear portion of the ( s - shaped ) dose - response curve ; \u00a9 2008 Adis Data Information BV .", "label": "", "metadata": {}, "score": "86.480576"}
{"text": "These results , therefore , should be viewed as the very preliminary findings .Fourthly , as with all meta - analyses , publication bias must be considered .", "label": "", "metadata": {}, "score": "86.51964"}
{"text": "PubMed .Valtonen H , Suominen K , Mantere O , Leppamaki S , Arvilommi P , Isometsa ET : Suicidal ideation and attempts in bipolar I and II disorders .", "label": "", "metadata": {}, "score": "86.58156"}
{"text": "The impact of psychiatric symptoms , interpersonal style , and coercion on aggression and self - harm during psychiatric hospitalization .Psychiatry .Nicholls D , Love M , Daniel J .", "label": "", "metadata": {}, "score": "86.76956"}
{"text": "J Clin Psychiatry 2007 ; 68 ( 6 ) : 832 - 42 10 .Kay SR , Fiszbein A , Opler LA .The positive and negative syndrome scale ( PANSS ) for schizophrenia .", "label": "", "metadata": {}, "score": "86.80829"}
{"text": "Pinson L , Gray GE .Psychopharmacology : number needed to treat : an underused measure of treatment effect .Psychiatr Serv .Rynn MA , Brawman - Mintzer O .", "label": "", "metadata": {}, "score": "86.81325"}
{"text": "AEs were coded using the lowest level term according to the Medical Dictionary for Regulatory Activities , version 10.0 .The time to withdrawal due to AEs was analysed using the Cox model .", "label": "", "metadata": {}, "score": "87.00444"}
{"text": "Effectiveness Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .", "label": "", "metadata": {}, "score": "87.02013"}
{"text": "Families and caregivers should be advised of the need for close observation and communication with the prescriber .SEROQUEL is not approved for use in pediatric patients .", "label": "", "metadata": {}, "score": "87.101265"}
{"text": "When starting treatment , patients with diabetes or risk factors for diabetes should undergo blood glucose testing before and during treatment ( Seroquel Prescribing Information 2012 ) .", "label": "", "metadata": {}, "score": "87.12125"}
{"text": "Interruption of selective serotonin reuptake inhibitor treatment .Double - blind , placebo - controlled trial .Br J Psychiatry .Hommel G .A stagewise rejective multiple test procedure based on a modified Bonferroni test .", "label": "", "metadata": {}, "score": "87.16971"}
{"text": "Number needed to treat ( NNT ) was calculated using the formula 1/([proportion of quetiapine XR - treated patients with positive response ] - [ proportion of placebo - treated patients with positive response ] ) .", "label": "", "metadata": {}, "score": "87.23037"}
{"text": "In recent years , various publica- tions have suggested the possibility that , in some patients , higher than licensed dosages are necessary for full therapeutic effect .", "label": "", "metadata": {}, "score": "87.30726"}
{"text": "Written informed consent was obtained from all patients prior to study participation .Details on the study design have been reported previously ( Calabrese et al .", "label": "", "metadata": {}, "score": "87.46311"}
{"text": "As a post - hoc analysis , the safety database was searched at preferred - term and verbatim - term level for possible suicide - related AEs , as described by the FDA ( Laughren , 2006 ) .", "label": "", "metadata": {}, "score": "87.55015"}
{"text": "Schizophrenia Bulletin .( 4 ) American Psychiatric Association .Diagnostic and Statistical Manual of Mental Disorders ( DSM - IV - TR ) .Fourth Edition .", "label": "", "metadata": {}, "score": "87.621185"}
{"text": "Quetiapine monotherapy demonstrated significant efficacy compared with placebo and was generally well tolerated in the treatment of bipolar II depression .Keywords .Bipolar II depression Efficacy Monotherapy Quetiapine Tolerability .", "label": "", "metadata": {}, "score": "87.66824"}
{"text": "Safety assessments .Safety and tolerability assessments included the incidence and severity of adverse events and discontinuations because of adverse events , which were recorded at each visit .", "label": "", "metadata": {}, "score": "87.984955"}
{"text": "Culpepper L : Understanding the burden of depression .J Clin Psychiatr 2011 , 72 ( 6 ) : e19 .View Article .Rush AJ , Wisniewski SR , Zisook S , Fava M , Sung SC , Haley CL , Chan HN , Gilmer WS , Warden D , Nierenberg AA , et al .", "label": "", "metadata": {}, "score": "88.00423"}
{"text": "The details of the randomization series were unknown to any of the investigators and were contained in a set of sealed opaque envelopes .At each study site , sequentially enrolled patients were assigned the low- est randomization number available in blocks of four .", "label": "", "metadata": {}, "score": "88.089134"}
{"text": "Primary efficacy endpoint .The PP population analysis of the primary efficacy variable confirmed the results of the primary analysis in the MITT population .MMRM analysis ( OCs , MITT population ) results were also similar to the primary efficacy analysis results .", "label": "", "metadata": {}, "score": "88.10452"}
{"text": "s.lee@alfred.org.au .Annals of Clinical Psychiatry \u00a9 2012 Frontline Medical Communications .To describe the efficacy , safety and tolerability of lurasidone for the acute treatment of schizophrenia using the metrics number needed to treat ( NNT ) and number needed to harm ( NNH ) .", "label": "", "metadata": {}, "score": "88.212074"}
{"text": "\u00a9 2008 Adis Data Information BV .All rights reserved .CNS Drugs 2008 ; 22 ( 1 ) Table VI .Single fixed - dose study Study design Subjects No .", "label": "", "metadata": {}, "score": "88.252884"}
{"text": "As might be expected , the study findings demonstrate that plasma concentrations of que- tiapine increase with larger dosages of quetiapine ( table VII ) .", "label": "", "metadata": {}, "score": "88.493225"}
{"text": "56 Sparshatt et al .\u00a9 2008 Adis Data Information BV .All rights reserved .CNS Drugs 2008 ; 22 ( 1 ) Table IV .", "label": "", "metadata": {}, "score": "88.629364"}
{"text": "It is important to distinguish shifts from nor- mal to abnormal values vs. from borderline to abnormal values .Moreover , high - density lipoprotein cholesterol was not examined .", "label": "", "metadata": {}, "score": "88.659256"}
{"text": "This study ( Palladium , D1441L00016 ) was funded by AstraZeneca Pharmaceuticals .The authors thank Jocelyn Woodcock , MPhil , from Complete Medical Communications , who provided medical writing support funded by AstraZeneca .", "label": "", "metadata": {}, "score": "88.68343"}
{"text": "Washington , DC : American Psychiatric Association ; 2000 .American Psychiatric Association : Practice guideline for the treatment of patients with bipolar disorder ( revision ) .", "label": "", "metadata": {}, "score": "88.697975"}
{"text": "Full - text .Lundbeck A / S , Copenhagen , Denmark 4Institut d'Investigacions Biomediques de Barcelona , CSIC , Barcelona , Spain Abstract The efficacy , safety , and tolerability of Lu AA21004 vs. placebo using venlafaxine XR as active reference in patients with DSM - IV - TR major depressive disorder ( MDD ) were evaluated .", "label": "", "metadata": {}, "score": "88.759705"}
{"text": "References .Am J Psychiatry 2006 , 163 ( 2):313 - 5 .PubMed .American Psychiatric Association : Diagnostic and Statistical Manual of Mental Disorders , Fourth Edition , Text Revision .", "label": "", "metadata": {}, "score": "88.79848"}
{"text": "The statements herein include forward - looking statements .By their nature , forward - looking statements and forecasts involve risk and uncertainty .For a discussion of those risks and uncertainties please see the company 's Annual Report / Form 20-F for 2006 .", "label": "", "metadata": {}, "score": "88.89981"}
{"text": "Different serotonin receptor subtypes turn the serotonergic system into a complex neurochemical arrangement that influences diverse neurotransmitters in various brain regions .Classical antidepressants as well as other psychopharmacological agents have various crucial effects on serotonin receptors .", "label": "", "metadata": {}, "score": "88.954994"}
{"text": "View Article .Uher R , Farmer A , Maier W , Rietschel M , Hauser J , Marusic A , Mors O , Elkin A , Williamson RJ , Schmael C , et al .", "label": "", "metadata": {}, "score": "89.054596"}
{"text": "AstraZeneca has been named one of the \" 100 Best Companies for Working Mothers \" by Working Mother magazine and is the only large pharmaceutical company named to FORTUNE magazine 's 2007 list of \" 100 Best Companies to Work For . \"", "label": "", "metadata": {}, "score": "89.3205"}
{"text": "Patient population .The first patient was enrolled on August 31 , 2007 , and the last patient completed the study on September 2 , 2008 .", "label": "", "metadata": {}, "score": "89.38084"}
{"text": "Variable - Dose Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .", "label": "", "metadata": {}, "score": "89.4942"}
{"text": "Fixed - Dose Trials Trials in which subjects are randomly assigned to single fixed doses of a drug provide the most robust evidence of dose - response relationships , assuming that studies recruit sufficiently large numbers of patients to reveal true differences and include a sufficiently wide range of doses .", "label": "", "metadata": {}, "score": "89.7471"}
{"text": "Glucose ( mg / dL ) b .Total cholesterol ( mg / dL ) b .HDL - cholesterol ( mg / dL ) b .", "label": "", "metadata": {}, "score": "89.88182"}
{"text": "A test of heterogeneity is necessary for evaluating the similarity of the study results .Before conducting this meta - analysis , we hypothesized that the effect size may differ due to the methodological quality of the studies .", "label": "", "metadata": {}, "score": "89.97511"}
{"text": "Biological Psychiatry 65 ( 8 Suppl . 1 ) , 73S. Puig MV , Santana N , Celada P , Mengod G , Artigas F ( 2004 ) .", "label": "", "metadata": {}, "score": "90.22738"}
{"text": "He has not been compensated for consulting or speaking on behalf of these companies , nor does he own stock in any of these or other pharmaceutical companies .", "label": "", "metadata": {}, "score": "90.60947"}
{"text": "PubMed View Article .Cipriani A , Furukawa TA , Salanti G , Geddes JR , Higgins JP , Churchill R , Watanabe N , Nakagawa A , Omori IM , McGuire H , et al .", "label": "", "metadata": {}, "score": "90.61826"}
{"text": "PubMed Central PubMed .Goodwin GM : Evidence - based guidelines for treating bipolar disorder : recommendations from the British Association for Psychopharmacology .J Psychopharmacol 2003 , 17 ( 2):149 - 73 .", "label": "", "metadata": {}, "score": "90.64674"}
{"text": "Study design and participants .The study ( registered with clinicaltrials.gov ; identifier NCT00986167 ) was an open - label trial including male and female patients age 18 to 65 admitted to the adult acute psychiatry inpatient wards of St. Vincent 's Hospital or Alfred Hospital in Melbourne , Victoria , Australia .", "label": "", "metadata": {}, "score": "90.723854"}
{"text": "2011 ; Swartz and Thase 2011 ) .Further studies are required to establish the relative therapeutic position of these agents in the bipolar II disorder treatment armamentarium , with long - term trials being essential .", "label": "", "metadata": {}, "score": "90.82117"}
{"text": "Goodwin GM : Evidence - based guidelines for treating bipolar disorder : revised second edition - recommendations from the British Association for Psychopharmacology .J Psychopharmacol 2009 , 23 ( 4):346 - 88 .", "label": "", "metadata": {}, "score": "90.88436"}
{"text": "Ms Sparshatt and Ms Jones have no conflicts of interest that are directly relevant to the content of this review .References 1 .Citrome L , Jaffe A , Levine J , et al .", "label": "", "metadata": {}, "score": "91.00757"}
{"text": "Escitalopram is a new , highly selective serotonin reuptake inhibitor ( SSRI ) indicated for the treatment of MDD and is the therapeutically active S - enantiomer of citalopram , a well- recognised antidepressant agent .", "label": "", "metadata": {}, "score": "91.02774"}
{"text": "Data were obtained from carefully structured studies and , hence , the results may not be generalizable to patients outside the confines of a clinical trial .", "label": "", "metadata": {}, "score": "91.088196"}
{"text": "Females and males ages 18 - 65 years old .Female patients of childbearing potential must by using a reliable method of contraception and have a negative urine human chorionic gonadotropin ( HCG ) test at enrollment .", "label": "", "metadata": {}, "score": "91.23772"}
{"text": "Analysis .Analysis for each primary and secondary outcome measure involved repeated analysis of variance ( ANOVA ) measures with time ( baseline and follow - up time points ) as a repeated measures factor .", "label": "", "metadata": {}, "score": "91.248024"}
{"text": "Trisha Suppes , for the period 2008 - 2011 , has received research funding or medication support from Abbott Laboratories , AstraZeneca , JDS Pharmaceuticals , NIMH , Pfizer , the Stanley Medical Research Institute , and Sunovion Pharmaceuticals .", "label": "", "metadata": {}, "score": "91.2852"}
{"text": "Seroquel Study Group .Arch Gen Psy- chiatry 1997 ; 54 ( 6 ) : 549 - 57 16 .Fabre Jr LF , Arvanitis L , Pultz J , et al .", "label": "", "metadata": {}, "score": "91.312355"}
{"text": "Statistical analysis .The per - protocol ( PP ) population was a subset of the MITT population who had no significant protocol violations or deviations that would potentially affect efficacy .", "label": "", "metadata": {}, "score": "91.37223"}
{"text": "Dr. Lee , Ms. Foley , and Ms. Hannagan report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products .", "label": "", "metadata": {}, "score": "91.383606"}
{"text": "Journal of Neurology , Neurosurgery and Psychiatry 23 , 56 - 62 .ICH ( 1996 ) .Accessed 9 March 2011 .Kahn RS , Fleischhacker WW , Boter H , Davidson M , et al .", "label": "", "metadata": {}, "score": "91.53676"}
{"text": "Andreasen N. Scale for the assessment of negative symptoms ( SANS ) .Br J Psychiatry 1989 ; 155 Suppl .Small JG , Hirsch SR , Arvanitis LA , et al .", "label": "", "metadata": {}, "score": "91.63866"}
{"text": "For most instances , the assumption of one true effect size may be implausible .Although the included studies are relatively similar , there is generally no reason to assume that they are exactly the same .", "label": "", "metadata": {}, "score": "91.9685"}
{"text": "Recruitment took place between January 2010 and December 2010 .Sixteen patients were enrolled from the 2 centers .One patient withdrew as a result of moderate - severe sedation that resolved after ceasing the study medication ; this patient was excluded from subsequent analyses .", "label": "", "metadata": {}, "score": "92.1499"}
{"text": "Each item was scored on a scale of 1 ( very poor ) to 5 ( very good ) for overall satisfaction .The total score was the sum of the scores for items 1 to 14 .", "label": "", "metadata": {}, "score": "92.19852"}
{"text": "Rev. ed .Rockville ( MD ) : National Institute of Mental Health , 1976 : 157 - 69 8 .Overall JE , Gorham DR .", "label": "", "metadata": {}, "score": "92.33434"}
{"text": "Clin Ther 1995 ; 17 ( 3 ) : 366 - 78 17 .Small JG , Kolar MC , Kellams JJ .Relationship between que- tiapine dose and efficacy .", "label": "", "metadata": {}, "score": "92.53421"}
{"text": "Biol Psychiatry 1997 ; 42 ( 4 ) : 233- 46 7 .Guy W. The clinical global impressions scale .In : Guy W , editor .", "label": "", "metadata": {}, "score": "92.54704"}
{"text": "Brain Research 731 , 199 - 202 .M\u00f8rk A , Brennum LT , Fallon SM , Lassen AB , et al .( 2009 ) .", "label": "", "metadata": {}, "score": "92.69366"}
{"text": "N is the safety population .the proportion ( n / N ) of subjects for each treatment arm who spontaneously reported AEs by event type .", "label": "", "metadata": {}, "score": "92.72907"}
{"text": "Procedure .Both the Alfred Hospital 's and St. Vincent 's Hospital 's Human Research and Ethics Committees approved this study .The clinical team discussed potentially eligible patients at the daily clinical business meeting .", "label": "", "metadata": {}, "score": "92.79828"}
{"text": "Poster presentation II-45 .NCDEU 50th Anniversary Meeting .Boca Raton , FL , 2010 June 14 - 17 .FDA .Drug Approval Package .", "label": "", "metadata": {}, "score": "92.873566"}
{"text": "CNS Drugs 2008 ; 22 ( 1 ) .Page 12 .60 Sparshatt et al .\u00a9 2008 Adis Data Information BV .All rights reserved .", "label": "", "metadata": {}, "score": "93.048256"}
{"text": "( 2011 ) .Discovery of 1-[2-(2,4-dimethylphenylsulfanyl ) phenyl]piperazine ( Lu AA21004 ) : a novel multimodal compound for the treatment of mood and anxiety disorders .", "label": "", "metadata": {}, "score": "93.06236"}
{"text": "All AEs of suicidality ( suicide attempts , ideation , completed suicide , and suicidal behavior ) were monitored during the study .A physical examination and electrocardiogram ( ECG ) were conducted at enrollment and week 8 .", "label": "", "metadata": {}, "score": "93.15468"}
{"text": "Dr. Atkinson receives grant / research support from AstraZeneca , Eli Lilly and Company , Forest Pharmaceuticals , Lundbeck , Merck , Naurex , Otsuka , Pfizer , Sunovion , Takeda , and Targacept ; and is a consultant to Eli Lilly and Company .", "label": "", "metadata": {}, "score": "93.174706"}
{"text": "Design and inclu- sion / exclusion criteria are shown in table V. \u00a9 2008 Adis Data Information BV .All rights reserved .CNS Drugs 2008 ; 22 ( 1 ) .", "label": "", "metadata": {}, "score": "93.19467"}
{"text": "In order to determine the impact of the failed study on the overall pattern of results , these PANSS analyses were re- peated by including the failed study in the pooling process .", "label": "", "metadata": {}, "score": "93.24746"}
{"text": "Fixed - Dose Trials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .", "label": "", "metadata": {}, "score": "93.45236"}
{"text": "Quetiapine Dose - Response Relationship in Schizophrenia Anna Sparshatt , Sarah Jones and David Taylor Pharmacy Department , Maudsley Hospital , Denmark Hill , London , England Contents Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .", "label": "", "metadata": {}, "score": "93.49313"}
{"text": "NNT is traditionally used to de-note potential desirable outcomes ( benefits ) that a clinician and patient would want to encounter and NNH is ordinar- ily used to denote potential undesirable outcomes ( harms ) that a clinician and patient would like to avoid .", "label": "", "metadata": {}, "score": "93.567764"}
{"text": "Northwest Clinical Research Center , Bellevue , Washington , USA ; Duke University School of Medicine , Department of Psychiatry and Behavioral Sciences , Durham , North Carolina , USA .", "label": "", "metadata": {}, "score": "93.61804"}
{"text": "Br J Soc Clin Psychol 1967 ; 6 ( 4 ) : 278 - 96 24 .Margolese HC , Chouinard G , Beauclair L , et al .", "label": "", "metadata": {}, "score": "93.63484"}
{"text": "Philos Trans R Soc Lond B Biol Sci .Zeller SL , Rhoades RW .Systematic reviews of assessment measures and pharmacologic treatments for agitation .", "label": "", "metadata": {}, "score": "93.70931"}
{"text": "Competing interest .NM has received travel reimbursement from GlaxoSmithKline , Pfizer , Janssen - Cilag and Lundbeck .BM has received honoraria and/or travel reimbursement from GlaxoSmithKline , and Pfizer .", "label": "", "metadata": {}, "score": "94.03363"}
{"text": "Case Series and Cohort Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .", "label": "", "metadata": {}, "score": "94.068695"}
{"text": "SDM has received honoraria , consultancy fees and research grants from Astra Zeneca , Eli Lilly , Janssen - Cilag , Sanofi - Aventis , Novartis and Wyeth .", "label": "", "metadata": {}, "score": "94.072"}
{"text": "Poster presentation NR06 - 38 .American Psy- chiatric Association 164th Annual Meeting .Honolulu , HI , 2011May 14 - 18 .Loebel A , Cucchiaro J , Ogasa M , Silva R , Pikalov AA , Hsu J , et al .", "label": "", "metadata": {}, "score": "94.0999"}
{"text": "Single Fixed - Dose Study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .", "label": "", "metadata": {}, "score": "94.38717"}
{"text": "J Clin Psychiatry 2003 ; 64 ( 5 ) : 524 - 31 26 .Sacchetti E , Panariello A , Regini C , et al .", "label": "", "metadata": {}, "score": "94.39072"}
{"text": "\u00a9 2008 Adis Data Information BV .All rights reserved .CNS Drugs 2008 ; 22 ( 1 ) .Page 6 .54 Sparshatt et al .", "label": "", "metadata": {}, "score": "94.46665"}
{"text": "Schizophrenia is a serious brain disorder with symptoms including distorted perceptions of reality , hallucinations and delusions , illogical thinking , and flat or blunted emotions .", "label": "", "metadata": {}, "score": "94.6548"}
{"text": "Medical dictionary for regulatory activities .MMRM : . Declarations .Acknowledgments .We thank AnushaBolonna , PhD , and Chris Langford , PhD , from PAREXEL MMS , who provided medical writing support funded by AstraZeneca .", "label": "", "metadata": {}, "score": "94.69998"}
{"text": "France , Germany ... and Israel ) .It includes a 10-year epidemiology forecast ... segmented by age and sex in these markets .", "label": "", "metadata": {}, "score": "94.82747"}
{"text": "J Clin Psychopharmacol 2004 ; 24 ( 2 ) : 192 - 208 38 .National Institute of Mental Health .Abnormal involuntary movement scale ( AIMS ) .", "label": "", "metadata": {}, "score": "94.84539"}
{"text": "Columbia Classification Algorithm of Suicide Assessment ( C - CASA ) : classification of suicidal events in the FDA 's pediatric suicidal risk analysis of antidepressants .", "label": "", "metadata": {}, "score": "94.8845"}
{"text": "J Clin Psychopharmacol 2002 ; 22 ( 4 ) : 347 - 52 25 .Velligan DI , Prihoda TJ , Sui D , et al .", "label": "", "metadata": {}, "score": "94.89541"}
{"text": "Orygen Youth Health Research Centre , Centre for Youth Mental Health .The Mental Health Research Institute of Victoria .Department of Psychiatry , Melbourne University .", "label": "", "metadata": {}, "score": "94.97298"}
{"text": "American Journal of Psychiatry 163 , 28 - 40 .Wang Y , Wojtkowski T , Agyemang A , Homery M - C , et al .", "label": "", "metadata": {}, "score": "95.37625"}
{"text": "J Clin Psychiatry 2005 ; 66 ( 12 ) : 1512 - 6 \u00a9 2008 Adis Data Information BV .All rights reserved .CNS Drugs 2008 ; 22 ( 1 ) .", "label": "", "metadata": {}, "score": "95.78043"}
{"text": "Methods .Study design .All studies adhered to the current amendment of the Declaration of Helsinki and the International Conference on Harmonisation / Good Clinical Practice guidelines .", "label": "", "metadata": {}, "score": "95.82895"}
{"text": "La lurasidone poss\u00e8de \u00e9galement une bonne tol\u00e9rance cardiovasculaire , sans hypotension orthostatique ni allongement de l'intervalle QT , qu'elle que soit la posologie utilis\u00e9e .\" [ Show abstract ] [ Hide abstract ] ABSTRACT : La lurasidone est un nouvel antipsychotique de deuxi\u00e8me g\u00e9n\u00e9ration approuv\u00e9e par l'Agence europ\u00e9enne du m\u00e9dicament en mars 2014 dans le traitement de la schizophr\u00e9nie .", "label": "", "metadata": {}, "score": "96.12119"}
{"text": "Version 5.1.0 ( Updated March 2011 ) .Edited by : Higgins JPT , Green S. The Cochrane Collaboration ; 2011 .Papakostas GI : Tolerability of modern antidepressants .", "label": "", "metadata": {}, "score": "96.21936"}
{"text": "Urban Gustafsson is a former employee of AstraZeneca .Willie Earley is a former employee of AstraZeneca Pharmaceuticals LP .Authors ' contributions .AY , JC , SM , TS , and MT made substantial contributions to the acquisition of data and interpretation of data ; UG , MB , and WE contributed to the analysis and interpretation of data .", "label": "", "metadata": {}, "score": "96.43567"}
{"text": "( 5 ) National Institutes of Mental Health .The Numbers Count : Mental Disorders in America .NIH Publication No . 06- 4584 .", "label": "", "metadata": {}, "score": "96.54494"}
{"text": "Method : We searched the Cochrane library , Pub Med , CRD , Scopus , and Central Register of Controlled Trials to January 2015 .We also searched Clinical - Trials . gov , International depressive disorder Conference and the Anxiety Disorders and Depression Conference .", "label": "", "metadata": {}, "score": "96.56356"}
{"text": "Precautions include the risk of seizures , orthostatic hypotension , and cataracts .Examination of the lens by methods adequate to detect cataract formation , such as slit lamp exam or other appropriately sensitive methods , is recommended at initiation of treatment or shortly thereafter , and at 6-month intervals during chronic treatment .", "label": "", "metadata": {}, "score": "96.66466"}
{"text": "Study appraisal and synthesis methods .All abstracts identified by the electronic searches were examined .The full reports of relevant studies were assessed , and the data of interest were extracted .", "label": "", "metadata": {}, "score": "96.72214"}
{"text": "Pirie W. Jonckheere tests for ordered alternatives .In : Kotz S , Johnson NL , editors .Encyclopedia of statistical sciences .New York : John Wiley and Sons , Inc. , 1983 : 315 - 8 12 .", "label": "", "metadata": {}, "score": "97.16516"}
{"text": "Dr. Castle receives grant or research support from Allergen , AstraZeneca , Bristol - Myers Squibb , Eli Lilly and Company , Hospira , Janssen - Cilag , Lundbeck , Pfizer , and Roche .", "label": "", "metadata": {}, "score": "97.22666"}
{"text": "Psychol Rep 1962 ; 10 ( 799 ) : 799 - 812 9 .Kahn RS , Schulz SC , Palazov VD , et al .", "label": "", "metadata": {}, "score": "97.47682"}
{"text": "Cerebral Cortex 14 , 1365 - 1375 .Sheehan DV , Lecrubier Y , Sheenan KH , Amorim P , et al .( 1998 ) .", "label": "", "metadata": {}, "score": "97.62606"}
{"text": "MATERIALS AND METHODS Study Population Data were pooled from three different clinical trials , each similar in design ( placebo - controlled ) , inclusion / exclusion criteria , primary endpoints and assessment schedules , as described by Auquier et al .", "label": "", "metadata": {}, "score": "97.8442"}
{"text": "Dose - Response Relationship of Quetiapine in Schizophrenia67 2 .Pierre JM , Wirshing DA , Wirshing WC , et al .High - dose que- tiapine in treatment refractory schizophrenia .", "label": "", "metadata": {}, "score": "97.898865"}
{"text": "Also , he was a consultant at AstraZeneca , Bristol - Myers Squibb , Eli Lilly , Glaxo SmithKline , Janssen Cilag , Lundbeck , and Servier .", "label": "", "metadata": {}, "score": "98.08292"}
{"text": "These results should be viewed as the very preliminary one .Further studies in this area are warranted .Funding .This review had no funding .", "label": "", "metadata": {}, "score": "98.088585"}
{"text": "Authors ' original submitted files for images .Below are the links to the authors ' original submitted files for images .Competing interests .Michael Berk has received grant / research support from NIH , NHMRC , Simons Autism Foundation , Stanley Medical Research Foundation , MBF , Beyond Blue , Geelong Medical Research Foundation , Bristol - Myers Squibb , Eli Lilly , Glaxo SmithKline , Organon , Novartis , MaynePharma , and Servier .", "label": "", "metadata": {}, "score": "98.12152"}
{"text": "Citrome L. Compelling or irrelevant ?Using number needed to treat can help decide .Acta Psychiatr Scand 2008;117(6):412 - 419 .Citrome L. Number needed to treat : what it is and what it is n't , and why every clinician should know how to calculate it .", "label": "", "metadata": {}, "score": "98.34697"}
{"text": "AstraZeneca is listed in the Dow Jones Sustainability Index ( Global ) as well as the FTSE4Good Index .In the United States , AstraZeneca is a $ 12.44 billion healthcare business with more than 12,000 employees .", "label": "", "metadata": {}, "score": "98.596054"}
{"text": "Shaded entries represent NNT values where the 95 % CI does not include infinity and , hence , considered statistically significant .Data provided are for informational purposes only .", "label": "", "metadata": {}, "score": "98.60259"}
{"text": "Flexible Dosage within Fixed - Dose Range Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .", "label": "", "metadata": {}, "score": "98.76019"}
{"text": "Randomization in the studies was achieved using an interactive voice - response central randomization system , and numbers were not sequential within a site .No member of the investigational teams had access to the randomization schemes during the conduct of the studies .", "label": "", "metadata": {}, "score": "98.81506"}
{"text": "Joseph Calabrese has received federal funding from the Department of Defense , Health Resources Services Administration and National Institute of Mental Health .He has received research support from Abbott , AstraZeneca , Bristol - Myers Squibb , Cephalon , Cleveland Foundation , Eli Lilly , GlaxoSmithKline , Janssen , NARSAD , Repligen , Stanley Medical Research Institute , Takeda , and Wyeth .", "label": "", "metadata": {}, "score": "98.93721"}
{"text": "AEs were obtained from the clinical trial reports .N is the safety population and where a baseline and at least one post - baseline assessment for each metabolic variable were available .", "label": "", "metadata": {}, "score": "99.155594"}
{"text": "All rights reserved .CNS Drugs 2008 ; 22 ( 1 ) Table III .Flexible - dose within fixed range studies Study design Subjects No .", "label": "", "metadata": {}, "score": "99.414024"}
{"text": "This disease causes disorder in social , mental and physical functions of patients [ 2].\" [ Show abstract ] [ Hide abstract ] ABSTRACT : Background : Major depressive disorder is a serious public health problem affecting the lives of millions in the worldwide and leading causes of disability and disease .", "label": "", "metadata": {}, "score": "99.56058"}
{"text": "All authors conceived the idea , prepared the study protocol , prepared the manuscript , and approved the manuscript in its current form .NM and BM searched the databases , extracted the data , and analysed the data .", "label": "", "metadata": {}, "score": "99.602844"}
{"text": "Susan L McElroy has served as a consultant to or on the advisory boards of Alkermes , AstraZeneca , Bracket , Corcept , Eli Lilly , Jazz Pharmaceuticals , MedAvante , Pfizer , Shire , and Teva .", "label": "", "metadata": {}, "score": "99.70781"}
{"text": "Neuroimaging Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .", "label": "", "metadata": {}, "score": "99.76852"}
{"text": "Copyright .\u00a9 Young et al . ; licensee Springer .This article is published under license to BioMed Central Ltd.New Study Analyses Confirm Once - Daily Seroquel XR Extended - Release , Tablets as Effective Treatment for Schizophrenia .", "label": "", "metadata": {}, "score": "99.77252"}
{"text": "2008 ) .Lu AA21004 is extensively metabolized in the liver and at least five cytochrome P450 isoenzymes appear to be involved .The metabolism of Lu AA21004 to its major metabolite ( pharmacologically inactive ) is mediated primarily by CYP2D6 .", "label": "", "metadata": {}, "score": "99.794876"}
{"text": "NWCRC enrolled 17 patients in the trial of quetiapine XR for generalized anxiety disorder .In 2009 Dr. Khan founded Columbia Northwest Pharmaceuticals , LLC , and is Medical Director of the company .", "label": "", "metadata": {}, "score": "99.96125"}
{"text": "Mnie - Filali O , Faure C , Lamba \u00b4 s - Sen \u02dcas L , Mansari ME , et al .( 2011 ) .", "label": "", "metadata": {}, "score": "100.0533"}
{"text": "\" Si les effets secondaires des APIG sont domin\u00e9s par l'apparition d'effets extrapyramidaux , les APIIG sont souvent associ\u00e9s \u00e0 un risque de survenue d'effets secondaires m\u00e9taboliques ( prise de poids , diab\u00e8te , dyslipid\u00e9mie ) .", "label": "", "metadata": {}, "score": "100.15549"}
{"text": "Kasper S. First - episode schizophrenia : the importance of early intervention and subjective tolerability .J Clin Psychiatry 1999 ; 60 Suppl .23 : 5 - 9 Correspondence : Prof. David Taylor , Pharmacy Depart- ment , Maudsley Hospital , Denmark Hill , London , SE5 8AZ , England .", "label": "", "metadata": {}, "score": "100.43584"}
{"text": "The authors are en- tirely responsible for the scientific content of this article .F. Artigas declares having received lecture fees from CSC Pharmaceuticals and Lilly on antidepressant drugs .", "label": "", "metadata": {}, "score": "100.49043"}
{"text": "The study was conducted in accordance with the prin- ciples of Good Clinical Practice ( ICH , 1996 ) and the Declaration of Helsinki ( WMA , 1964 ) .", "label": "", "metadata": {}, "score": "100.61545"}
{"text": "Examination of the lens by methods adequate to detect cataract formation , such as slit lamp exam or other appropriately sensitive methods , is recommended at initiation of treatment or shortly thereafter , and at 6-month intervals during chronic treatment .", "label": "", "metadata": {}, "score": "101.04884"}
{"text": "The shares are being sold to ... share .The selling stockholders will receive all of the ... of its directors , officers or other stockholders is selling ... .", "label": "", "metadata": {}, "score": "102.02253"}
{"text": "Any disputes between reviewers were resolved by consensus .If no agreement could be reached , the third author ( MS ) would decide .Data items .", "label": "", "metadata": {}, "score": "102.12718"}
{"text": "Although carefully collected , accuracy can not be guaranteed .The impact factor represents a rough estimation of the journal 's impact factor and does not reflect the actual current impact factor .", "label": "", "metadata": {}, "score": "102.477234"}
{"text": "International Journal of Neuropsychopharmacology ( 2012 ) , 15 , 589 - 600 .f CINP and Cambridge University Press 2011 doi:10.1017/S1461145711001027 ARTICLE .", "label": "", "metadata": {}, "score": "103.088196"}
{"text": "We searched MEDLINE , EMBASE , CINHL , PsycINFO and Cochrane Controlled Trials Register databases in February 2012 .According to MEDLINE search , the first publication of the ICI 204,636 ( the drug code of quetiapine ) was in 1991 .", "label": "", "metadata": {}, "score": "103.47543"}
{"text": "Professor Taylor has received con- sultancies fees , lecturing honoraria and/or research funding from AstraZeneca , Janssen - Cilag , Servier , Sanofi - Aventis , Lundbeck , Bristol - Myers Squibb , Novartis , Eli Lilly and Wyeth .", "label": "", "metadata": {}, "score": "103.47786"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "103.48137"}
{"text": "APA ( 1994 ) .Diagnostic and Statistical Manual of Mental Disorders , 4th edn .Text Revision ( DSM - IV - TR ) .", "label": "", "metadata": {}, "score": "103.58119"}
{"text": "The study was approved by the institutional review board or independent ethics committee for each site and performed in accordance with the Declaration of Helsinki , the International Conference on Harmonisation Guideline for Good Clinical Practice , and applicable regulatory requirements .", "label": "", "metadata": {}, "score": "103.77512"}
{"text": "Address for correspondence : Dr M. Dragheim , ICR Mood & Anxiety Disorders , H. Lundbeck A / S , Ottliavej 9 , DK-2500 Valby , Denmark .", "label": "", "metadata": {}, "score": "103.826065"}
{"text": "Two reviewers ( NM and BM ) independently examined all abstracts identified by electronic searches to determine those meeting the eligible studies described above .The full - text articles of relevant studies were obtained .", "label": "", "metadata": {}, "score": "104.12408"}
{"text": "All analyses were conducted using the RevMan 5.1 ( The Nordic Cochrane Centre , Copenhagen , Denmark ) .Results .Study selection .After the remove of duplicates , 141 trials remained .", "label": "", "metadata": {}, "score": "104.493126"}
{"text": "Medications are classified into two categories -- \" conventional \" and \" atypical \" antipsychotics .About AstraZeneca .AstraZeneca is a major international healthcare business engaged in the research , development , manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services .", "label": "", "metadata": {}, "score": "104.644806"}
{"text": "If having tried everything from sprays to puppy pads and find nothing works , ... .( Date:2/5/2016 ) ... ...February 05 , 2016 , ...", "label": "", "metadata": {}, "score": "104.8696"}
{"text": "The management of NMS should include immediate discontinuation of antipsychotic drugs .Tardive dyskinesia ( TD ) , a potentially irreversible syndrome of involuntary dyskinetic movements , may develop in patients treated with antipsychotic drugs .", "label": "", "metadata": {}, "score": "105.5611"}
{"text": "The management of NMS should include immediate discontinuation of antipsychotic drugs .Tardive dyskinesia ( TD ) , a potentially irreversible syndrome of involuntary dyskinetic movements , may develop in patients treated with antipsychotic drugs .", "label": "", "metadata": {}, "score": "105.5611"}
{"text": "All authors were involved in drafting the manuscript or revising it critically for important intellectual content .All authors read and approved the final manuscript .", "label": "", "metadata": {}, "score": "105.61465"}
{"text": "Accessed 9 March 2011 .600E. Alvarez et al . .Data provided are for informational purposes only .Although carefully collected , accuracy can not be guaranteed .", "label": "", "metadata": {}, "score": "105.86081"}
{"text": "University of Cincinnati College of Medicine .Department of Psychiatry , University of Pennsylvania School of Medicine .Department of Psychiatry and Behavioral Sciences , Stanford Medical Center and VA Palo Alto Health Care System .", "label": "", "metadata": {}, "score": "106.207275"}
{"text": "Review Articles and Meta - Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .", "label": "", "metadata": {}, "score": "106.76613"}
{"text": "Diagnostic and statistical manual of mental disorders , 4th edition .Washington , DC : American Psychiatric Association ; 1994 .Sheehan DV , Lecrubier Y , Sheehan KH , et al .", "label": "", "metadata": {}, "score": "107.79142"}
{"text": "Disputes were resolved through consensus .Data collection process .We developed a data extraction form .A reviewer ( NM ) extracted the data into the form .", "label": "", "metadata": {}, "score": "108.65912"}
{"text": "Acknowledgements This study was sponsored by H. Lundbeck A / S. The authors gratefully acknowledge the participation of the following investigators at the psychiatric sites in this study .", "label": "", "metadata": {}, "score": "109.44566"}
{"text": "Synthesis of results .Both fixed effect and random effect models can be used for data synthesis .For the fixed effect approach , we assume that all included studies share a common effect size .", "label": "", "metadata": {}, "score": "109.49148"}
{"text": "Ms. She , Mr. Leathers , and Dr. Pathak are employees of AstraZeneca .REFERENCES .Bruce SE , Yonkers KA , Otto MW , et al .", "label": "", "metadata": {}, "score": "110.94177"}
{"text": "The online version of this article ( doi : 10 .1186/\u200b2194 - 7511 - 1 - 10 ) contains supplementary material , which is available to authorized users .", "label": "", "metadata": {}, "score": "112.40515"}
{"text": "Loft(biostatistician ) employees of H. Lundbeck A / S , Denmark .The Editor- in - Chief of this Journal , Dr Alan Frazer , serves on an advisory board for Lundbeck that deals with the mechanism of action of Lu AA21004 .", "label": "", "metadata": {}, "score": "113.43205"}
{"text": "Kasper , Margot Schmitz , Harald Schubert .Canada : Javed Ali , David Bakish , Martin Tremblay , Raymond Matte , Marie - Jose \u00b4 e Filteau .", "label": "", "metadata": {}, "score": "114.871414"}
{"text": "Funding for the conduct of this investigator - initiated study was provided by AstraZeneca Australia ( Study Code : D1443C00043 ) .The authors would like to thank research assistants Matt Donato and Sara Greenbaum who conducted recruitment for this project .", "label": "", "metadata": {}, "score": "115.02719"}
{"text": "2016 Henry Schein , Inc. ( NASDAQ : HSIC ) , the ... to office - based dental , animal health and medical practitioners , announced ... acquire a majority ownership interest in Dental Cremer S.A. , ... Brazil .", "label": "", "metadata": {}, "score": "116.15093"}
{"text": "Department of Psychiatry , Imperial College .University Hospitals Case Medical Center , Case Western Reserve University .Formerly AstraZeneca R&D .School of Medicine , Deakin University .", "label": "", "metadata": {}, "score": "119.49237"}
{"text": "Effectiveness Studies Effectiveness studies examine the use of drugs in comparatively naturalistic settings and compare drugs using pragmatic outcomes rather than surro-Table IX .All rights reserved .", "label": "", "metadata": {}, "score": "119.56917"}
{"text": "Valerio Iani , Bay Area Disc Program Director of ... .( Date:2/6/2016 ) ...St. Petersburg , FL ( PRWEB ) , ... February 06 , 2016 , ... ...", "label": "", "metadata": {}, "score": "120.49497"}
{"text": "( Date:2/6/2016 ) ...San Rafael , CA ( PRWEB ) , ... February 06 , 2016 , ... ...2016 Youth Ultimate Coaching Conference ( YUCC ) .", "label": "", "metadata": {}, "score": "121.411285"}
{"text": "Malaysia : Teck - Hoe Yen , Sulaiman Ahmad Hatim .Slovakia : Marek Zelman , Viera Korinkova , Eva Janikova , Molcan .Sweden : Ingemar Sjo \u00a8din , Eva Scheutz , Kurt Wahlstedt , Anders Elverfors , Maj - Liz Persson , Angela Marre \u00b4 -Lippitz .", "label": "", "metadata": {}, "score": "122.11751"}
{"text": "Germany , Italy , Spain ... .( Date:2/7/2016 ) ... ...February 07 , 2016 , ...Dr. Todd Hobgood , ... medical and surgical expertise .", "label": "", "metadata": {}, "score": "123.09212"}
{"text": "Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .", "label": "", "metadata": {}, "score": "125.82922"}
{"text": "Finland : Antti Ahokas , Anna Savela , Hannu Koponen , Riitta Jokinen , Ulla Lepola , Anneli Sorvaniemi , Markku Timonen .Gailledreau , Francis Gheysen , Pierre Le Goubey , Marcel Zins - Ritter , Paule Khalifa , Christian Gaussares , Daniel Bonnaffoux .", "label": "", "metadata": {}, "score": "128.18065"}
{"text": "The impact factor represents a rough estimation of the journal 's impact factor and does not reflect the actual current impact factor .Publisher conditions are provided by RoMEO .", "label": "", "metadata": {}, "score": "144.02106"}
